[Federal Register Volume 81, Number 251 (Friday, December 30, 2016)]
[Rules and Regulations]
[Pages 96992-97044]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-28966]



[[Page 96991]]

Vol. 81

Friday,

No. 251

December 30, 2016

Part IV





 Department of Justice





-----------------------------------------------------------------------





 Drug Enforcement Administration





-----------------------------------------------------------------------





 21 CFR Parts 1300, 1301, 1302, et al.





 Revision of Import and Export Requirements for Controlled Substances, 
Listed Chemicals, and Tableting and Encapsulating Machines, Including 
Changes To Implement the International Trade Data System (ITDS); 
Revision of Reporting Requirements for Domestic Transactions in Listed 
Chemicals and Tableting and Encapsulating Machines; and Technical 
Amendments; Final Rule

  Federal Register / Vol. 81 , No. 251 / Friday, December 30, 2016 / 
Rules and Regulations  

[[Page 96992]]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

21 CFR Parts 1300, 1301, 1302, 1303, 1304, 1308, 1309, 1310, 1312, 
1313, 1314, 1315, 1316, and 1321

[Docket No. DEA-403]
RIN 1117-AB41


Revision of Import and Export Requirements for Controlled 
Substances, Listed Chemicals, and Tableting and Encapsulating Machines, 
Including Changes To Implement the International Trade Data System 
(ITDS); Revision of Reporting Requirements for Domestic Transactions in 
Listed Chemicals and Tableting and Encapsulating Machines; and 
Technical Amendments

AGENCY: Drug Enforcement Administration, Department of Justice.

ACTION: Final rule.

-----------------------------------------------------------------------

SUMMARY: The Drug Enforcement Administration is updating its 
regulations for the import and export of tableting and encapsulating 
machines, controlled substances, and listed chemicals, and its 
regulations relating to reports required for domestic transactions in 
listed chemicals, gamma-hydroxybutyric acid, and tableting and 
encapsulating machines. In accordance with Executive Order 13563, the 
Drug Enforcement Administration has reviewed its import and export 
regulations and reporting requirements for domestic transactions in 
listed chemicals (and gamma-hydroxybutyric acid) and tableting and 
encapsulating machines, and evaluated them for clarity, consistency, 
continued accuracy, and effectiveness. The amendments clarify certain 
policies and reflect current procedures and technological advancements. 
The amendments also allow for the implementation, as applicable to 
tableting and encapsulating machines, controlled substances, and listed 
chemicals, of the President's Executive Order 13659 on streamlining the 
export/import process and requiring the government-wide utilization of 
the International Trade Data System (ITDS). This rule additionally 
contains amendments that implement recent changes to the Controlled 
Substances Import and Export Act (CSIEA) for reexportation of 
controlled substances among members of the European Economic Area made 
by the Improving Regulatory Transparency for New Medical Therapies Act. 
The rule also includes additional substantive and technical and 
stylistic amendments.

DATES: This rule is effective January 30, 2017. However, compliance 
with the revisions to DEA regulations made by this rule is not required 
until June 28, 2017.

FOR FURTHER INFORMATION CONTACT: Michael J. Lewis, Diversion Control 
Division, Drug Enforcement Administration; Mailing Address: 8701 
Morrissette Drive, Springfield, Virginia 22152; Telephone: (202) 598-
6812.

SUPPLEMENTARY INFORMATION: 

Outline

I. Background and Purpose
    A. Legal Authority
    B. Purpose of Regulatory Action
    1. Executive Order 13659
    2. Pilot Program
    3. Notice of Proposed Rulemaking
    C. Summary of the Major Provisions of the Regulatory Action
    1. Mandatory Electronic Applications and Filings
    2. Import and Export Permits for Controlled Substances
    3. Import and Export Declarations for Controlled Substances
    4. Imports, Exports, and International Transactions for Listed 
Chemicals
    5. Reexportation of Controlled Substances Among Members of the 
European Economic Area
    6. Domestic Transaction and Import and Export Reports for 
Tableting and Encapsulating Machines
    7. Mail Order Reporting for Ephedrine, Pseudoephedrine, 
Phenylpropanolamine, and Gamma-Hydroxybutyric Acid
    8. Transshipments of Controlled Substances
    9. Transshipments of Listed Chemicals
    D. List of Changes in the Final Rule
II. Discussion of Comments
    A. Electronic Applications and Filings, Generally (5 Issues)
    B. Import and Export Permits for Controlled Substances (6 
Issues)
    C. Import and Export Declarations for Controlled Substances (1 
Issue)
    D. Import and Export Declarations and Notices for Listed 
Chemicals (13 Issues)
    E. Reexportation of Controlled Substances Among Members of the 
European Economic Area (3 Issues)
    F. Miscellaneous Comments (2 Issues)
    G. Others
III. Section by Section Summary of the Final Rule
    A. 21 CFR Part 1300
    B. 21 CFR Part 1301
    C. 21 CFR Part 1302
    D. 21 CFR Part 1303
    E. 21 CFR Part 1304
    F. 21 CFR Part 1308
    G. 21 CFR Part 1309
    H. 21 CFR Part 1310
    I. 21 CFR Part 1312
    J. 21 CFR Part 1313
    K. 21 CFR Part 1314
    L. 21 CFR Part 1315
    M. 21 CFR Part 1316
    N. 21 CFR Part 1321
IV. Regulatory Analyses

I. Background and Purpose

A. Legal Authority

    The DEA implements and enforces titles II and III of the 
Comprehensive Drug Abuse Prevention and Control Act of 1970, as 
amended. 21 U.S.C. 801-971. Titles II and III are known as the 
``Controlled Substances Act'' and the ``Controlled Substances Import 
and Export Act,'' respectively, and are collectively referred to as the 
``Controlled Substances Act'' or ``CSA'' for the purpose of this 
action. The DEA publishes implementing regulations for these statutes 
in title 21 of the Code of Federal Regulations (21 CFR), chapter II. 
The CSA and its implementing regulations are designed to prevent, 
detect, and eliminate the diversion of controlled substances and listed 
chemicals into the illicit market while ensuring an adequate supply is 
available for the legitimate medical, scientific, research, and 
industrial needs of the United States. Controlled substances have the 
potential for abuse and dependence and are controlled to protect the 
public health and safety.
    Under the CSA, each controlled substance is classified into one of 
five schedules based upon its potential for abuse, its currently 
accepted medical use in treatment in the United States, and the degree 
of dependence the substance may cause. 21 U.S.C. 812. The initial 
schedules of controlled substances established by Congress are found at 
21 U.S.C. 812(c), and pursuant to 21 U.S.C. 812(a) and (b), the current 
list of all scheduled substances is published at 21 CFR part 1308. 
Controlled substances generally include narcotics, stimulants, 
depressants, and hallucinogens that have a potential for abuse and 
physical and psychological dependence, as well as anabolic steroids. 
Listed chemicals are separately classified based on their use and 
importance to the illicit manufacture of controlled substances (list I 
or list II chemicals). 21 U.S.C. 802(33)-(35).
    Through the enactment of the CSA and its amendments, Congress has 
established a closed system of distribution making it unlawful to 
handle any controlled substance (manufacture, distribute, reverse 
distribute, dispense, conduct research, engage in narcotic treatment or 
maintenance, import, export, collect, conduct chemical analysis, 
dispose, or possess) or manufacture, distribute, import, or export any 
listed chemical except in a manner authorized by the CSA. See e.g., 
Gonzales v. Raich, 545

[[Page 96993]]

U.S. 1, 12-13 (2005) (stating ``The main objectives of the CSA were to 
conquer drug abuse and to control the legitimate and illegitimate 
traffic in controlled substances. Congress was particularly concerned 
with the need to prevent the diversion of drugs from legitimate to 
illicit channels. To effectuate these goals, Congress devised a closed 
regulatory system making it unlawful to manufacture, distribute, 
dispense, or possess any controlled substance except in a manner 
authorized by the CSA. 21 U.S.C. 841(a)(1), 844(a); H.R. REP. NO. 91-
1444, pt. 1 at 3 (1970) (stating: ``Title II: Control and 
Enforcement.--The bill provides for control by the Justice Department 
of problems related to drug abuse through registration of 
manufacturers, wholesalers, retailers, and all others in the legitimate 
distribution chain, and makes transactions outside the legitimate 
distribution chain illegal.'').
    In order to maintain this closed system of distribution, the CSA 
requires handlers of controlled substances, unless exempt from 
registration, to be registered with the DEA at each principal place of 
business or professional practice where controlled substances are 
manufactured, distributed, or dispensed. 21 U.S.C. 822. The CSA also 
requires persons who manufacture or distribute, or who propose to 
manufacture or distribute, list I chemicals to be registered at each 
principal place of business or professional practice, unless exempt. 21 
U.S.C. 822; 21 CFR 1309.22. A separate registration is also required 
for each principal place of business where controlled substances or 
list I chemicals are imported or exported, unless exempt from 
registration. 21 U.S.C. 958. A ``registrant'' is any person who is 
registered pursuant to either section 303 or section 1008 of the CSA 
(codified at 21 U.S.C. 823 or 958).\1\ 21 CFR 1300.01(b). Registrants 
are permitted to possess controlled substances and list I chemicals as 
authorized by their registration and must comply with the applicable 
requirements associated with their registration. 21 U.S.C. 822 and 958.
---------------------------------------------------------------------------

    \1\ Unless otherwise noted, all references to registrant(s) in 
this preamble include persons exempt from DEA registration and 
persons not registered with the DEA as an importer or exporter who 
are authorized to perform importing or exporting activities as a 
coincident activity of their research or chemical analysis 
registration in accordance with 21 CFR 1301.13(e).
---------------------------------------------------------------------------

    In contrast, a ``regulated person'' means ``a person who 
manufactures, distributes, imports, or exports a listed chemical, a 
tableting machine, or an encapsulating machine or who acts as a broker 
or trader \2\ for an international transaction \3\ involving a listed 
chemical, a tableting machine, or an encapsulating machine.'' 21 U.S.C. 
802(38). (Tableting machines and encapsulating machines are also 
commonly known as ``pill presses'' and ``capsule fillers'' 
respectively.) Regulated persons who engage in ``regulated 
transactions,'' defined at 21 U.S.C. 802(39),\4\ are subject to 
specific recordkeeping and reporting requirements pursuant to 21 U.S.C. 
830, 971; 21 CFR part 1310. In addition, a person located in the United 
States who is a broker or trader for an international transaction in a 
listed chemical that is a regulated transaction shall, with respect to 
that transaction, be subject to all of the notification, reporting, 
recordkeeping, and other requirements placed upon exporters of listed 
chemicals. 21 U.S.C. 971(e).
---------------------------------------------------------------------------

    \2\ A ``broker'' and ``trader'' are persons that assist in 
arranging an international transaction in a listed chemical by: 
negotiating contracts; serving as an agent or intermediary; or 
bringing together a buyer and seller, a buyer and transporter, or a 
seller and transporter. 21 U.S.C. 802(43).
    \3\ An ``international transaction'' is a transaction that 
involves ``the shipment of a listed chemical across an international 
border (other than a United States border) in which a broker or 
trader located in the United States participates.'' 21 U.S.C. 
802(42).
    \4\ The CSA defines a ``regulated transaction'' as being: (1) 
With certain enumerated exceptions, ``a distribution, receipt, sale, 
importation, or exportation of, or an international transaction 
involving shipment of, a listed chemical, or if the Attorney General 
establishes a threshold amount for a specific listed chemical, a 
threshold amount, including a cumulative threshold amount for 
multiple transactions (as determined by the Attorney General, in 
consultation with the chemical industry and taking into 
consideration the quantities normally used for lawful purposes), of 
a listed chemical;'' and (2) ``a distribution, importation, or 
exportation of a tableting machine or encapsulating machine.'' 21 
U.S.C. 802(39).
---------------------------------------------------------------------------

    The CSA grants the Attorney General authority to promulgate rules 
and regulations relating to: The registration of controlled substance 
and list I chemical handlers; control of the manufacture, distribution, 
and dispensing of controlled substances; control of the manufacture and 
distribution of listed chemicals; maintenance and submission of records 
and reports; and for the efficient execution of her statutory 
functions. 21 U.S.C. 821-822, 825, 827-831, 871, 952, 954, 956, 958, 
971. The Attorney General is further authorized by the CSA to 
promulgate rules and regulations relating to the registration and 
control of importers and exporters of controlled substances or listed 
chemicals. 21 U.S.C. 958(f). The Attorney General has delegated these 
authorities to the Administrator of the DEA, who in turn redelegated 
many of these authorities to the Deputy Administrator of the DEA and 
the Deputy Assistant Administrator of the DEA Office of Diversion 
Control.\5\ 28 CFR 0.100 et seq.
---------------------------------------------------------------------------

    \5\ Due to an internal reorganization, on September 19, 2016, 
the DEA Office of Diversion Control became the Diversion Control 
Division. Throughout the document any references referring to the 
Office of Diversion Control have been updated to reflect this 
change.
---------------------------------------------------------------------------

    Within the DEA, the Diversion Control Division is the strategic 
focus area that carries out the mandates of the CSA to ensure that 
adequate supplies of controlled substances and listed chemicals are 
available to meet legitimate domestic medical, scientific, industrial, 
and export needs. The Diversion Control Division carries out the 
mission of the DEA to prevent, detect, and eliminate the diversion of 
these substances into the illicit drug market. Activities in support of 
the Diversion Control Division and its mission include: Determination 
of program priorities; field management oversight; coordination of 
major investigations; drafting and promulgating regulations; the design 
and proposal of national legislation; advice and leadership on State 
legislation/regulatory initiatives; oversight of the importation and 
exportation of tableting and encapsulating machines, controlled 
substances, and listed chemicals; establishment of national drug 
production quotas; activities related to drug scheduling and compliance 
with international treaty obligations; the design and execution of 
diplomatic missions; computerized monitoring and tracking of the 
distribution of certain controlled substances; planning and allocation 
of program resources; and liaison efforts with industry and their 
representative associations as well as to the DEA's regulatory and law 
enforcement counterparts at the federal, State, tribal, and local 
levels.

B. Purpose of Regulatory Action

1. Executive Order 13659
    Section 3 of the President's Executive Order 13659 of February 19, 
2014, ``Streamlining the Export/Import Process for America's 
Businesses,'' directs participating agencies to have capabilities, 
agreements, and other requirements in place to allow electronic filing 
through the International Trade Data System (ITDS) and supporting 
systems of data and other relevant documents (exclusive of applications 
for permits, licenses, or certifications) required for imported and 
exported goods. Participating agencies are ``[a]ll federal agencies 
that require

[[Page 96994]]

documentation for clearing or licensing the importation and exportation 
of cargo.'' Section 3 of Executive Order 13659 describes the ITDS as 
``an electronic information exchange capability, or ``single window,'' 
through which businesses will transmit data required by participating 
agencies for the importation or exportation of cargo.'' Within the 
ITDS, businesses are able to transmit their import and export data 
using through an Electronic Data Interchange (EDI), an electronic 
communication framework providing standards for exchanging data via any 
electronic means. CBP has identified the Automated Commercial 
Environment (ACE), and any successor system to ACE, to serve as an 
authorized EDI for purposes of import and export data required by CBP 
and participating agencies.
    In light of Executive Order 13659, the DEA is updating its 
regulations regarding the import and export of tableting and 
encapsulating machines, controlled substances, and listed chemicals. 
The amendments codify existing practices, incorporate existing 
procedures and technological advancements, and implement the 
President's Executive Order on streamlining the export/import process.
    Previous DEA regulations specifically required applications for 
permits, declarations, and other required notices and reports to be 
filed in paper form, or by electronic means in some circumstances. To 
comply with Executive Order 13659, the DEA is amending its regulations 
to integrate DEA procedures related to the importation and exportation 
of tableting and encapsulating machines, controlled substances, and 
listed chemicals with the ITDS.
    The ITDS excludes applications for permits, licenses, or 
certifications. In light of this, DEA registrants and regulated persons 
will continue to use the DEA application and filing process for permit 
applications that must be completed in advance of importation or 
exportation; however, the processes will be electronic rather than 
paper. As a result, DEA registrants or regulated persons applying for 
permits (DEA Forms 161, 161R, 161R-EEA, and 357) or filing 
notifications or reports with the DEA will apply or file directly with 
DEA electronically through the Diversion Control Division secure 
network application.
    The DEA import/export declarations (DEA Forms 236, 486 and 486A), 
will also be replaced with an electronic process. Upon receipt of a 
complete declaration through the Diversion Control Division secure 
network application, DEA will provide the importer or exporter with the 
notice of receipt that must then be filed with CBP as part of the CBP 
import or export filing through ACE, or any successor system. DEA will 
also transmit the declaration information electronically to CBP so that 
customs officers can validate importations and exportations subject to 
DEA regulations.
    Because of the requirement that regulated persons submit reports of 
regulated transactions in tableting machines and encapsulating machines 
to the DEA, the DEA is requiring such domestic regulated transaction 
reports to be submitted through the DEA Diversion Control Division 
secure network application, in addition to import and export regulated 
transactions. Mandatory reporting requirements for domestic regulated 
transactions are included as part of this rule because it allows for 
the DEA to create, at one time, an efficient, streamlined reporting 
structure of regulated activities applicable to tableting and 
encapsulating machines.
    Additionally, this final rule contains amendments that implement 
section 4, Re-exportation Among Members of the European Economic Area, 
of the Improving Regulatory Transparency for New Medical Therapies Act, 
Public Law 114-89, which was signed into law on November 25, 2015. 
Section 4 amended section 1003 of the Controlled Substances Import and 
Export Act (21 U.S.C. 953) by making changes to paragraph (f) and 
adding paragraph (g) that allows for reexportation of controlled 
substances among members of the European Economic Area.
    This rule also includes technical and stylistic changes to several 
regulations to clarify and simplify the language and to further the 
goals of the President's memorandum on Transparency and Open 
Government. 74 FR 4685, Jan. 26, 2009.
2. Pilot Program
    The DEA published a general notice in the Federal Register 
announcing, in coordination with U.S. Customs and Border Protection 
(CBP), a pilot test of the ITDS involving the electronic submission of 
data related to the importation and exportation of controlled 
substances and listed chemicals.\6\ The pilot program is testing the 
electronic transmission through CBP's ACE system, of data, forms and 
documents required by the DEA using the Partner Government Agency (PGA) 
Message Set and the Document Image System (DIS). The data, forms, and 
documents will be transmitted for review by the DEA. The PGA Message 
Set and DIS would enable importers, exporters, and brokers to 
electronically transmit data required by the DEA directly through ACE; 
this electronic process will replace certain paper-based processes that 
are used outside of the pilot program.
---------------------------------------------------------------------------

    \6\ Electronic Filing of Certain Import/Export Data Relating to 
Controlled Substances and Listed Chemicals: Announcement of the 
Partner Government Agency Message Set/Document Image System Test and 
Request for Participants, July 15, 2016. 81 FR 46058-89. To be 
eligible to apply for and participate in the pilot, an applicant had 
to be a self-filing importer or broker, with the ability to file ACE 
Entry and Entry Summaries certified for cargo release using a 
software program that has completed ACE certification testing for 
the PGA Message Set and DIS, and, if an exporter, must have the 
ability to file electronically in the Automated Export System (AES) 
or in ACE AES Direct.
---------------------------------------------------------------------------

    The test commenced on August 1, 2016, and will continue until 
publication of a notice in the Federal Register. Any party seeking to 
participate in the test was instructed to contact their CBP client 
representative.
    The DEA anticipated that this pilot program would help prepare for 
a successful transition from the paper-based process to the electronic 
entry and transmission of data to ACE. As of October 25, 2016 there 
were 35 companies, representing 95 registration numbers, participating 
in the pilot program.
    DEA and CBP have determined that the pilot program has successfully 
tested the functionality for electronic submission of data related to 
the importation and exportation of controlled substances and listed 
chemicals. As a result, the pilot program will be concluded as of the 
effective date of this final rule. At that time, all importers, 
exporters, and brokers will be able to use ACE to electronically file 
required data and documentation associated with the importation and 
exportation of controlled substances and listed chemicals.
3. Notice of Proposed Rulemaking
    The DEA published a notice of proposed rulemaking (NPRM) in the 
Federal Register incorporating all the above changes on September 15, 
2016.\7\ The NPRM provided an opportunity for

[[Page 96995]]

persons to submit written comments on the proposal on or before October 
17, 2016. The DEA specifically solicited comments on the economic 
impact of the rule, and requested that commenters describe the specific 
nature of any impact on small entities and provide empirical data to 
illustrate the extent of such impact.
---------------------------------------------------------------------------

    \7\ Revision of Import and Export Requirements for Controlled 
Substances, Listed Chemicals, and Tableting and Encapsulating 
Machines, Including Changes to Implement the International Trade 
Data System; Revision of Reporting Requirements for Domestic 
Transactions in Listed Chemicals and Tableting and Encapsulating 
Machines; and Technical Amendments, September 15, 2016. 81 FR 63575. 
The DEA's Economic Impact Analysis (EIA), was made available in its 
entirety under ``Supporting Documents'' in the public docket of this 
action at http://www.regulations.gov, under FDMS Docket ID: DEA-
2016-0017 (Docket No. DEA-403).
---------------------------------------------------------------------------

C. Summary of the Major Provisions of the Regulatory Action

    The DEA is finalizing the rule as proposed except where otherwise 
stated in the paragraphs below.
    Below are summaries of provisions contained in the final rule.
1. Mandatory Electronic Applications and Filings
    The DEA is amending its regulations to authorize electronic 
submission of data, and make the procedure mandatory over paper in most 
circumstances. 21 U.S.C. 958(f). The use of electronic applications and 
filings is consistent not only with the requirements of Executive Order 
13659, but also with the general principles outlined in the 
Government's Open Data Policy which requires agencies to collect or 
create information in a way that supports downstream information 
processing and dissemination. The Open Data Policy states that 
information should be collected electronically by default.
    Executive Order 13659 directs participating agencies to have 
capabilities, agreements, and other requirements in place to allow 
electronic filing through ITDS and supporting systems of data and other 
relevant documents (exclusive of applications for permits, licenses, or 
certifications) required for imported and exported goods. Businesses 
are able to transmit their import and export data through using an EDI, 
an electronic communication framework providing standards for 
exchanging data via any electronic means. Data is transmitted through 
the EDI links to ACE, which serves as the single window for CBP.
    Mandatory electronic applications and filings allow for the DEA to 
create an efficient, streamlined reporting structure of regulated 
activities.
2. Import and Export Permits for Controlled Substances
    The DEA is amending its regulations regarding expiration dates 
associated with imports and exports of controlled substances. The DEA 
is changing the current expiration period of import and export permits 
found in Sec. Sec.  1312.16 and 1312.25 from not more than six months 
to not more than 180 calendar days after the date of issuance. This 
change standardizes expiration procedures as not all months have the 
same number of days.
    The DEA is revising Sec. Sec.  [thinsp]1312.16 and 1312.25 to 
clearly specify how and under what conditions controlled substance 
import and export permits may be amended or cancelled after issuance 
and when a new permit is required instead of an amendment. Registrants 
will submit a request to amend or cancel an application for an import 
or export permit, amend an issued import or export permit, or request 
cancelation of an issued import or export permit to the Administration 
through the DEA Diversion Control Division secure network application.
    Consistent with current practice, importers and exporters will 
continue to be able to request an amendment to a permit for the 
following data fields: The National Drug Control number, description of 
the packaging, or trade name of the product, so long as the description 
is for the same basic class of controlled substance(s) as in the 
original permit; the proposed port of entry or export; the proposed 
date of import or export;[thinsp]the method of transport; any 
registrant notes; and the justification entered by the importer or 
exporter for why an import or export is needed to meet the medical, 
scientific, or other legitimate needs of the United States or foreign 
jurisdiction. The DEA allows amendments to these fields as these are 
areas that may be easily mis-keyed or subject to change as part of the 
normal import and export business practice.
    Consistent with current practice, importers and exporters will 
continue to generally be allowed to amend the base weight of controlled 
substance(s) listed on their permit prior to the start of an import or 
export transaction (i.e., prior to shipment). However, also consistent 
with current practice, exporters will not be allowed to exceed the 
total base weight of controlled substance(s) listed on the 
corresponding foreign permit. Neither will exporters be allowed to 
exceed the strength of a controlled substance product if product 
strength information has been included on the import permit issued by 
the foreign competent national authority. Under Sec.  
[thinsp]1312.15(a), importers will continue to be allowed to request an 
amendment to the quantity of controlled substances specified on an 
import permit once a shipment has arrived at the U.S. customs port of 
entry if the increase in the amount of controlled substance to be 
imported is less than 1% of that listed on the issued import permit. 
Importers and exporters need not request an amendment for the sole 
purpose of decreasing the amount authorized.
    Consistent with current practice, importers and exporters would 
continue to be able to request that an import or export permit be 
amended to remove a controlled substance.
    However, importers and exporters may not amend permits to add or 
replace a controlled substance/Administration controlled substance code 
number to the item(s) to be imported or exported. Importers and 
exporters who desire to import or export a different controlled 
substance than that contained on their issued permit or permit 
application must submit a request for the permit or permit application 
to be canceled and request a new permit.
    The DEA understands that sometimes the incorrect controlled 
substance is identified on the permit application due to clerical 
error, for example because a similar item was selected from the drop-
down selection in the DEA Diversion Control Division secure network 
application that was located near the correct item. However, the DEA 
has closely considered this issue and ultimately determined that 
because the listed controlled substance proposed to be imported or 
exported is such a critical element of determining whether or not a 
permit should be issued and, if issued, the amount allowed to be 
imported or exported, this element should not be amendable. As stated 
elsewhere in this preamble, the DEA reminds importers and exporters 
that the duty to file reports and other documents with the DEA includes 
the duty that these filings be complete and accurate.
    Similarly, in a change from current practice, the DEA is not 
allowing exporters to amend foreign permit information on permit 
applications and issued permits.
    The DEA understands that sometimes, especially in the case of less 
experienced exporters, the incorrect foreign permit number is entered 
onto the permit application. This is often the result of numbers being 
transposed or a different number on the foreign permit being entered 
instead of the actual permit identification number. However, similar to 
the controlled substance identified on the permit, the DEA has closely 
considered this matter and ultimately determined that, because the 
authorization from the foreign competent national authority is such a 
critical element in determining whether a permit can be issued and the 
amount of the controlled substance to be exported, this element should 
not be amendable. As stated above and

[[Page 96996]]

elsewhere in this document, the DEA reminds importers and exporters 
that the duty to file reports and other documents with the DEA includes 
the duty that these filings be complete and accurate.
    Consistent with current practice, importers and exporters will not 
be able to request an amendment to a permit for changes to the importer 
or exporter's name (as it appears on their DEA certificate of 
registration) or the name of the foreign importer or exporter. The DEA 
considers the name of the foreign importer or exporter to be a key 
factor in determining associated risks of the diversion of controlled 
substances and subsequently whether or not to issue an import or export 
permit. Therefore, these fields are not amendable.
    However, also consistent with current practice, as stated above, 
the DEA will continue to allow importers and exporters to amend any 
additional associated company names they are DBA (doing business as) 
that they wish to have included in the notes section of the permit. The 
only change from current practice is that such amendments would be 
required to be made through the DEA Diversion Control Division secure 
network application.
    Importers and exporters will be required to make an official 
request through the DEA Diversion Control Division secure network 
application for an amendment. Supplementary information submitted by an 
importer or exporter through the DEA Diversion Control Division secure 
network application will not automatically trigger the amendment 
process. An amendment will have no effect on the date of expiration of 
the permit; an amended import or export permit will have the same 
expiration date as the originally issued permit. Importers and 
exporters will be able to request that an issued import or export 
permit be canceled provided that no shipment has yet been made.
    Under revised Sec.  [thinsp]1312.16(a)(5), registrants and 
regulated persons will be required to submit all requests for an 
amendment that would affect the total base weight of each controlled 
substance, other than those submitted in accordance with Sec.  
[thinsp]1312.15(a), at least three business days in advance of the date 
of release by a customs officer. Three business days are the minimum 
amount of time that the DEA needs to review this type of requested 
amendment, approve or deny the request, and transmit the applicable 
data to the ITDS. All other requests for amendment will be required to 
be submitted to the DEA at least one business day before the date of 
release by a customs officer at the port of entry. One business day is 
the minimum amount of time that the DEA needs to review the requested 
amendment, approve or deny the request, and transmit the applicable 
data to the ITDS.
    DEA registrants have been able to submit DEA forms electronically 
for several years, and are familiar with the DEA Diversion Control 
Division secure network application system. If a DEA registrant needs 
to change information on an application for a permit that is not 
amendable, they must submit a new application for a permit. The 
registrant will follow the same process used with the original 
submission and submit the forms electronically. The DEA will review the 
submission, process the document and issue a Transaction Identification 
Number (TIN). The estimated time to complete the online document is 
minimal. Requiring the new submission will ensure the integrity of the 
information in the DEA system as well as what is transmitted to CBP.
    To make an allowable amendment, a DEA registrant will access the 
DEA secure network application and provide the Transaction 
Identification Number which was assigned with the original submission. 
The system will provide access to the registrant's application for a 
permit, and the registrant can then make the appropriate changes. The 
DEA will review the changes and process the document. To ensure that 
there is no delay in CBP releasing a product from being imported or 
exported, the DEA provides the amended documents or new submissions to 
CBP in its daily feed.
    As a result of the ITDS/ACE system relying on the Harmonized Tariff 
System (HTS) used by CBP to properly release products for import or 
export, the DEA had to identify the proper HTS codes for the substances 
under its control. The HTS codes are utilized in ACE and directly 
correlate to Administration Controlled Substance Code Number. As a 
result, the DEA will not allow a registrant to amend an application by 
adding a controlled substance that has a different Administration 
Controlled Substance Code Number. This will ensure a more streamlined 
process and will allow CBP to efficiently release product in a timely 
manner.
    Countries that are parties to international drug control treaties 
have an established competent national authority (CNA) (identified in 
the United Nations Office on Drugs and Crime publication ``Competent 
National Authorities Under the International Drug Control Treaties'') 
that oversees the handling of controlled substances and listed 
chemicals to include the approval of imports and exports. All CNAs make 
certain reports to the International Narcotics Control Board (INCB) on 
the distribution of the substances being imported and exported. The DEA 
communicates directly with CNAs or through the INCB if issues arise 
regarding official authorization documents submitted to the DEA by DEA 
registrants.
    For the reasons discussed above, the DEA is also requiring 
electronic reporting of return information for controlled substances 
imported or exported under permit procedures.
3. Import and Export Declarations for Controlled Substances
    The DEA is also amending Sec. Sec.  1312.18 and 1312.27 to specify 
an expiration date for import and export declarations for controlled 
substances.
    Such declarations did not have an expiration date assigned to them; 
however, permits to import and export controlled substances expire not 
more than six months after approved under the previous regulation. 21 
CFR 1312.16 and 1312.25. Similar to permits, declarations filed with 
the DEA are sometimes never actually utilized. The DEA is concerned 
that absence of an expiration date for these declarations may lead to 
incomplete or inaccurate records in the ITDS. Therefore, declarations 
expire 180 calendar days after the date the declaration is deemed filed 
with the Administration.
    The DEA is incorporating the mandatory electronic filing of DEA 
import declarations and DEA export declarations for controlled 
substances with the DEA into Sec. Sec.  1312.18 and 1312.27. This 
requirement is also incorportated into a new Sec.  1312.03 which 
references a list of applicable forms for part 1312, and will state the 
declaration forms are electronic. This information is listed multiple 
in the applicable regulations.
    Consistent with current requirements, controlled substance 
declarations will be required to be filed at least 15 calendar days in 
advance of the anticipated date of release by a customs officer at the 
port of entry or port of export. 21 CFR 1312.18(b), 1312.27(a). The DEA 
is retaining this 15-day-advance filing time period to ensure enough 
time for the DEA to review the submission for completeness and conduct 
any necessary follow-up prior to the import/export transaction. Under 
revised Sec. Sec.  [thinsp]1312.18(b) and 1312.27(a), controlled 
substance declarations are not deemed filed until the

[[Page 96997]]

Administration issues a transaction identification number. However, the 
DEA is allowing registrants and regulated persons to proceed with the 
import or export transaction as soon as the transaction identification 
number has been issued, regardless of whether 15 calendar days have 
elapsed since its issuance. Finally, DEA regulations requiring 
declarations to be completed in triplicate would be eliminated.
    The DEA is amending its import/export regulations to describe the 
procedures relating to amendments following the filing of a controlled 
substance import or export declaration with implementation of the ITDS. 
The DEA is changing Sec. Sec.  [thinsp]1312.18(f) and 1312.27(e) to 
clearly specify how and under what conditions controlled substance 
import and export declarations may be amended or cancelled after having 
been filed and when a new declaration is required instead of an 
amendment. Registrants and regulated persons will submit a request to 
amend or cancel a filed declaration to the Administration through the 
DEA Diversion Control Division secure network application.
    Consistent with current practice, importers and exporters will 
continue to be able to amend a declaration for the following data 
fields: The National Drug Control number, description of the packaging, 
or trade name of the product, so long as the description is for the 
same basic class of controlled substance(s) as in the original 
declaration; the proposed port of entry or export; the anticipated date 
of release by a customs officer at the port of entry or port of export; 
the method of transport; any registrant notes; and the justification 
entered by the importer or exporter for why an import or export is 
needed to meet the legitimate scientific or medical needs of the United 
States or foreign jurisdiction. The DEA allows amendments to these 
fields as these are areas that may be easily mis-keyed or subject to 
change as part of the normal import and export business practice.
    Importers and exporters will continue to generally be allowed to 
amend the base weight of controlled substance(s) listed on their filed 
declaration prior to the start of an import or export transaction 
(i.e., prior to shipment). However, exporters would not be allowed to 
exceed the total base weight of controlled substance(s) listed on the 
corresponding authorization for import issued by the foreign competent 
national authority. Neither would exporters be allowed to exceed the 
strength of a controlled substance product if product strength 
information has been included on the authorization for import issued by 
the foreign competent national authority. Consistent with Sec.  
[thinsp]1312.15(a) for imports of controlled substances under permit 
procedure, importers under declaration procedures will be allowed to 
request an amendment to an import declaration regarding the quantity of 
controlled substances once a shipment has arrived at the U.S. customs 
port of entry if the increase in the amount of controlled substance to 
be imported is less than 1% of that listed on the filed declaration. 
Importers and exporters need not request an amendment for the sole 
purpose of decreasing the amount authorized.
    Importers and exporters will continue to be able to amend a filed 
import or export declaration to remove a controlled substance. However, 
importers and exporters will no longer be able to amend declarations to 
add a new controlled substance or replace a controlled substance with 
another controlled substance. Instead, importers and exporters who need 
to make changes to any of these fields will need to cancel the existing 
declaration and file a new declaration.
    The DEA understands that sometimes the incorrect controlled 
substance is identified on the declaration due to clerical error, for 
example because a similar item was selected from the drop-down 
selection in the DEA Office of Diversion Control secure network 
application that was located near the correct item. However, the DEA 
has closely considered this issue and ultimately determined that 
because the identification of the controlled substance proposed to be 
imported or exported is such a critical element of the closed system of 
distribution, that this element should not be amendable. As stated 
elsewhere in this preamble, the DEA reminds importers and exporters 
that the duty to file reports and other documents with the DEA includes 
the duty that these filings be complete and accurate.
    The DEA is not allowing importers and exporters to amend 
information related to the authorization to import or export from the 
foreign competent national authority. The DEA understands that 
sometimes, especially in the case of less experienced importers and 
exporters, the incorrect foreign authorization identifier is entered 
onto the declaration. This is often the result of numbers being 
transposed or a different number on the foreign permit being entered 
instead of the actual authorization identifier. However, similar to the 
identification of the controlled substance to be imported or exported, 
the DEA has closely considered this matter and ultimately determined 
that because the authorization from the foreign competent national 
authority to import or export a controlled substance is such a critical 
element to the Administration's ability to monitor and ensure the 
closed system of distribution, this element should not be amendable. As 
stated above and elsewhere in this document, the DEA reminds importers 
and exporters that the duty to file reports and other documents with 
the DEA includes the duty that these filings be complete and accurate.
    Importers and exporters will not be able to request an amendment to 
a filed import or export declaration for changes to the importer or 
exporter's name (as it appears on their DEA certificate of 
registration) or the name of the foreign importer or exporter. The DEA 
considers the name of the foreign importer or exporter to be a key 
factor in determining associated risks of the diversion of controlled 
substances. Therefore, these fields would not be amendable.
    The DEA will continue to allow importers and exporters to amend any 
additional associated company names they are DBA (doing business as) 
that they wish to have included in the notes section of the 
declaration; such amendments would be required to be made through the 
DEA Diversion Control Division secure network application.
    Importers and exporters will be required to make an official 
request through the DEA Diversion Control Division secure network 
application for an amendment. Supplementary information submitted by an 
importer or exporter through the DEA Diversion Control Division secure 
network application will not automatically trigger the amendment 
process. An amendment will have no effect on the date of expiration of 
the declaration; an amended import or export declaration will have the 
same expiration date as the originally filed declaration.
    Importers and exporters will be able to request that filed import 
or export declarations be canceled provided that no shipment has yet 
been made.
    Registrants will be required to submit all requests for an 
amendment that will affect the total base weight of each controlled 
substance, other than those allowed to be released into the United 
States pursuant to Sec. Sec.  [thinsp]1312.18(f) and 1312.16(a)(5), at 
least three business days in advance of the date of release by CBP. 
Three business days are the minimum amount of time that the DEA needs 
to review this type of requested amendment and transmit the applicable

[[Page 96998]]

data to the ITDS. All other requests for amendment will be required to 
be submitted to the DEA at least one business day before the 
anticipated date of release by a customs CBP officer at the port of 
entry or port of export. One business day is the minimum amount of time 
that the DEA needs to review and accept the requested amendment and 
transmit the applicable data to the ITDS.
    DEA registrants have been able to submit DEA forms electronically 
for several years, and are familiar with the DEA Diversion Control 
Division secure network application system. If a DEA registrant needs 
to change information on a declaration that is not amendable, they must 
submit a new declaration. 21 CFR 1312.12, 1312.18, 1312.22, and 
1312.27. The registrant will follow the same process used with the 
original submission and submit the forms electronically. The DEA will 
review the submission, process the document and issue a Transaction 
Identification Number (TIN). The estimated time to complete the online 
document is minimal. Requiring the new submission will ensure the 
integrity of the information in the DEA system as well as what is 
transmitted to CBP.
    To make an allowable amendment, a DEA registrant will access the 
DEA Secure Network Application and provide the Transaction 
Identification Number which was assigned with the original submission. 
The system will provide access to the registrant's declaration, and the 
registrant can then make the appropriate changes. The DEA will review 
the changes and process the document. To ensure that there is no delay 
in CBP releasing a product from being imported or exported, the DEA 
provides the amended documents or new submissions to CBP in its daily 
feed.
    As a result of the ITDS/ACE system relying on the Harmonized Tariff 
System (HTS) used by CBP to properly release products for import or 
export, the DEA had to identify the proper HTS codes for the substances 
under its control. The HTS codes are utilized in ACE and directly 
correlate to Administration Controlled Substance Code Number. As a 
result, the DEA will not allow a registrant to amend a declaration by 
adding a controlled substance that has a different Administration 
Controlled Substance Code Number. This will ensure a more streamlined 
process and will allow CBP to efficiently release product in a timely 
manner.
    As stated previously all countries that are parties to 
international drug control treaties have an established CNA that 
oversees the handling of controlled substances and listed chemicals to 
include the approval of imports and exports. All CNAs make certain 
reports to the INCB on the distribution of the substances being 
imported and exported. The DEA communicates directly with CNAs or 
through the INCB if issues arise regarding official authorization 
documents submitted to the DEA by DEA registrants.
    For the reasons stated above, the DEA is also requiring mandatory 
electronic filing of return information for controlled substances 
imported or exported under declaration procedures.
4. Imports, Exports, and International Transactions for Listed 
Chemicals
    The DEA is amending part 1313 to provide that each regulated person 
who seeks to import or export a listed chemical that meets or exceeds a 
threshold quantity, must notify/provide a declaration to the DEA (by 
filing a DEA Form 486/486A through the DEA Diversion Control Division 
secure network application) of the intended import or export not later 
than 15 calendar days before the date of release by a customs officer 
at the port of entry. Regarding imports and exports for those entities 
with regular customer and regular importer status, the notification 
must be filed at least three business days before the date of release 
by a customs officer at the port of entry. All declarations must be 
signed and dated by the importer or exporter and must contain the 
address of the final destination for the shipment.
    The DEA is specifying that all listed chemical declarations expire 
in 180 calendar days, consistent with the controlled substance import/
export permits. If release by a customs officer will occur more than 
180 calendar days after the declaration is deemed filed, the declarant 
must submit a new declaration for the transaction.
    In Sec.  1313.32 the DEA is incorporating the mandatory electronic 
filing of notifications of international transactions involving listed 
chemicals which meet or exceed the threshold amount identified in Sec.  
1310.04. The broker or trader must notify the DEA (by filing a DEA Form 
486 through the DEA Diversion Control Division secure network 
application) of the intended international transaction not later than 
15 calendar days before the transaction is to take place. The DEA is 
amending Sec.  1313.32 to require that notifications of international 
transactions would not be deemed filed until a transaction 
identification number has been issued by the DEA. This change is 
designed to ensure that electronically submitted notifications are 
received by the DEA, are completed, and can be appropriately tracked 
and monitored; to streamline the notification filing process; and 
eliminate duplicate filings.
5. Reexportation of Controlled Substances Among Members of the European 
Economic Area
    This final rule implements section 4, Re-exportation Among Members 
of the European Economic Area, of the Improving Regulatory Transparency 
for New Medical Therapies Act, Public Law 114-89 (hereinafter ``the 
2015 Act''), which was signed into law on November 25, 2015. Section 4 
of the 2015 Act amended section 1003 of the Controlled Substances 
Import and Export Act (CSIEA) (21 U.S.C. 953) by making changes to 
paragraph (f) and adding paragraph (g), changes that allow for expanded 
reexportation of certain controlled substances among members of the 
European Economic Area (EEA). Prior to passage of the 2015 Act, the 
CSIEA (21 U.S.C. 953(f)) provided, with respect to controlled 
substances in schedule I or II and narcotic drugs in schedule III or 
IV, that such substances could be exported from the United States for 
subsequent reexport from the recipient country (the ``first country'') 
to another country (the ``second country'')--but with no further 
reexports from the second country. The 2015 Act removed this latter 
limitation, provided that every country involved is an EEA country, and 
provided that the conditions specified in the 2015 Act are met.
    In order to effectuate the changes contained in the 2015 Act, the 
final rule implements the following changes:
     Allowing unlimited reexports among EEA countries.
     Eliminating the 180 day time period to complete reexport 
(reexport from first country to the second country (ies)).
     No longer requiring bulk substances to undergo further 
manufacturing processes within the first EEA country if the substance 
is to be reexported within the EEA.
     No longer requiring that the exporter must provide product 
and consignee information beyond the first country in advance of (prior 
to) export from the United States.
     Establishing a new Form 161R-EEA for the reporting of 
reexports among members of the EEA. (The form is accessed, completed, 
and submitted through the DEA Diversion Control Division secure network 
application.)
    All other requirements that existed prior to the enactment of the 
2015 Act (and which were not modified by Congress in 2015 Act) remain. 
Additionally, persons who export

[[Page 96999]]

controlled substances for reexport among members of the EEA are 
required by the law to provide return information to the Attorney 
General within 30 days after each reexportation, including 
certification that the reexportation has occurred and ``information 
concerning the consignee, country, and product.'' 21 U.S.C. 
953(f)(6)(B). Finally, while the new law did not have a direct impact 
on reexports for nonnarcotic controlled substances in schedules III and 
IV or controlled substances in schedule V, for the purpose of 
consistency, the DEA is making corresponding changes to its reexport of 
controlled substances under declaration procedures found in Sec.  
1312.27.
6. Domestic Transaction and Import and Export Reports for Tableting and 
Encapsulating Machines
    The DEA is mandating electronic reporting requirements in Sec.  
1310.05 for all regulated transactions involving tableting machines and 
encapsulating machines, including domestic, import, and export 
transactions. To standardize and streamline the electronic filing of 
these reports, the DEA is implementing usage of a new form, DEA Form 
452, Reports for Regulated Machines, which covers imports, exports, and 
domestic regulated transactions of tableting and encapsulating 
machines. The new form will be accessed, completed, and submitted by 
regulated persons entirely though the DEA Diversion Control Division 
secure network application. Upon receipt and review, the Administration 
will assign each completed report a transaction identification number. 
The DEA Form 452 will not be deemed filed until the Administration 
issues a transaction identification number. This change is designed to 
ensure that electronically submitted reports are indeed received by the 
DEA, are completed, and can be appropriately tracked and monitored; to 
streamline the report filing process; and to eliminate duplicate 
filings.
    The DEA Form 452 is used for both domestic transactions and import/
export transactions of tableting and encapsulating machines, and the 
reporting requirements implemented by this final rule differ.
    Domestic Transactions: Previously in 21 CFR 1310.05(a)(4) and (b), 
regulated persons who engaged in a domestic regulated transaction in a 
tableting or encapsulating machine are required, whenever possible, to 
make an oral report to the DEA Divisional Office in advance of the 
transaction, followed by a written report. The new Sec.  1310.05(b)(2) 
in the final rule, makes the oral reporting mandatory and mandates the 
electronic filing of the written report. Additionally, the new Sec.  
1310.05(b)(2) requires regulated persons to orally report domestic 
regulated transactions in a tableting machine or an encapsulating 
machine when an order is placed rather than at the earliest practicable 
opportunity after the regulated person becomes aware of the 
circumstances involved. The written report (DEA Form 452) is required 
to be filed within 15 calendar days after the order has been shipped by 
the seller.
    Import/Export Transactions: The DEA is requiring that the DEA Form 
452 be submitted to the DEA through the DEA Diversion Control Division 
secure network application 15 calendar days before the anticipated date 
of arrival at the port of entry or port of export. Under this final 
rule, an importer or exporter may not initiate an import or export 
transaction involving a tableting machine or encapsulating machine 
until the regulated person has been issued a transaction identification 
number from the Administration. The importer or exporter may proceed 
with the import or export of the machine(s) as soon as the transaction 
identification number has been issued. These changes are in Sec.  
1310.05(c). Additionally, the DEA revised Sec.  1310.06(e)(1)(v) so 
that reports of importation of tableting or encapsulating machines 
include the reason for the importation, i.e., medical, commercial, 
scientific, or other legitimate use of the machine.
    The DEA also added paragraph (c)(2) to Sec.  1310.05 to require 
import shipments of tableting machines or encapsulating machines that 
have been denied release by customs to be reported to the 
Administration, through the DEA Diversion Control Division secure 
network application, within 5 business days of denial. If an importer 
subsequently receives notice from a customs officer that their shipment 
will be released into the United States, the importer is required to 
file an amended DEA Form 452 with the DEA before the shipment may be 
released. In such circumstances, the regulated person may seek to have 
the tableting machines or encapsulating machines released by customs 
upon receipt of a transaction identification number for the refiled and 
amended DEA Form 452 without regard to the 15-day advance filing 
requirement.
    The DEA is requiring electronic filing of return information, 
specifying the particulars of the transaction, for tableting and 
encapsulating machines imported or exported within 30 calendar days 
after actual receipt of a tableting or encapsulating machine, or within 
10 calendar days after receipt of a written request by the 
Administration to the importer, whichever is sooner. Return information 
requirements are incorporated into a new paragraph (h) in Sec.  1310.06 
and requires the filing of the report with the Administration (on DEA 
Form 452) utilizing the DEA Diversion Control Division secure network 
application.
7. Mail Order Reporting for Ephedrine, Pseudoephedrine, 
Phenylpropanolamine, and Gamma-Hydroxybutyric Acid
    The DEA is incorporating mandatory electronic reporting 
requirements into part 1310 for monthly reports of mail-order 
transactions involving ephedrine, pseudoephedrine, phenylpropanolamine, 
and gamma-hydroxybutyric acid (including drug products containing these 
chemicals or controlled substance) required to be filed in accordance 
with Sec.  1310.03(c) pursuant to 21 U.S.C. 830(b)(3). To standardize 
and streamline the electronic filing requirements of these monthly 
mail-order reports, the DEA is implementing usage of a new form, DEA 
Form 453. The new form will be accessed, completed, and submitted by 
regulated persons entirely through the DEA Diversion Control Division 
secure network application. 21 CFR 1310.03(c) is further revised to 
reflect that reports would not be deemed filed until the Administration 
issues a transaction identification number unless they are complete 
upon submission. This change is designed to ensure that electronically 
submitted reports are indeed received by the DEA, are complete, and can 
be appropriately tracked and monitored; to streamline the report filing 
process; and to eliminate potential duplicate filings. The previous 
Sec.  1310.06(i), redesignated in this final rule as Sec.  1310.06(k), 
is revised to reflect that the monthly mail-order information is 
required to be submitted to the DEA on Form 453. 21 CFR 1310.03(c) is 
further revised by separately listing the requirement for monthly 
reports to be submitted by regulated persons who engage in the 
specified domestic mail-order transactions and export transactions. 
This revision also more plainly lays out the requirement that the 
regulated person must be engaged in a transaction with one of the 
specified chemicals or controlled substance and use or attempt to use 
the U.S. Postal Service or any private or commercial carrier for both 
activities in order to be required to file the monthly report. This 
revision is not intended to impose any different requirements than the 
current regulation, but only to ease understanding of the reporting

[[Page 97000]]

requirements. 21 CFR 1310.05(e) would correspondingly be amended to 
reflect the implementation of the mandatory electronic filing 
requirement.
    The DEA is also technically amending Sec.  1310.05(d) to revise the 
mailing information in the second sentence and to replace the term 
``shall'' in three locations without changing the requirements.
8. Transshipments of Controlled Substances
    Applications for transshipment permits are still allowed to be 
submitted to the DEA via paper in accordance with the existing 
procedures under Sec.  1312.31 for schedule I controlled substances. 
Information will be posted to the DEA Diversion Control Division Web 
site informing persons seeking to transship schedule I controlled 
substances on how to submit an application for a transshipment permit. 
Advance notification of transshipments for schedule II, III, and IV 
controlled substances would also still be allowed to be submitted to 
the DEA via paper in accordance with the current Sec.  1312.32. The 
electronic application and filing process is not feasible in such 
circumstances because foreign IP addresses are blocked by the 
Department of Justice's firewall and are prevented from accessing the 
DEA Diversion Control Division secure network application. Although the 
transshippers themselves would not have direct access to the 
instructions on the DEA Web site due to the firewall protection, it is 
the DEA's understanding that most transshippers have someone in the 
United States as a domestic presence facilitating the transaction who 
will be able to access the instructions. There is no change from the 
current operational system. The DEA is explicitly stating in Sec. Sec.  
1312.31 and 1312.32 that a separate filing is required for each 
shipment, conforming the requirements of this section with the 
requirements for imports and exports of controlled substances in part 
1312.
9. Transshipment of Listed Chemicals
    Advance notification is still allowed to be submitted to the DEA 
via paper in accordance with the existing procedures under Sec.  
1313.31 for persons seeking to import a listed chemical that meets or 
exceeds the threshold reporting requirements into the United States for 
transshipment. Advance notification is also still allowed to be 
submitted to the DEA via paper in accordance with the existing 
procedures under Sec.  1313.31 for persons seeking to transfer, or 
transship listed chemicals within the United States for immediate 
exportation. The electronic application and filing process is not 
feasible in such circumstances because foreign IP addresses are blocked 
by the Department of Justice's firewall and are prevented from 
accessing the secure network application on the DEA Diversion Control 
Division Web site. While a broker or trader for an international 
transaction might be able to electronically submit the required 
information from a domestic IP address, for consistency and fairness 
across all transshipment activities, the DEA is allowing paper 
applications and notices to continue for all transshipment 
transactions. Although the transshippers themselves would not have 
direct access to the instructions on the DEA Web site due to the 
firewall protection, it is the DEA's understanding that most 
transshippers have someone in the United States as a domestic presence 
facilitating the transaction who will be able to access the 
instructions. There is no change from the current operational system.

D. List of Changes in the Final Rule

    This section discusses the minor changes implemented by this final 
rule that were not discussed in the NPRM. The minor changes include, 
among others, correcting minor typographical errors and updating 
citation listings and internal organizational changes within the DEA.
    The effective date of this final rule remains 30 days from the date 
of publication. However, the compliance date was extended to 180 days 
after the publication of the final rule for all transactions, not only 
for tableting and encapsulating machines.
    The DEA has eliminated the definitions of shipment and split 
shipment that were proposed in the NPRM. Because of the elimination of 
these definitions, the DEA has amended Sec. Sec.  1312.13(e) and 
1312.23(e) in a manner that is different than proposed. The language 
added to this section emphasizes that a shipment of controlled 
substances is limited to a single transaction between a single importer 
or exporter and a single consignee on a single loading document, but 
also that the shipment must occur on a single conveyance as opposed to 
multiple conveyances. In addition, the language will coincide with 
current policy by prohibiting a load of goods from being divided into 
multiple parts to be placed onto more than one conveyance, even if the 
goods are on the same loading document. A single permit could not be 
used for this situation above.
    In Sec. Sec.  1310.05, 1312.12, 1312.18, 1312.22, 1312.27, 1313.17, 
and 1313.27, the 24-hour reporting requirement to the DEA for the 
denial of imported/exported controlled substances, listed chemicals, 
tableting or encapsulating machines, has been changed to five business 
days.
    In revised Sec. Sec.  1312.22(d)(1), 1312.31(d)(4), and 1312.32(b), 
the phrase ``and the attestation has been notarized'' has been deleted.

II. Discussion of Comments

    The DEA received 12 comments on the NPRM. Eleven commenters 
generally supported this rule while also raising issues of concern and 
one commenter expressed opposition to the NPRM. Three comments were not 
posted due to the entire comment containing confidential business 
information; one comment was not posted because it was unrelated to the 
NPRM; thus, only eight comments were posted. All of the relevant 
comments are summarized below, along with the DEA's responses.

A. Electronic Applications and Filings, Generally (5 Issues)

    [1] Comment: Two commenters asked for clarification regarding the 
signature requirement applicable to declarations and applications 
submitted via the DEA Diversion Control Division secure network 
application.
    Response: The user will login to the DEA Diversion Control Division 
secure network application using the user name and password. Upon 
completion of any of the forms associated with this rule, the user must 
submit the form by acknowledging the information on the form is 
complete and accurate. The acknowledgement serves as a signature. The 
DEA believes the use of electronic forms will eliminate the need for 
manual signatures and result in an overall reduction in burden. In 
addition, this rule does not alter the signature requirements for other 
documents; the definitions of ``digital signature'' and ``electronic 
signature'' (as defined in Sec.  1300.03), and the requirements for 
signatures associated with electronic orders and electronic 
prescriptions (as found in part 1311) remain unchanged.
    [2] Comment: Three commenters suggested that the DEA should provide 
for the continued availability and use of paper forms and hard copy 
reporting for imports and exports. Two commenters stated that other DEA 
systems such as CSOS and ARCOS have similar provisions, and in the 
event that the DEA's electronic system was unavailable for any reason, 
an alternate method of applying for and approving imports and exports 
is needed as a

[[Page 97001]]

contingency. However, the commenter stated that the DEA needs to have a 
stable electronic declaration system with no programming issues, 
because if a glitch in the system occurs, this could result in delayed 
shipments and significant cost for industry. The commenter stated that 
it was essential for importers and exporters to continue to have the 
paper option for more time to correct any information derived from 
other databases that may be inaccurate. The commenters also requested 
that CBP provide additional guidance on how and by whom the electronic 
[CBP] certifications should be submitted, in order to ensure that 
companies are able to meet all of the DEA legal requirements.
    Response: Upon review of results from the ITDS Pilot Program, the 
DEA is extending the compliance date of the final rule to 180 days 
after publication for all provisions contained in the rule.\8\ The ITDS 
Pilot Program (discussed above and in the General Notice at 81 FR 
46058, July 15, 2016) has been underway since August 2016. Although no 
system failures or processing errors occurred during the ITDS Pilot 
Program, the DEA believes that more electronic transactions will 
provide a better test of the secure network application. The DEA 
anticipates that, during the extended compliance period, registrants 
and regulated persons will utilize both the secure network application 
and the current paper-based system. This will allow DEA to continue to 
test the integrity of the secure network application and enable DEA to 
correct any systemic issues while also ensuring an alternate method to 
conduct business is available so that trade is not impeded.
---------------------------------------------------------------------------

    \8\ The final rule will be effective 30 days after publication 
in the Federal Register so registrants and regulated persons may opt 
to either submit forms and report information electronically via the 
secure network application in anticipation of the mandatory 
compliance date, or registrants and regulated persons may continue 
with paper submissions until the mandatory compliance date. This 
will not affect DEA's ability to continue to submit data to the 
ITDS/ACE.
---------------------------------------------------------------------------

    In response to the request that CBP provide additional guidance on 
how the electronic certifications should be submitted and by whom, the 
DEA recommends reviewing the ITDS implementation guidelines on CBP's 
Web site, https://www.cbp.gov/document/guidance/dea-implementation-guide-ace.
    [3] Comment: Three commenters stated that currently, the only way 
to submit a Declaration/Application for import/export from an 
analytical laboratory registrant is by sending a hard copy to the DEA, 
and that the DEA Diversion Control Division secure network application 
does not support imports/exports from analytical laboratory 
registrants. The commenter noted that, since an analytical laboratory 
is not required to register drug codes on the registration, the drop 
down list on the secure network application would need to be extensive 
or a free text box would need to be added. In addition, because there 
are many drug impurity reference standards that are imported/exported, 
the commenter suggested that the continued use of a paper-based system 
for imports/exports from analytical laboratory registrants is necessary 
until a free text box is added to the secure network application.
    Response: As discussed, the DEA is extending the compliance date of 
the final rule to 180 days after publication for all provisions 
contained in the rule. The ITDS Pilot Program (as discussed and in the 
General Notice at 81 FR 46058, July 15, 2016) has been underway since 
August 2016. Although no system failures or processing errors occurred 
during the ITDS Pilot Program, the DEA believes an extended compliance 
date will enable more electronic transactions to test the integrity of 
the secure network application and ensure DEA can address any systemic 
issues before mandatory compliance. However, with the implementation of 
ITDS, the DEA Diversion Control Division secure network application 
will enable analytical laboratory registrants to provide all of the 
required information electronically. Any registrant, including 
analytical laboratories, unable to complete the necessary import/export 
forms for any reason may contact Diversion Control Division's 
Regulatory Section at 202-307-7194 or [email protected]. Unforeseen 
issues that prevent any registrant from completing the necessary 
import/export forms will be resolved on a case-by-case basis.
    [4] Comment: Two commenters expressed concern that requiring 
registrants to report the date that the product was released by a 
customs official as well as the amount released by a customs official 
is repetitive since the Automated Commercial Environment (ACE) systems 
will include this information. The commenters requested that the DEA 
remove this requirement from the proposed rule. In support of their 
request, the commenters stated that it would be difficult for the 
registrant to obtain this information since these activities are 
handled by their brokers, and the registrant does not have access to 
the ACE system. The commenters went on to say that traditionally, the 
registrant reports when the substances leave their facility as this is 
the only date the registrant has direct knowledge of.
    Response: The DEA appreciates the commenter's concerns. The DEA 
believes the release date is available. Some importers/exporters may 
need to obtain this information from their brokers. To remove the 
ambiguity created from the ``date of import,'' the DEA chose the date 
of release by a customs officer. In addition, the DEA is requiring the 
date the shipment arrives (for imports) or leaves (for exports) the 
registered location or place of business. These two dates provide the 
proper accountability of the amounts of controlled substances or listed 
chemicals.
    [5] Comment: One commenter expressed concern about the protection 
of data submitted electronically. The commenter supported the use of 
electronic submissions to streamline customs procedures, and requested 
additional information regarding how electronically submitted 
confidential business information would be protected, especially in 
light of the significant security and competitive business interests at 
stake regarding the data contained in such transmissions. The commenter 
stated that it was essential that CBP take adequate measures to secure 
and protect this data from public access and release, and suggested 
that CBP implement training and certification procedures for employees 
with access to such information.
    Response: The DEA cannot respond to questions regarding CBPs 
information system security practices. All questions regarding CBPs 
information system security practices should be directed to CBP.

B. Import and Export Permits for Controlled Substances (5 Issues)

    [1] Comment: One commenter requested that the DEA eliminate the 
proposed requirement that a translation be notarized when a translation 
of a foreign government-issued import license or Permit is necessary, 
because the wording in the current DEA regulations is sufficient. The 
commenter stated that the requirement that any such translation be 
notarized is not necessary, because it would place an additional burden 
on exporters without a commensurate benefit.
    Response: The DEA proposed that translations be notarized in order 
to ensure that translations are complete and accurate. However, the DEA 
has reviewed this comment and after further consideration has removed 
the

[[Page 97002]]

requirement for a notarized translation in Sec. Sec.  1312.22, 1312.31, 
and 1312.32. The DEA is retaining the requirement that the translator 
certify the translation. For the purposes of this requirement, 
certified translation means that the translator has signed the 
translation legally attesting to the accuracy of the translation. The 
regulatory text in Sec. Sec.  1312.22(d)(1), 1312.31(d)(4), and 
1312.32(b) have been modified to reflect this change.
    [2] Comment: One commenter asked for clarification about what is 
meant by ``serial number'' and how this information would be used to 
identify the foreign consignee. The commenter also wanted to know what 
to do if no such designation is present on the current packaging. 
Finally, the commenter wanted to know what the definition of 
``narcotic'' was in this context.
    Response: The DEA proposed to modify Sec.  1312.26 because it 
required exporters to keep Copy 3 of the export permit along with ``any 
serial numbers that might appear on packages of narcotic drugs in 
quantities of one ounce or more in such a manner as will identify the 
foreign consignee.'' As discussed in the NPRM, with the implementation 
of ITDS, Copy 3 is obsolete and with this final rule, exporters will be 
required to keep an ``official record of the export permit,'' rather 
than Copy 3, with any such serial numbers. As the NPRM did not propose 
or discuss any other modifications to Sec.  1312.26, the comment will 
be considered as a basis for potential modifications in the future.
    [3] Comment: Two commenters sought further modification of the pre-
NPRM and pre-final rule regulation at Sec.  1312.22(d)(7) (implemented 
as Sec.  1312.22(h)(6) by this final rule) which requires that a 
controlled substance ``will be exported from the first country to the 
second country (or second countries) no later than 180 days after the 
controlled substance was exported from the United States.'' As these 
commenters noted, this 180-day requirement was established by the DEA 
in the 2007 regulation implementing the Controlled Substance Export 
Reform Act of 2005 (CSERA), but was not imposed by the CSERA itself. 
Noting that the 2015 Act contains a provision (21 U.S.C. 953(g)(1)) 
that eliminates the 180-day requirement for reexports within the EEA, 
some commenters requested that the DEA remove this requirement for all 
markets (not just the EEA countries) as they view it as an unnecessary 
hindrance. One commenter requested that the DEA increase the 180-day 
requirement to 365 days for reexports outside of the EEA.
    Response: This category of comments is outside the scope of the 
NPRM. As indicated above, the 180-day requirement was implemented in a 
rulemaking that concluded in 2007 (72 FR 72921, December 26, 2007), and 
this requirement was not issued for public comment in the NPRM. For the 
reasons stated above and in the NPRM, consistent with the 2015 Act, the 
DEA eliminated the 180-day requirement for reexports within the EEA. 
However, the 2015 Act left intact the reexport requirements for 
reexports outside of the EEA and, accordingly, the NPRM did not reopen 
for public comment the regulatory requirements for reexports outside 
the EEA. Rather, with regard to reexports, the NPRM only sought 
comments on the new regulations that were necessitated by the 2015 
Act.\9\ While the 180-day requirement for reexports outside the EEA is 
therefore outside the scope of the NPRM, DEA continues to believe that 
the justification for the requirement set forth in the 2006 proposed 
rule (71 FR 61436, October 18, 2006) and 2007 final rule remains valid.
---------------------------------------------------------------------------

    \9\ For formatting purposes, the NPRM renumbered certain 
regulations relating to reexports outside the EEA, and thus the text 
of such regulations was included in the proposed rule section of the 
NPRM. However, the substance of such regulations was not altered 
from that promulgated in the 2007 final rule.
---------------------------------------------------------------------------

    [4] Comment: One commenter asked for clarification in reference to 
adding a reexport market to the list of countries on the Export 
Declaration after the initial U.S. Export.
    Response: All countries that are parties to any of the Conventions 
referred to in 21 U.S.C. 953(f)(1) will be included in the list of 
countries when completing forms 161R and 161R-EEA. Countries that are 
not parties to any of the Conventions will not be included as, 
consistent with the statute, reexport permits would not be granted for 
shipments to those countries.
    [5] Comment: One commenter commented on the DEA's proposed 
definition of shipment. This commenter stated that the definition of 
shipment conflicts with how it is used in the DEA's regulations. First, 
the commenter reasoned that because the definition of shipment is 
placed in Sec. Sec.  1300.01 and 1300.02 then this definition will 
apply to all parts of the DEA's regulations. Second, this commenter 
noted that the definition of shipment applies only to goods that are 
imported or exported. By defining shipment in this manner, the 
commenter reasoned that the term shipment can no longer be used in 
reference to domestic transactions involving controlled substances and 
listed chemicals. In addition, the commenter stated that shipment as 
defined conflicts with the definition of international transaction as 
set forth in 21 U.S.C. 802(42). International transaction is defined in 
part as, ``a transaction involving the shipment of listed chemicals 
across an international border (other than a United States Border) * * 
*.'' As such, this commenter noted that the CSA contemplates shipments 
that are not imports into the United States or exporters from the 
United States.
    Response: The DEA appreciates this comment. Based on this comment 
the DEA has decided to modify the regulation text in a way that is 
different than what was proposed. To remove the possibility of having 
the definition of shipment apply to all of DEA's regulations, the DEA 
is removing the definition of shipment from the definition sections of 
Sec. Sec.  1300.01 and 1300.02. In addition, the DEA is removing the 
definition of split shipment from the same sections. The DEA has 
modified the text of Sec. Sec.  1312.13(e) and 1312.23(e) relating to 
the issuance of import and export permits. The language added in these 
sections allows for the same intended effect as the proposed language 
while eliminating the possibility of having the definition of shipment 
apply to all DEA regulations. Therefore, the introduction of this 
language will emphasize that a shipment of controlled substances is 
limited to a single transaction between a single importer or exporter 
and a single consignee on a single loading document, but also that the 
shipment must occur on a single conveyance (e.g., one plane, one ship, 
or one freight train--but not each rail car), as opposed to multiple 
conveyances (e.g., two planes, two ships, two freight trains, or any 
combination thereof). In addition, the language will coincide with 
current policy by prohibiting a load of goods from being divided into 
multiple parts to be placed onto more than one conveyance, even if the 
goods are on the same loading document. A single permit could not be 
used for this situation above.

C. Import and Export Declarations for Controlled Substances (1 Issue)

    [1] Comment: One commenter requested that the DEA clarify whether 
an import or export declaration is effective immediately upon 
assignment of a Transaction Identification Number by the DEA so that 
the importer or exporter does not need to wait the full 15 days. The 
commenter also asked for additional clarification to make clear

[[Page 97003]]

that if the DEA has not issued a Transaction Identification Number 
within 15 days of submission of the declaration, the import or export 
can be shipped, as is currently allowed. The commenter stated that if 
this was not the case then importers or exporters could have to wait 
much longer than 15 days for DEA to issue the Transaction 
Identification Number, which would be a significant change from current 
practice.
    Response: Controlled substances may be imported or exported as soon 
as a Transaction Identification Number (TIN) is issued. The DEA works 
expeditiously to confirm the accuracy of the declarations and will 
issue a TIN as soon as possible. When the TIN is issued for a 
controlled substances declaration in less than 15 days the importers 
and exporters may immediately request release by a customs official and 
do not need to wait for the expiration of the 15 days. Any delay in 
issuing a TIN is generally due to incomplete or inaccurate information 
on the declaration form and the submitters delay in providing complete 
and correct information. The declaration is deemed submitted when a TIN 
is issued; therefore, in the rare instances where 15 days have elapsed 
without the issuance of a TIN, the importer or exporter must wait for 
the TIN and may not request release by a customs official. As a 
practical matter, in the new ITDS/ACE system the customs official will 
not release a shipment without DEA's transmission of the TIN (among 
other data) to CBP.

D. Import and Export Declarations and Notices for Listed Chemicals (13 
Issues)

    [1] Comment: One commenter was concerned with the proposal to 
require electronic filing of the DEA Form 486 via the Diversion Control 
Division secure network application. The commenter was concerned 
whether steps have or will be taken to reduce confusion or delays in 
releasing an import or export declaration that may be associated with 
multiple electronic DEA Form 486s but only a single invoice. In 
addition, the commenter wanted clarification on whether the DEA had 
consulted with foreign competent national authorities regarding the 
impact of requiring the processing of multiple electronic DEA Form 486s 
relating to the same order, in light of the fact that foreign competent 
authority applications are not limited to a specific number of lines 
for a particular order or license application.
    Response: The DEA appreciates the commenter's concerns. The 
concerns raised by the commenter are beyond the scope of this 
rulemaking and will not be addressed. However the DEA does not take 
issue with the use of multiple Form 486s.
    [2] Comment: One commenter requested clarification on the differing 
requirements for an import or export transaction to proceed upon 
receipt of the TIN. The commenter wanted to know if the DEA intended 
for exporters to request release from customs immediately after 
issuance of the TIN as explicitly stated for importers.
    Response: The DEA intends to treat importers and exporters the same 
in regards to the import or export transaction proceeding upon receipt 
of the TIN. However, allowing listed chemicals to ship before the 15-
day notification requirement would be in conflict with 21 U.S.C. 
971(a). Referring to import declarations, Sec.  1313.12(b) states that 
listed chemicals that meet or exceed threshold quantities identified in 
Sec.  1310.04(f), or which do have an established threshold, may not be 
imported until a transaction identification number (TIN) has been 
issued, and the Administrator shall be notified of the importation of 
the listed chemical not later than 15 days before it takes place. 
Referring to export declarations, Sec.  1313.21(b) states that 
exporters may not request that the listed chemical be released until a 
transaction identification number (TIN) has been issued. The 
Administrator shall be notified of the importation of the listed 
chemical not later than 15 days before it takes place. Therefore prior 
to export or import a TIN has to be issued and importers and exporters 
have to wait the 15-day period.
    [3] Comment: Four commenters recommended that the DEA establish a 
regulatory timeframe by which the agency will issue transaction 
identification numbers to allow for business certainty. One commenter 
recommended an initial deadline of three business days for the DEA to 
review a transaction and issue the transaction identification number. 
The commenters expressed a concerned about business decisions and 
timing. They stated that the lack of a definite deadline to issue the 
transaction identification number will cause delayed or canceled 
shipments and lost revenues.
    Response: The DEA understands the commenters' sensitivity to time 
and potential for competitive advantage/disadvantage based on timely 
shipment of products. However, the DEA declines to set a specific 
timeframe for the issuance of a TIN. The DEA works expeditiously to 
confirm the accuracy of the declarations and will issue a TIN as soon 
as possible. Any delay in issuing a TIN is generally due to incomplete 
or inaccurate information on the declaration form and the submitters' 
delay in providing complete and correct information.
    [4] Comment: Two commenters requested that the DEA clarify the 
discrepancy between whether the timeframe is three calendar days or 
three business days advance notification before the date of release by 
customs officers at the port of entry. One commenter suggested that 
since the time period is so small, the DEA should use its proposed text 
to require three business days to allow sufficient time for businesses 
to react to the unexpected delays or unexpected promptness of 
shipments. The commenter recommends that the DEA add appropriate 
language within the text of the rule clarifying its statement in the 
preamble that registrants can proceed with the import or export 
transaction as soon as the transaction identification number has been 
issued regardless of whether the three days have passed.
    Response: The DEA appreciates the opportunity to correct any 
errors. After reviewing the language in the preamble the DEA, in two 
instances, erroneously stated 3 ``calendar'' days, rather than 
``business'' days. The DEA has corrected the language in the preamble. 
The term three ``business'' days is also discussed repeatedly in the 
preamble and clearly stated in the regulatory text. However, importers 
and exporters may proceed with the transaction as soon as the TIN is 
issued regardless of whether the three days have elapsed. The 
regulatory text has been updated to clarify this requirement.
    [5] Comment: One commenter requested that the DEA issue waivers/
exemptions with respect to the proposed revisions in Sec. Sec.  
1313.12, 1313.14, and 1313.17. These proposed revisions would require 
that all imported shipments first go to the registered location before 
being subsequently shipped to the final destination (referred to within 
the industry as ``drop shipment''). The commenter cited potential 
shipping risks and the substantial economic hardships small U.S. 
businesses would face in the competitive world market as a result of 
the proposed revisions. The commenter also expressed concern about the 
fact that the proposed revision to Sec.  1313.14, did not specify 
whether it applied to List I or List II chemicals or both.
    Response: The DEA appreciates the commenter's concerns. The 
proposed revision to Sec.  1313.14 still applies to List I chemicals. 
``Drop shipments'' have

[[Page 97004]]

always been permitted for List II chemicals, and this rulemaking will 
not change that. However with respect to List I chemicals, page 63598 
of the published NPRM stated,

The final destination for an import of a list I chemical must be the 
registered location of the registered importer. The import must be 
received at the registered address of the importer before being 
moved to another location of the importer or delivered to a 
customer. The receipt of imported goods is a principal activity of 
registered list I chemical importers. Pursuant to 21 U.S.C. 958(h), 
a separate registration is required at each principal place of 
business where applicants import or export list I chemicals. 
Accordingly, the final destination of a shipment of an imported list 
I chemical is the registered location of the registrant. Drop 
shipments, i.e., deliveries made by an importer directly to a 
customer without passing through the registered location of the 
importer, are explicitly prohibited under the proposed revisions to 
Sec.  [thinsp]1313.14.

    [6] Comment: Five commenters suggested that the DEA allow listed 
chemicals to be relieved of the 15-day waiting period as allowed for 
controlled substances. The commenters stated that the DEA did not 
explain the reasoning behind this decision, and that it was 
inconsistent with other DEA regulations that treat controlled 
substances with stronger regulation than listed chemicals. The 
commenters recommended that the DEA modify the proposed rule to state 
that listed chemicals can also proceed with the import or export 
transaction as soon as the transaction identification number has been 
issued, regardless of whether the 15 calendar days have elapsed since 
its issuance
    Response: After careful consideration, the DEA has decided not to 
allow the shipment to proceed when the TIN is issued. As stated above 
prior to export or import a TIN has to be issued and importers and 
exporters have to wait the 15-day period.
    [7] Comment: One commenter stated that the proposed amendments to 
Sec. Sec.  1313.12(d) and 1313.21(d) to require an import or export 
declaration on DEA Form 486 or 486A at least three business day before 
the date of release by a customs officer exceeds the statutory 
authority granted to DEA under 21 U.S.C. 971(b). The commenter stated 
that the previous versions of Sec. Sec.  1313.12(d) and 1313.21(d) are 
consistent with the statutory limit on the timing of the waiver for 
transactions involving regular importers and regular customers.
    Response: The DEA appreciates this comment. However, the DEA 
continues to believe that this modification is within its statutory 
authority pursuant to 21 U.S.C. 971. As stated in the NPRM it is 
necessary for DEA to provide customs officers with the necessary 
information first so that the customs officers can then clear a 
shipment of relevant listed chemicals. Because of this, the DEA 
determined that three business days is needed to review all pertinent 
information relating to the shipment and transmit the data accurately 
to the ITDS. As a result, the waiver of the entire 15 day period can no 
longer be applied in these specific instances.
    As stated in the NPRM accompanying this final rule, 21 U.S.C. 
971(b) provides the DEA with authority to waive the 15 day requirement, 
by regulation, for imports of listed chemicals by regular importers and 
exports of listed chemicals between regulated persons and regular 
customers. The DEA is exercising this authority in the final rule. The 
DEA does acknowledge that 21 U.S.C. 971(b)(1) requires regulated 
persons subject to waivers to notify the DEA of the transaction ``at 
the time of any importation or exportation.'' To maintain the effect of 
this provision the DEA is allowing registrants to proceed with the 
import and export transaction as soon as the transaction identification 
number is issued, regardless of whether the three-calendar day period 
has concluded. In addition, the DEA considers the notification provided 
to the DEA by the customs officers at the time of release to meet the 
requirements of 21 U.S.C. 971(b)(1). With these two allowances the DEA 
believes that it is meeting the statutory requirements and is setting 
forth reasonable requirements.
    [8] Comment: One commenter stated that the wording used in revised 
Sec. Sec.  1313.12(d) and 1313.21(d) is ambiguous. The commenter noted 
that the ``name and description'' of a listed chemical may not appear 
on the product label, and that DEA labeling requirements apply to 
controlled substances and not listed chemicals. The commenter suggested 
that the phrase ``name and description of each listed chemical'' would 
be better phrased as ``trade name of the listed chemical or mixture 
containing one or more listed chemical.'' The commenter argues that 
this wording would be consistent with Sec.  1310.13, which requires an 
applicant for exemption from registration to provide the DEA with the 
trade name(s) of it chemical mixture(s).
    Response: Under the DEA labeling requirements, the ``name and 
description'' of a listed chemical does not necessarily mean the trade 
name. The DEA is looking to determine what the listed chemical is. 
Therefore the trade name is not the only description that can be used.
    [9] Comment: One commenter suggested an amendment to the DEA Form 
Data. The commenter stated that the current wording could require that 
any waiting period in the consignee country be completed before 
beginning any waiting period in the United States. The commenter stated 
that variations in national requirements may result in situations where 
the consignee is not required to have a permit; this would accommodate 
situations in which the competent national authority of a consignee may 
require documentation of a bona fide intent to import prior to issuing 
a permit; finally this would expedite shipments by allowing concurrent 
waiting periods in both countries.
    Response: The registrant would still be required to abide by the 
laws of the country of import.
    [10] Comment: Two commenters expressed concern over the proposed 
amendment to the language in Sec. Sec.  1313.17 and 1313.27 to require 
an importer or exporter to notify the DEA within 24 hours of the denial 
of the release of an import or export of listed chemicals. The 
commenters asked that the DEA remove the 24-hour period, because the 
need for the shortened time frame was not apparent, and cited instances 
where it might been unworkable because the consignor and customs agents 
are working different schedules, the denial occurs late Friday or over 
the weekend, or the business office is closed for 24 or more hours 
during which customs may have denied the release.
    Response: Thank you for your comment. Two commenters expressed 
similar concerns, and the DEA has decided to change the 24-hour 
reporting requirement to a 5-business-day reporting requirement. The 
DEA believes that this will give registrants enough time to notify the 
DEA and work with Customs to secure a release. See regulation text 
changes in Sec. Sec.  1310.05, 1312.12, 1312.18, 1312.22, 1312.27, 
1313.17, and 1313.27.
    [11] Comment: In proposed 21 CFR 1310.05(b)(1), the DEA added 
several factors that regulated persons may consider when determining 
whether a loss or disappearance of a listed chemical was unusual or 
excessive. One commenter stated that they are not certain the added 
language provides clarity to persons that handle listed chemicals or 
the DEA field staff. Specifically, the commenter suggested that the 
determination of whether a loss or disappearance of a listed chemical 
is unusual or excessive is fact specific and

[[Page 97005]]

could vary even within a specific entity. Against this backdrop the 
commenter suggested that the DEA remove these factors from 21 CFR 
1310.05(b)(1). The commenter also suggested that the inclusion of these 
factors, while being similar to those factors in 21 CFR 1301.74(c), 
might cause DEA field staff to consider these factors mandatory.
    In the alternative to removing the factors from the regulatory 
text, this same commenter submitted two suggestions. The commenter 
suggested that listed chemical handlers should consider these factors 
only if the factors help the handler determine whether a loss is 
unusual or excessive. In addition, the commenter suggested that the 
factors should only be applied as to the specific facts surrounding the 
loss or disappearance.
    Lastly, this commenter requested that the DEA discuss its reasoning 
for using slightly different factors than the agency uses in 21 CFR 
1301.74(c) and to discuss the impact to regulated persons based on this 
change, including the interpretation.
    Response: The DEA appreciates this comment. As noted in the text of 
21 CFR 1310.05(b)(1) the consideration of these factors is not 
mandatory. The DEA states that regulated persons should consider, among 
others, the factors enumerated. The DEA recognizes that each business 
entity is unique and has different business practices. As a result, by 
enumerating these factors the DEA is providing factors that may assist 
the regulated person. The DEA recognizes and recommends that each 
regulated person will tailor their system to detect unusual or 
excessive loss or disappearance of listed chemicals to meet their 
specific business model. As a result, if the regulated person's 
business practice allows for the consideration of these factors then 
the DEA would expect the regulated person to consider the factors in 
determining if the loss or disappearance of a listed chemical is 
excessive or unusual. The language used by the DEA in Sec.  
1310.05(b)(1) allows for this flexibility. Furthermore, the DEA does 
not believe that the inclusion of these factors will cause DEA field 
staff to consider these factors mandatory. It should be noted that the 
factors used in Sec.  1301.74(c) are not mandatory. Based on the above 
reasoning the DEA does not think it is prudent to amend the language in 
Sec.  1310.05(b)(1).
    [12] Comment: One commenter stated that the DEA's Combat 
Methamphetamine Epidemic Act (CMEA) provided that listed chemicals 
could only be imported if a valid customer order was in place. The 
commenter stated that although they had been abiding by the new 
language, it was challenging and presented an economic disadvantage due 
to the business nature of the chemicals they were handling.
    Response: This comment is outside the scope of this rulemaking, and 
the DEA has no authority to modify the requirements of the CMEA.
    [13] Comment: One commenter asked for electronic IDs for two 
locations--one for the List I Chemical Registered address and one for 
the List II Place of Business. The commenter stated that they had been 
told that all electronic entries are to be under the List I registered 
address electronic ID. The commenter objected to this, stating that the 
regulations and accepted addresses are different for List I and List II 
chemicals. For this reason, the commenter stated that there should be 
two electronic IDs to differentiate List I chemicals from List II 
chemicals, and that this should be addressed in the regulations since 
the DEA was requiring electronic filing of the DEA 486 Forms.
    Response: The DEA allows more than one system account, one for List 
I registered location and one for List II place of business. To resolve 
any issues regarding system account setup or any other questions 
regarding listed chemicals declarations, please contact the Regulatory 
Section at 202-307-7194 or [email protected].

E. Reexportation of Controlled Substances Among Members of the European 
Economic Area (3 Issues)

    [1] Comment: Several commenters expressed the view that DEA should 
strike the proposed regulatory text (Sec.  1312.22(g)(2)) that requires 
persons who reexport within the EEA to report to DEA, within 30 days 
after each reexportion, information concerning the consignee, country, 
and product that was reexported. According to these commenters, this 
requirement is difficult, if not impossible, for them to comply with 
because, according to the commenters, they are unable to track the 
controlled substances once they are transferred to another owner. As to 
this point, one of the commenters attached a letter from four members 
of Congress, written seven months after the bill was enacted, stating 
that holding the manufacturer responsible for complying with this 
reporting requirement after a product has ``left the manufacturer's 
ownership'' would be contrary to the intent of the 2015 Act. In 
addition, commenters assert that the requirement is unnecessary from a 
diversion control standpoint and that it could cause them to lose sales 
to foreign competitors who are not subject to this requirement. As to 
the letter point, some of the commenters assert that the purpose of the 
reexport provisions of the 2015 Act is to encourage U.S. commerce 
abroad and to prevent U.S. drug firms from moving U.S. manufacturing 
jobs overseas. Some of the commenters also contended that their request 
to strike this requirement is supported by the provision of the 2015 
Act (21 U.S.C. 953(g)) that prohibits DEA from issuing any regulation 
``which impedes re-exportation of any controlled substance among [EEA] 
countries.''
    Response: While DEA has considered carefully the concerns of the 
commenters regarding their compliance with the 30-day reporting 
requirement, the law precludes the interpretation offered by these 
commenters that would eliminate this requirement once the controlled 
substances are no longer owned by the exporter. As stated in 21 U.S.C. 
953(f)(6)(B), ``In the case of re-exportation among members of the 
European Economic Area, within 30 days after each re-exportation, the 
person who exported the controlled substance from the United States 
delivers to the Attorney General documentation certifying that such re-
exportation has occurred and information concerning the consignee, 
country, and product.'' (Emphasis added.) The language of this statute 
is clear and there is no mention of ownership being a condition 
precedent to reporting pursuant to 21 U.S.C. 953(f)(6)(B).
    As the United States Supreme Court has repeatedly held, ``If the 
intent of Congress is clear, that is the end of the matter; for the 
court, as well as the agency, must give effect to the unambiguously 
expressed intent of Congress.'' Chevron, U.S.A., Inc. v. Natural 
Resources Defense Council, Inc., 467 U.S. 837, 842-843 (1984). Because 
21 U.S.C. 953(f)(6)(B) unambiguously requires reporting ``within 30 
days after each re-exportation'' within the EEA, and because the 
statute makes no exception to this requirement based on lack of 
ownership, DEA is obligated to incorporate this requirement in its 
regulations.
    With regard to the letter from four members of Congress attached by 
one of the commenters, because this letter was written after the law 
was enacted, it cannot be considered legislative history. But even if 
it were part of the legislative history, Chevron indicates that the 
agency cannot rely on it if is inconsistent with the plain language of 
the statute.

[[Page 97006]]

    The provision of 21 U.S.C. 953(g) prohibiting DEA from promulgating 
any regulation that ``impedes'' reexportation within the EEA does not 
alter this conclusion. Congress could not have meant by this provision 
that DEA cannot enforce a requirement that Congress itself explicitly 
enacted. Rather, the logical interpretation of this clause is that DEA 
cannot impose any additional requirements (beyond those imposed by 
Congress) that would impede reexports within the EEA. As explained in 
the NPRM, DEA has adhered to this requirement by, for example, omitting 
from the EEA reexport regulations the requirement in the 2007 
regulations that bulk substances undergo further manufacturing 
processes in the first country before reexporting to the second 
country.
    [2] Comment: Two commenters requested that the shipping date should 
still be acceptable for reexports reported to the DEA, because customs 
clearance dates are not readily accessible by exporters in the first 
countries. One commenter expressed concern that requiring first country 
customs clearance dates would be burdensome and lead to reporting 
delays. Another commenter stated that for reexports within the EEA, 
subsequent reexports beyond the second country should not be reportable 
to the DEA, because this information serves no purpose for the DEA and 
would be unduly burdensome for U.S. exporters to collect and report.
    Response: As stated earlier, the requirement to report the date of 
release by a customs official remains as proposed. Some importers/
exporters may need to obtain this information from their brokers. To 
remove the ambiguity created from the ``date of import'' and ``date of 
export,'' the DEA chose the date of release by a customs officer. In 
addition, the DEA is requiring the date the shipment arrives (for 
imports) or leaves (for exports) the registered location or place of 
business. These two dates provide the proper accountability of the 
amounts of controlled substances or listed chemicals.
    [3] Comment: One commenter requested that the European Economic 
Area (EEA) should apply to member countries as of November 25, 2015. 
For example, this commenter noted that when the 2015 Act was passed on 
November 25, 2015, the United Kingdom was still a member of the 
European Union. The commenter suggested that it is unclear whether or 
not the United Kingdom's EEA membership will be affected after it 
separates from the European Union. To provide stability in implementing 
the 2015 Act's provisions, the commenter requested that the DEA 
consider, for purposes of the 2015 Act, that the EEA countries include 
those that were members on November 25, 2015.
    Response: The 2015 Act is devoid of any language stating that the 
EEA includes those members as of November 25, 2015. Accordingly, the 
DEA interprets that for the EEA provisions to apply, the country must 
be a member at the time the export leaves the United States.

F. Miscellaneous Comments (2 Issues)

    Two comments were received that were not within the scope of this 
rulemaking, and will not be addressed. Both addressed drug scheduling 
actions that were outside the subject area of this final rule.

III. Section by Section Summary of the Final Rule

A. 21 CFR Part 1300

    For purposes of clarity and transparency, the DEA is updating its 
regulations for consistency of terminology (within DEA regulations, 
between DEA regulations and the CSA, and between DEA regulations and 
the regulations of other agencies that regulate imports and exports), 
to reflect name changes to referenced entities, and to add new 
definitions. These changes involve both technical and substantive 
amendments. Additionally, the DEA is making a technical change to more 
concisely incorporate U.S. obligations under international treaties of 
drug control, as statutorily codified in the CSA.

B. 21 CFR Part 1301

    The DEA is amending Sec. Sec.  1301.24, 1301.26, to denote the 
responsibility of customs services of Insular Areas, and not just CBP, 
to enforce the import and export requirements of the CSA. When 
controlled substances, listed chemicals, and tableting or encapsulating 
machines are imported into, or exported from, a U.S. territory (or 
possession) or an Insular Area of the United States that is not part of 
the customs territory of the United States, these items are cleared by 
the customs service of an Insular Area and not CBP.
    The DEA is also adding the following citations to be directed to 
the DEA Federal Register Representative: Sec.  1301.34(a)--Filing of 
written comments regarding application for importation of Schedule I 
and II substances.
    This topic has been added so that comments corresponding to Federal 
Register publications can be sent directly to the Federal Register 
Representative whose responsibility it is to review comments and make 
them publicly available, as appropriate. The DEA is additionally 
amending this portion of the table to revise the attention line of the 
mailing address for the DEA Federal Register Representative. The 
address will be changed from ``Drug Enforcement Administration, Attn: 
Federal Register Representative/DRL, 8701 Morrissette Drive, 
Springfield, VA 22152'' to ``Drug Enforcement Administration, Attn: 
Federal Register Representative/DRW, 8701 Morrissette Drive, 
Springfield, VA 22152.'' Additionally, this rule adds the Web address 
for the Federal eRulemaking Portal, http://www.regulations.gov, under 
the heading ``DEA Federal Register Representative.'' This Web address 
provides the ability to type short comments directly into the comment 
field on the Web page or to attach a file for lengthier comments. This 
change conforms to the DEA's current practice, referenced in the DEA's 
recent Federal Register publications, which requires that comments 
either be submitted through http://www.regulations.gov or be directed 
to the DEA Federal Register Representative.

C. 21 CFR Part 1302

    Corresponding to the removal of ``jurisdiction of the United 
States'' and the revised definitions of ``export'' and ``import,'' the 
DEA is making a corresponding technical change to Sec.  1302.07 to 
reflect those definitional changes. The sealing requirement would be 
separately stated for imports and exports. This change allows the 
import statement to clearly reflect that the sealing requirement for 
imported controlled substances applies regardless of whether the import 
occurred inside or outside of the customs territory of the United 
States. Separating the import and export requirements also makes clear 
that the distinction between the customs territory and the non-customs 
territory is only applicable to imports and not exports.

D. 21 CFR Part 1303

    Corresponding to recent internal DEA reorganization, the mailing 
addresses for Sec. Sec.  1303.12(b) and (d), 1303.22, 1304.31(a), 
1304.32(a), 1315.22, 1315.32(e) and (g), 1315.34(d), and 1315.36(b), 
regarding quota applications and reporting, will be moved from the DEA 
Drug & Chemical Evaluation Section to the UN Reporting & Quota Section 
under a new corresponding header.

[[Page 97007]]

E. 21 CFR Part 1304

    The DEA is making a technical amendment to Sec.  1304.02 to reflect 
that definitions found in Sec.  1300.02, ``Definitions relating to 
listed chemicals,'' are not applicable to part 1304, that addresses the 
records and reports that are required of controlled substance handlers. 
(21 CFR part 1310 addresses records and reports of listed chemicals and 
certain machines.)
    The DEA is also making a technical amendment to amend Sec.  
1304.21(d) to separately state reporting requirements concerning 
imports and exports of controlled substances. The record date for 
receipt, distribution, other transfer, or destruction will not change. 
The regulation will be amended to state that the record date for 
imports or exports of controlled substances is the anticipated date of 
release by a customs officer for permits and declarations and the date 
on which the controlled substance was released by a customs officer at 
the port of entry or port of export.

F. 21 CFR Part 1308

    The DEA is making two technical updates to part 1308. First, the 
DEA is amending Sec.  1308.01 to denote that part 1308 also includes 
nonnarcotic substances, chemical preparations, veterinary anabolic 
steroid implant products, prescription products, and anabolic steroid 
products excluded pursuant to 21 U.S.C. 811. Second, the DEA is 
amending Sec.  1308.49 to reflect the current requirements of the CSA 
regarding issuance of temporary scheduling orders. 21 U.S.C. 811(h) was 
amended by section 1153 of the Food and Drug Administration Safety and 
Innovation Act of 2012, Public Law 112-144, July 9, 2012, to make 
temporary scheduling orders effective for two years, with an option to 
extend for up to one year during the pendency of proceeding under 21 
U.S.C. 811(a). The CFR was not updated when the law changed. The DEA is 
also realigning the paragraphs of Sec.  1308.49 to properly separate 
the discussion of the circumstances in which a temporary scheduling 
order will be vacated.

G. 21 CFR Part 1309

    The DEA is amending Sec.  1309.32(d) to add ``manufactured'' to the 
list of business activities each application can include for each list 
I chemical. Adding ``manufactured'' would accurately reflect an 
``activity'' that an applicant could conduct with list I chemicals if 
appropriately registered. No change is required to DEA Form 510 because 
``manufacturer'' is already listed as an option.
    The DEA is correcting and updating the cross-reference in Sec.  
1309.46(d) by removing the reference ``Sec.  1309.54'' and replacing it 
with the reference ``Sec.  1309.53.'' Section 1309.46(d) currently 
instructs an applicant to file a request for a hearing pursuant to 
Sec.  1309.54. However, Sec.  1309.54 is entitled ``Burden of Proof,'' 
and therefore is an inaccurate cross-reference.
    The DEA is correcting and updating the cross-reference in Sec.  
1309.51(a) by removing the cross-reference to Sec.  1309.57 and 
replacing it with the cross-reference ``Sec.  1309.55.'' Currently, 
Sec.  1309.57 is a misleading cross-reference since it does not exist 
in title 21, chapter II of the CFR. The ``Hearings'' section in part 
1309 concludes at Sec.  1309.55. The DEA is therefore changing the 
cross-reference in Sec.  1309.51(a) from ``1309.57'' to ``Sec.  
1309.55.'' Finally, the DEA is correcting two minor typographic issues 
in Sec.  1309.71: capitalizing the first word of paragraph (b)(5) and 
adding an ``and'' at the end of paragraph (b)(7).

H. 21 CFR Part 1310

i. Mail Order Reporting for Ephedrine, Pseudoephedrine, 
Phenylpropanolamine, and Gamma-Hydroxybutyric Acid
    The DEA is incorporating mandatory electronic reporting 
requirements into part 1310 for monthly reports of mail-order 
transactions involving ephedrine, pseudoephedrine, phenylpropanolamine, 
and gamma-hydroxybutyric acid (including drug products containing these 
chemicals or controlled substance) required to be filed in accordance 
with Sec.  1310.03(c) pursuant to 21 U.S.C. 830(b)(3). To standardize 
and streamline the electronic filing requirement of these monthly mail-
order reports, the DEA is implementing usage of a new form, DEA Form 
453. The new form is accessed, completed, and submitted by regulated 
persons entirely through the DEA Diversion Control Division secure 
network application. 21 CFR 1310.03(c) is further revised to reflect 
that reports would not be deemed filed until the Administration issues 
a transaction identification number unless they are complete upon 
submission. This change is designed to ensure that electronically 
submitted reports are indeed received by the DEA, are complete, and can 
be appropriately tracked and monitored; to streamline the report filing 
process; and to eliminate potential duplicate filings. The current 
Sec.  1310.06(i) is revised to reflect that the monthly mail-order 
information required to be submitted would now be submitted on the DEA 
Form 453 and is designated as Sec.  1310.06(k). 21 CFR 1310.03(c) is 
further revised by separately listing the requirement for monthly 
reports to be submitted by regulated persons who engage in the 
specified domestic mail-order transactions and export transactions. 
This revision also more plainly lays out the requirement that the 
regulated person must be engaged in a transaction with one of the 
specified chemicals or controlled substance and use or attempt to use 
the U.S. Postal Service or any private or commercial carrier for both 
activities in order to be required to file the monthly report. This 
revision is not intended to impose any different requirements than the 
current regulation, but only to ease understanding of the reporting 
requirements. 21 CFR 1310.05(e) would correspondingly be amended to 
reflect the implementation of the mandatory electronic filing 
requirement.
    The DEA is making a technical amendment to Sec.  1310.05(d) to 
revise the mailing information in the second sentence and to replace 
the term ``shall'' in three locations without changing the substantive 
requirements.
ii. Listed Chemicals and Tableting and Encapsulating Machines
    The DEA is amending Sec.  1310.05 to require reports of unusual or 
excessive loss or disappearance of a listed chemical to be filed 
through the DEA Diversion Control Division secure network application. 
When determining whether a loss is unusual or excessive, the guidelines 
that the regulated person should consider are: (1) The actual quantity 
of a listed chemical; (2) the specific listed chemical involved; (3) 
whether the loss or disappearance of the listed chemical can be 
associated with access to those listed chemical by specific 
individuals, or whether the loss or disappearance can be attributed to 
unique activities that may take place involving the listed chemical; 
and (4) a pattern of losses or disappearances over a specific time 
period, whether the losses or disappearances appear to be random, and 
the result of efforts taken to resolve the losses. If known, the 
regulated person would also need to report whether (1) the specific 
listed chemical was a likely candidate for diversion and (2) local 
trends and other indicators of the diversion potential of the listed 
chemical. This language is similar to the current regulatory language 
relating to theft and loss of controlled substances in Sec.  
1301.74(c).
    In addition, the DEA is clarifying in the revised Sec.  
1310.05(b)(1) that regulated persons must submit a report of unusual or 
excessive loss or

[[Page 97008]]

disappearance whether or not the listed chemical is subsequently 
recovered. The DEA also has revised Sec.  1310.05(b)(1) to clarify 
which party has the responsibility for reporting during domestic and 
international transactions. These changes will streamline the data 
collection process and allow the DEA to more efficiently respond to 
diversion as well as to respond to reporting requests concerning these 
items from the United Nations.
    The DEA is also removing the phrase ``whenever possible'' from the 
oral reporting requirements of the current Sec.  1310.05(b). The DEA 
believes that the phrase is redundant given the stated requirement that 
such reports be made ``at the earliest practicable opportunity.'' 
Removing this phrase would better align the reporting requirements with 
the statutory language of 21 U.S.C. 830(b)(1).
    In response to the above discussed changes, the DEA is 
restructuring Sec.  1310.05(a) and (b) to reflect the revised reporting 
structure. Paragraph (a) is addressing those reports made solely to the 
local DEA office in accordance with the current and revised Sec.  
1310.05(a)(1) and (2). Paragraph (b) is addressing those reports made 
orally to the local DEA office with written reports being submitted 
through the DEA Diversion Control Division secure network application. 
The reporting requirements now located in Sec.  1310.05(b) will be 
transferred to paragraphs (a)(1) and (2), and (b)(1) and (2), as 
applicable. This change consolidates the reporting requirements for 
each of the applicable reports into their applicable paragraphs; 
readers would no longer be required to look at both paragraphs to 
determine when and how they must initially report these transactions. 
In addition, the DEA is clarifying Sec.  1310.05(a)(2) that regulated 
persons must report orally, not in writing, any proposed regulated 
transaction with a person whose description or other identifying 
characteristic the Administration has provided to the regulated person. 
Regulated persons are required to orally report the other types of 
actions at the earliest practicable opportunity to the Special Agent in 
Charge of the DEA Divisional Office for the area in which the regulated 
person making the report is located.
    21 CFR 1310.06 is revised to reflect the various changes in 
Sec. Sec.  1310.03-1310.05. Cross-citations have been amended to 
reflect where regulations have been moved and new forms instituted. In 
Sec.  1310.06(a)(3) regulated persons are required to include the NDC 
number of the product containing the listed chemical, if applicable, in 
all records required by Sec.  1310.03(a). If the record contains the 
NDC number, information about the ``form of packaging'' would not be 
necessary. The restructuring of Sec.  1310.05(a) also corrects a long-
standing typographical error in the previous Sec.  1310.06(c), which 
incorrectly referenced Sec.  1310.05(a)(4) instead of Sec.  
1310.05(a)(3). 21 CFR 1310.06(c) previously stated that a report 
submitted pursuant to Sec.  1310.05(a)(4), domestic regulated 
transactions, must include a description of the circumstances leading 
the regulated person to make the report. However, the corresponding 
example relates to an unusual loss, which is addressed in the previous 
Sec.  1310.05(a)(3) (now Sec.  1310.05(b)(1)). The DEA also is making 
technical amendments in Sec.  1310.06, including replacing the term 
``shall'' in paragraphs (a) and (b).
    The DEA is standardizing submissions of domestic and import and 
export regulated transaction reports involving tableting and 
encapsulating machines through the introduction of a new form, the DEA 
Form 452. In the revised Sec.  1310.05(b)(2), the DEA is making the 
oral reporting mandatory and mandating the electronic filing of the 
written report. The DEA also is providing specific guidelines on when 
those reports must be given. The revised Sec.  1310.05(b)(2) requires 
regulated persons to orally report domestic regulated transactions in a 
tableting machine or an encapsulating machine when an order is placed 
rather than at the earliest practicable opportunity after the regulated 
person becomes aware of the circumstances involved. The written report 
(DEA Form 452) is required to be filed within 15 calendar days after 
the order has been shipped by the seller.
    The previous standard was originally adopted for reporting of 
domestic regulated transactions for uniformity with the reporting 
timeframe standard imposed by 21 U.S.C. 830(b)(1)(A) for transactions 
involving an extraordinary quantity of a listed chemical, an uncommon 
method of payment or delivery, or other suspicious circumstances. 
However, the DEA is exercising its authority under 21 U.S.C. 830(b)(1) 
to impose a different reporting timeframe standard for machines. The 
revised standards are not only less ambiguous for regulated persons to 
follow; they also ensure the DEA receives the information in time to 
take appropriate action as may be necessary. The new DEA Form 452, 
covers not only import and export regulated transactions of tableting 
and encapsulating machines required under the current Sec.  1310.05(c) 
but also the domestic regulated transactions of tableting machines or 
encapsulating machines required by the previous Sec.  1310.05(a)(4). 
The requirements for the content of domestic reports were moved from 
Sec.  1310.06(d) to a new Sec.  1310.06(f), while the requirements for 
reports of importations and exportations are all contained within Sec.  
1310.06(e). The DEA also is amending the recordkeeping requirements in 
Sec.  1310.06(a) and reporting requirements in Sec.  1310.06(e) and (f) 
to require the inclusion of information about whether the machine is 
manual or electric. In Sec.  1310.06(e)(1)(vi) and (f)(3), the DEA is 
requiring reports of importations and domestic transactions to include 
any proposed changes to the identifying information of imported 
machines that will occur after the importation or other transaction.
    The DEA also is amending Sec.  1310.06 to require regulated persons 
who import or export a tableting or encapsulating machine to report 
return information to the Administration within 30 calendar days of the 
release of the shipment by customs at the port of entry or port of 
export, or within 10 calendar days after receipt of a written request 
by the Administration. The DEA has included the provision for the 
requirement to submit return information earlier than the 30 days for 
two reasons. First, it conforms to the changes for controlled 
substances and listed chemicals in parts 1312 and 1313. Uniformity of 
requirements should simplify procedures and ease understanding of the 
requirements by regulated industry. Second, the option to request 
advance return information allows the DEA to receive information that 
may be needed for time-sensitive requirements, such as investigations 
that may need to result in immediate action to protect the public 
health and safety. Return information is required to be submitted 
electronically through the DEA Diversion Control Division secure 
network application on the DEA Form 452. Reports would not be deemed 
filed until a transaction identification number has been issued by the 
DEA. Pursuant to Sec.  1310.06(h), importers are required to report 
specifics on their return, including dates of the transaction, 
quantities of machines involved, and descriptions of the machines. 
Consistent with the current requirements, importers also are required 
to report subsequent transfers of the machines under Sec.  
1310.05(b)(2). Reports of transfers after import may be submitted with 
the return information or separately.
    The revisions relating to tableting and encapsulating machines that 
would standardize the submission of reports of

[[Page 97009]]

regulated transactions, whether domestic or import/export, and require 
return information, would enhance the monitoring of these machines and 
allow the DEA greater ability to detect and prevent their use for the 
illicit manufacture of controlled substances. While tableting machines 
and encapsulating machines are commonly used by legitimate companies to 
produce pharmaceuticals and nutritional supplements, they are also used 
by traffickers to produce single dosage units of illicit synthetic 
substances such as methylenedioxymethamphetamine (``MDMA'') (aka 
``Molly'' or ``ecstasy''), and other synthetic designer drugs 
classified as schedule I controlled substances or analogue substances. 
These machines have also been known to be used by marijuana 
dispensaries, steroid labs, and counterfeit drug manufacturers.
    Regulatory changes in the final rule require importers and 
exporters to report to the DEA when a shipment has been denied release 
by a customs officer for any reason, whether or not the denial was 
based on a violation of DEA regulations. In response to commenters who 
stated that the 24 hour notification requirement related to import or 
export denials was unreasonable, the DEA has modified this requirement 
from 24 hours to 5 business days. The DEA believes that 5 business days 
strikes a balance between investigative needs without unduly burdening 
the regulated community. Likewise, by unifying the reporting format for 
regulated transactions in tableting machines, whether domestic, import, 
or export, the DEA will be able to monitor the flow of these machines 
through the distribution chain. This will allow the DEA to better 
understand and monitor the trade in these machines and to adopt more 
efficient means of stopping the diversion of tableting and 
encapsulating machines, and prevent their use in the illicit 
manufacture of controlled substances.

I. 21 CFR Part 1312

    The DEA is making a technical amendment to Sec. Sec.  1312.11 and 
1312.22 to insert a cross-reference to part 1301 of chapter II of title 
21 of the Code of Federal Regulations when referencing the registration 
requirements for the importation of controlled substances.
    The DEA is amending Sec.  1312.14 to account for revised 
distribution procedures for import permits. The DEA is retaining the 
requirement that an official record of the permit (a ``copy'' under 
current DEA regulatory terms) accompany the shipment of controlled 
substances. This is an important tool utilized by the DEA for ensuring 
compliance with the closed system of distribution by allowing quick 
initial visual indication of compliance with requirements with the CSA. 
However, because customs officers will be able to electronically 
validate the legitimacy of the import permit through ITDS, customs 
officers will not need to physically detach the official record of the 
permit for validation. An official record of the permit must instead 
accompany the shipment until it reaches its final destination. The DEA 
is also amending Sec.  1312.14 to omit the discussion of the 
circumstances in which customs officers will refuse entry of a 
shipment.
    The final destination for an import must be the registered location 
of the importer. (The import must be received at the registered address 
of the importer before being moved to another location of the importer 
or delivered to a customer.) The receipt of imported goods is a 
principal activity of registered importers. Pursuant to 21 U.S.C. 
958(h), a separate registration is required at each principal place of 
business where applicants import or export controlled substances. 
Accordingly, the final destination of a shipment of imported controlled 
substances is the registered location of the registrant or regulated 
person. Drop shipments, i.e., deliveries made by an importer directly 
to a customer without passing through the registered location of the 
importer, are explicitly prohibited under the revisions to Sec.  
1312.19. Similarly, consistent with current requirements, deliveries 
may not be made directly to a warehouse exempted from registration 
pursuant to Sec.  1301.12(b)(1); they must arrive first at the 
registered location.
    A technical amendment to paragraph (a) of Sec.  1312.15 is made to 
cross-reference Sec.  1312.16, concerning shipments that may be in 
greater or lesser amount than what is authorized by the import permit.
    Associated with the foregoing changes, as discussed earlier in this 
document, the DEA is amending its regulations regarding expiration 
dates associated with imports and exports of controlled substances. The 
DEA is changing the current expiration period of import and export 
permits found in Sec. Sec.  1312.16 and 1312.25 from not more than six 
months to not more than 180 calendar days after the date of issuance. 
This change will standardize expiration procedures as not all months 
have the same number of days. The DEA is also amending Sec. Sec.  
1312.18 and 1312.27 to specify an expiration date for import and export 
declarations for controlled substances. Such declarations do not 
currently have an expiration date assigned to them; however, permits to 
import and export controlled substances expire not more than six months 
after approved under the current regulation. 21 CFR 1312.16 and 
1312.25. Similar to permits, at times declarations filed with the DEA 
are never actually utilized. The DEA is concerned that absence of an 
expiration date for these declarations may lead to incomplete or 
inaccurate records in the ITDS. Therefore, the DEA is requiring that 
declarations expire 180 calendar days after the date the declaration is 
deemed filed with the Administration.
    The DEA is modifying the condition previously found in Sec.  
1312.22(a) that requires an application for a permit to export 
controlled substances to contain an affidavit that the packages of 
controlled substances for export are labeled in conformance with 
obligations of the United States under international treaties, 
conventions, or protocols ``in effect on May 1, 1971.'' The regulation 
is amended to instead require that such affidavit state that packages 
of controlled substances for export are labeled in conformance with 
obligations of the United States under international treaties, 
conventions, or protocols which are in effect at the time of export or 
reexport. The DEA does not believe that this change will have any 
current effect on the regulated community because it is not a new 
requirement. However, the DEA is taking this opportunity in revising 
its other import and export regulations to account for any changes in 
international treaties, conventions, or protocols which might be made 
in the future.
    This final rule includes changes to harmonize, to the extent 
possible, return information requirements for import and export 
regulations throughout parts 1310, 1312, and 1313 for tableting and 
encapsulating machines, controlled substances, and listed chemicals. 
Although these provisions are similarly structured, the actual content 
of the return information varies across the regulations to account for 
international reporting requirements for machines, controlled 
substances, and listed chemicals. Variations in return reporting 
requirements also vary among controlled substances, listed chemicals, 
and tableting and encapsulating machines to maximize the detection, 
investigation, and prevention of diversion. The DEA has reviewed the 
return information currently collected for imported and exported 
controlled substances and is proposing changes.
    The DEA is amending Sec. Sec.  1312.12, 1312.18, 1312.22, and 
1312.27 to require

[[Page 97010]]

registrants or regulated persons, and those exempt from registration to 
report return information to the Administration following imports and 
exports of controlled substances authorized by permits and conducted 
pursuant to filed declarations. The DEA is requiring this information 
to be submitted within 30 calendar days, or within 10 calendar days 
after a request from the Administration, whichever is sooner. This 
regulatory text change is consistent with existing business practice, 
as importers and exporters generally submit such information to the DEA 
at the conclusion of transactions. The submission of such reports will 
allow the United States to meet its obligations under article 19 
(Estimates of drug requirements) and article 20 (Statistical returns to 
be furnished to the Board) of the Single Convention on Narcotic Drugs, 
1961, and article 16 (Reports to be furnished by the Parties) of the 
Convention on Psychotropic Substances, 1971. The DEA will continue to 
independently collect such return information outside of the single 
window as the ITDS does not capture all elements of the return 
information that the DEA needs to submit under those treaty obligations 
and otherwise adequately monitor the closed system of distribution of 
imports and exports to detect and prevent diversion. 21 U.S.C. 871(b). 
Additionally, the timing and frequency of required return information 
reporting is outside the scope of the single window. Requirements for 
return information to be submitted to the DEA are already specifically 
included in Sec.  1312.22(d)(6) for reexported controlled substances 
pursuant to 21 U.S.C. 953(f)(6).
    For imported and exported controlled substances there are four 
principal pieces of information that the DEA is requiring importers and 
exporters supply to the DEA in the returns: The date on which the 
controlled substances arrived/departed the registered location, the 
date on which a customs officer released the shipment, the actual 
quantity of controlled substances that arrived/left the registered 
location, and the actual quantity of controlled substances that a 
customs officer actually released. The current text in 21 CFR 1312.22 
relating to controlled substances exported for subsequent reexportation 
requires the reporting of the ``date shipped.'' This requirement has 
been interpreted differently, sometimes as the date it left the 
facility and sometimes as the date of release by customs. Both dates 
are needed to adequately monitor the closed system of distribution for 
import and export transactions.
    The DEA is revising Sec. Sec.  1312.12, 1312.18, 1312.22, and 
1312.27 to prohibit the importation/exportation of any shipment of 
controlled substances denied release by customs at the port of entry or 
port of export for any reason without resubmission of the permit 
application or declaration and issuance of a new permit or transaction 
identification number by the DEA. This change is needed to strengthen 
the DEA's ability to monitor and detect practices that may render an 
importer's or exporter's registration inconsistent with the public 
safety, especially in relation to the DEA's statutory obligation to 
take into consideration an applicant's compliance with applicable State 
and local laws and other relevant factors. 21 U.S.C. 823(a), 958(a).
    The DEA is amending Sec.  1312.22 to reflect that the 
Administration has discretion whether to issue a permit for reexport 
pursuant to 21 U.S.C. 953(f). The revision to Sec.  1312.22(g)(8), like 
the current regulation, specifies that the exporter must provide ``a 
brief summary of the facts that warrant the return'' of an export that 
has been refused or is otherwise unacceptable or undeliverable. The DEA 
Diversion Control Division secure network application contains a field 
appropriate for this information within the DEA Form 357. Likewise, the 
``written request for reexport'' of a controlled substance subject to 
declaration requirements, currently required in Sec.  
1312.27(b)(5)(iv), can be submitted in a field of the DEA Form 236 in 
the DEA Diversion Control Division secure network application. As in 
the current regulations, a refused or otherwise unacceptable or 
undeliverable controlled substance subject to the declaration 
requirements could be imported only after the DEA issues ``affirmative 
authorization in writing.'' A transaction identification number does 
not serve as such ``affirmative authorization in writing.''
    The DEA is amending Sec. Sec.  1312.22, 1312.31, and 1312.32 to 
require a certified translation of authorizations issued by foreign 
competent national authorities that are not issued either entirely in 
English or bilingual with English. If the foreign authorization, or the 
certified copy of such, is not written in English or bilingual with 
another language and English, the registrant must submit with their 
application or notice a certified translation of the permit or license. 
For the purposes of this requirement, certified translation will mean 
that the translator has signed the translation legally attesting to the 
accuracy of the translation. This change is meant to ensure that these 
foreign authorizations are complete and accurate, and that the 
information that they contain are accurately understood and applied to 
DEA import/export policies and procedures.
    In response to commenters who stated that the 24 hour notification 
requirement related to import or export denials was unreasonable, the 
DEA has modified this requirement from 24 hours to 5 business days. The 
DEA believes that 5 business days strikes a balance between 
investigative needs without unduly burdening the regulated community.
    As mentioned above, in response to comments the DEA amended 
Sec. Sec.  1312.13(e) and 1312.23(e) in a manner that is different than 
proposed. The language added to this section will emphasize that a 
shipment of controlled substances is limited to a single transaction 
between a single importer or exporter and a single consignee on a 
single loading document, but also that the shipment must occur on a 
single conveyance as opposed to multiple conveyances. In addition, the 
language will coincide with current policy by prohibiting a load of 
goods from being divided into multiple parts to be placed onto more 
than one conveyance, even if the goods are on the same loading 
document. A single permit could not be used for this situation above.

J. 21 CFR Part 1313

    The DEA is adding a new Sec.  1313.03 that will consolidate the DEA 
Form information applicable to part 1313 in a corresponding change for 
the new Sec.  1312.03. The new Sec.  1313.03 will consist of a table 
referencing the DEA Form number, form name, information about where the 
form may be accessed, and where the completed form should be submitted.
    The DEA is amending Sec.  1313.12(b) to require that all 
declarations (DEA Form 486/486A) must be complete and accurate when 
submitted. Under Sec.  1304.21, registrants must maintain complete and 
accurate records for controlled substances. That requirement applies to 
import and export declarations for controlled substances. This revision 
will impose the same requirement for import/export declarations as for 
listed chemicals.
    Declarations (DEA Forms 486/486A) will not be deemed filed until 
the transaction identification number has been issued by the DEA. Upon 
receipt and review, the DEA will assign each declaration a transaction 
identification number (a unique identifier). Once the declaration is 
accepted and assigned a

[[Page 97011]]

transaction identification number, registrants will be able to use the 
assigned transaction identification number to access the official 
record of the declaration. While current DEA regulations do not require 
confirmation of receipt from the DEA prior to importation or 
exportation pursuant to a declaration, the change is consistent with 
current practices. Currently, the DEA assigns a Web Tracking Number to 
each declaration when it is submitted and accepted. The regulatory 
codification of the issuance of a transaction identification number is 
designed to ensure that electronically submitted declarations are 
indeed received by the DEA, are completed, and can be appropriately 
tracked and monitored; to streamline the declaration filing process; 
and to eliminate duplicate filings. The fact that the DEA issues a 
transaction identification number after reviewing the filing does not 
waive the Administration's right to suspend a shipment under Sec.  
1313.41.
    The DEA wishes to clarify that import or export transactions may 
not proceed as soon as the transaction identification number has been 
issued, because the 15-calendar-day requirement since the filing of DEA 
Form 486/486A has not changed. Import or export transactions for which 
the 15-calendar-day notification has been waived, may proceed as soon 
as the transaction identification number has been issued, regardless of 
whether the 3 business days have elapsed since filing of DEA Form 486/
486A.
    The DEA is making changes in the regulatory text to reflect that 21 
U.S.C. 830 has been changed to require official records of import 
declarations involving listed chemicals to be retained for two years.
    As discussed above, return information requirements have been 
harmonized across parts 1310, 1312, and 1313, to the extent possible. 
The DEA is requiring that return information must be reported within 30 
calendar days after release by a customs officer at the port of entry, 
export, or reexport. All return information for applications or other 
initial filings that are required to be made electronically through the 
DEA Diversion Control Division secure network application would 
likewise be required to be filed electronically through the same 
system. As with controlled substance return information, the DEA is 
requiring listed chemical importers and exporters to include both the 
date a customs officer releases an imported item or releases an item 
for export, and the date that the shipment arrived at the location of 
the importer or exporter, the actual quantities of product both when 
released by a customs officer and at the time of shipment from the 
exporter's location or arrival at the importer's location, and the 
actual port of entry or export. These revised reporting requirements 
will better allow the DEA to track the flow of listed chemicals, and 
detect and prevent diversion. For example, by tracking and comparing 
diversion of listed chemicals against the actual port of entry or exit, 
the DEA will be better able to detect potential weak spots in the 
import/export system and direct more resources to that region. The DEA 
also is revising the regulatory text to clarify that the references to 
``chemical'' and ``container'' apply to the reporting of subsequent 
transfers.
    The final destination for an import of a list I chemical must be 
the registered location of the registered importer. The import must be 
received at the registered address of the importer before being moved 
to another location of the importer or delivered to a customer. The 
receipt of imported goods is a principal activity of registered list I 
chemical importers. Pursuant to 21 U.S.C. 958(h), a separate 
registration is required at each principal place of business where 
applicants import or export list I chemicals. Accordingly, the final 
destination of a shipment of an imported list I chemical is the 
registered location of the registrant. Drop shipments, i.e., deliveries 
made by an importer directly to a customer without passing through the 
registered location of the importer, are explicitly prohibited under 
the revisions to Sec.  1313.14. Similarly, consistent with current 
requirements, deliveries may not be made directly to a warehouse 
exempted from registration pursuant to Sec.  1309.23(b)(1); they must 
arrive first at the registered location.
    The DEA is amending Sec.  1313.22(a) to add a cross-reference to 
Sec.  1310.04(g) relating to listed chemicals that may be exported. 
This change will harmonize Sec.  1313.22(a) with Sec.  1313.21(a).
    In response to commenters who stated that the 24 hour notification 
requirement related to import or export denials was unreasonable, the 
DEA has modified this requirement from 24 hours to 5 business days. The 
DEA believes that 5 business days strikes a balance between meeting 
investigative needs and not unduly burdening the regulated community.

K. 21 CFR Part 1314

    Corresponding to recent internal DEA reorganization, in Sec.  
1314.110, in paragraphs (a)(1) and (2), the phrase ``Import/Export 
Unit,'' will be removed and in its place ``Regulatory Section, 
Diversion Control Division,'' will be added.

L. 21 CFR Part 1315

    Corresponding to recent internal DEA reorganization, the mailing 
addresses for Sec. Sec.  1303.12(b) and (d), 1303.22, 1304.31(a), 
1304.32(a), 1315.22, 1315.32(e) and (g), 1315.34(d), and 1315.36(b), 
regarding quota applications and reporting, will be moved from the DEA 
Drug & Chemical Evaluation Section to the UN Reporting & Quota Section 
under a new corresponding header.

M. 21 CFR Part 1316

    The DEA is amending Sec.  1316.47(a) to align with the DEA's 
current practice referenced in all recent Federal Register publications 
that requests for a hearing are to be sent directly to the Hearing 
Clerk. Specifically, this amendment will remove ``Attention: DEA 
Federal Register Representative'' from the template letter. Since the 
paragraph before the template letter states that persons requesting a 
hearing should refer to Sec.  1321.01 for current mailing addresses, 
the DEA is not adding an ``Attention'' field in the template letter.
    The DEA is amending Sec.  1316.48 so that the filing of notices of 
appearance corresponds with the DEA's practice that requests for 
hearing shall be sent to the Hearing Clerk. Specifically, the DEA would 
remove ``Attention: Federal Register Representative'' from the template 
letter. Since the paragraph before the template letter states that 
persons requesting a hearing should see Sec.  1321.01 for current 
mailing addresses, the DEA is not adding an ``Attention'' field in the 
template letter.
    The DEA is amending Sec.  1316.48 to provide that notices of 
appearance should be sent to the DEA Hearing Clerk instead of the DEA 
Administrator so that notices of appearance will be filed in a more 
efficient manner. The DEA is also amending Sec.  1316.47 to provide 
that requests for hearing should be sent to the DEA Hearing Clerk 
instead of the DEA Federal Register Representative so that such 
requests will be filed in a more efficient manner. In the Table of DEA 
Mailing Addresses in Sec.  1321.01, DEA is making the corresponding 
change, and to add Sec. Sec.  1301.43, 1303.34, 1308.44, and 
1316.47(a), regarding requests for hearing or appearance and/or 
waivers, under the DEA Hearing Clerk heading. These items are being 
directed to the DEA Hearing Clerk to expedite the hearing process and 
will lead to fewer delays. The DEA is additionally revising this 
portion of the table to correct the attention line of the mailing 
address for the DEA Hearing

[[Page 97012]]

Clerk. The address will be changed from ``Drug Enforcement 
Administration, Attn: Hearing Clerk/LJ, 8701 Morrissette Drive, 
Springfield, VA 22152'' to ``Drug Enforcement Administration, Attn: 
Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, VA 22152.''
    The DEA is adding the following citations to be directed to the DEA 
Federal Register Representative: Sec.  1301.34(a)--Filing of written 
comments regarding application for importation of Schedule I and II 
substances; Sec.  1303.11(c)--Filing of written comments regarding 
notice of an aggregate production quota; and Sec.  1303.13(c)--Filing 
of written comments regarding adjustments of aggregate production 
quotas. These topics have been added so that comments corresponding to 
Federal Register publications can be sent directly to the Federal 
Register Representative whose responsibility it is to review comments 
and make them publicly available, as appropriate. The DEA is 
additionally amending this portion of the table to revise the attention 
line of the mailing address for the DEA Federal Register 
Representative. The address will be changed from ``Drug Enforcement 
Administration, Attn: Federal Register Representative/DRL, 8701 
Morrissette Drive, Springfield, VA 22152'' to ``Drug Enforcement 
Administration, Attn: Federal Register Representative/DRW, 8701 
Morrissette Drive, Springfield, VA 22152.'' Additionally, this rule 
adds the Web address for the Federal eRulemaking Portal, http://www.regulations.gov, under the heading ``DEA Federal Register 
Representative.'' This Web address provides the ability to type short 
comments directly into the comment field on the Web page or to attach a 
file for lengthier comments. This change conforms to the DEA's current 
practice, referenced in the DEA's recent Federal Register publications, 
which requires that comments either be submitted through http://www.regulations.gov or be directed to the DEA Federal Register 
Representative.

N. 21 CFR Part 1321

    The DEA is amending the Table of DEA Mailing Addresses found in 
Sec.  1321.01 to account for changes in this rule as part of the 
implementation of ITDS. The DEA is also taking this opportunity to 
implement various technical amendments to the Table of DEA Mailing 
Addresses.
    Pursuant to this final action all import and export applications 
and filings would be submitted through the DEA Diversion Control 
Division secure network application. The DEA will amend the Table of 
DEA Mailing Addresses to retain a reference to the notifications that, 
prior to this rule, could be made by mail, but will note with an 
asterisk that those filings must now be made electronically. The CFR 
sections listed under the DEA Import/Export Unit will be merged with 
those under the DEA Regulatory Section and placed under the header of 
``DEA Regulatory Section.''
    The mailing addresses for Sec. Sec.  1308.21(a), 1308.23(b), 
1308.25(a), 1308.31(a), 1308.33(b), and 1310.13(b) will be transferred 
from the DEA Diversion Control Division to the DEA Drug & Chemical 
Evaluation Section (DRE), the subject matter experts on excluded and 
exempted products. This change will allow these matters to be processed 
in a more efficient manner. The reference to Sec.  1307.22, ``Disposal 
of Controlled substances by the Administration delivery application,'' 
will be revised to ``Delivery of surrendered and forfeited controlled 
substances'' in conformity with the final rule, Disposal of Controlled 
Substances, 79 FR 53520, Sept. 9, 2014. Corresponding to recent 
internal DEA reorganization, the mailing addresses for Sec. Sec.  
1303.12(b) and (d), 1303.22, 1304.31(a), 1304.32(a), 1315.22, 
1315.32(e) and (g), 1315.34(d), and 1315.36(b), regarding quota 
applications and reporting, will be moved from the DEA Drug & Chemical 
Evaluation Section to the UN Reporting & Quota Section under a new 
corresponding header.

IV. Regulatory Analyses

Executive Orders 12866, Regulatory Planning and Review, and 13563, 
Improving Regulation and Regulatory Review

    This final rule was developed in accordance with the principles of 
Executive Orders 12866 and 13563. The DEA has determined that this 
final rule is a significant regulatory action, and accordingly this 
rule has been submitted to the Office of Management and Budget for 
review.
    By business activity, the DEA estimates this rule will result in a 
combined annual savings of $424,640 for controlled substances 
importers, exporters, researchers, and analytical labs; a combined 
annual cost of $5,011 for listed chemical importers and exporters and 
tableting and encapsulating machine importers and exporters; and no 
economic impact for brokers, domestic transactions in tableting and 
encapsulating machines, and mail order transactions of ephedrine (EPH), 
pseudoephedrine (PSE), phenylpropanolamine (PPA), or gamma-
hydroxybutyric acid (GHB). Therefore, the estimated net annual impact 
of this rule is a cost savings of $419,629 and the estimated combined 
annual economic effect is $429,650. The DEA does not anticipate that 
this rulemaking will have an annual effect on the economy of $100 
million or more or adversely affect, in a material way, the economy, a 
sector of the economy, productivity, competition, jobs, the 
environment, public health or safety, or State, local, or tribal 
governments or communities. An economic analysis of the final rule can 
be found in the rulemaking docket at http://www.regulations.gov, under 
FDMS Docket ID: DEA-2016-0017 (Docket No. DEA-403).

Executive Order 12988, Civil Justice Reform

    The regulation meets the applicable standards set forth in sections 
3(a) and 3(b)(2) of Executive Order 12988, Civil Justice Reform to 
eliminate ambiguity, minimize litigation, establish clear legal 
standards, and reduce burden.

Executive Order 13132, Federalism

    This rulemaking does not have federalism implications warranting 
the application of Executive Order 13132. The rule does not have 
substantial direct effects on the States, on the relationship between 
the national government and the States, or the distribution of power 
and responsibilities among the various levels of government.

Executive Order 13175, Consultation and Coordination With Indian Tribal 
Governments

    This final rule is in accordance with the February 19, 2014, 
Executive Order 13659, ``Streamlining the Export/Import Process for 
America's Businesses,'' 79 FR 10657, Feb. 25, 2014. It does not have 
substantial direct effects on the States, on the relationship between 
the national government and the States, or the distribution of power 
and responsibilities between the Federal Government and Indian tribes.

Regulatory Flexibility Act

    The Administrator, in accordance with the Regulatory Flexibility 
Act (5 U.S.C. 601-612) (RFA), has reviewed this rule and by approving 
it certifies that it will not have a significant economic impact on a 
substantial number of small entities.
    Below is a summary of the threshold analyses conducted by the DEA 
to support the certification statement

[[Page 97013]]

above. The complete threshold analysis is available at http://www.regulations.gov for easy reference. The DEA specifically solicited 
written comments regarding the DEA's economic threshold analysis of the 
impact of these proposed changes. The DEA requested that commenters 
provide detailed descriptions in their comment of any expected economic 
impacts, especially to small entities. Commenters were asked to provide 
empirical data to illustrate the nature and scope of such impact. No 
comments were received; thus, the analysis that accompanied the NPRM 
remains unchanged below.
    In accordance with the RFA, the DEA evaluated the impact of this 
rule on small entities. This final rule affects all entities who import 
or export, or seek to import or export, controlled substances, listed 
chemicals, tableting and encapsulating machines, or who broker 
international transactions (from foreign country to another foreign 
country while in the United States). Additionally, this final rule 
affects all persons who would be required to report unusual or 
excessive loss or disappearance of a listed chemical under the control 
of the regulated person in accordance with proposed revised Sec.  
1310.05(b)(1), all persons who are required to report domestic 
regulated transactions in tableting or encapsulating machines in 
accordance with proposed revised 21 CFR 1310.05(b)(2), and all persons 
who are required to report mail order transactions of EPH, PSE, PPA, or 
GHB in accordance with 21 CFR 1310.03(c). The affected entities include 
DEA registrants and non-registrants. A DEA registration is required to 
import or export any controlled substance and most list I chemicals. A 
DEA registration is not required to import or export some list I 
chemicals or any list II chemical, to import or export tableting and 
encapsulating machines, or to broker international transactions. Also, 
a DEA registration is not required to conduct domestic transactions in 
tableting and encapsulating machines or mail order transactions of EPH, 
PSE, or PPA. (Registration is required for mail order transactions of 
GHB as GHB is a schedule I controlled substance.) The affected entities 
(DEA registrants and non-registrants) are grouped into ``business 
activities,'' based on types of activities performed by the entities. 
The business activities described in this analysis that are required to 
have DEA registrations are importers/exporters, researchers, analytical 
labs, and chemical importers/exporters that deal in the list I 
chemicals requiring registration (referred to as ``DEA-registered 
listed chemical importers/exporters''). The business activities 
described in this analysis that are not required to have DEA 
registrations are chemical importers/exporters that deal in list I 
chemicals not requiring registration and list II chemicals (referred to 
as ``non-registered listed chemical importers/exporters''), tableting/
encapsulating machine importers/exporters, brokers of international 
transactions, tableting/encapsulating machine domestic suppliers, and 
entities selling EPH, PSE, and/or PPA by mail order.
    The DEA estimates that 7,840 entities are affected by this rule, 
which consist of 331 controlled substances importers/exporters; 5,884 
researchers; 1,200 analytical labs; 231 DEA-registered listed chemical 
importers/exporters; 76 non-registered listed chemical importers/
exporter; 56 tableting/encapsulating machine importers/exporters; 12 
brokers of international transactions; 46 tableting/encapsulating 
machine domestic suppliers; and 4 entities selling EPH, PSE, PPA, and/
or GHB by mail order. Regulated persons potentially reporting unusual 
or excessive loss or disappearance of a listed chemical would be 
included in one of the business activities above.
    The DEA estimates 7,321 (93.4%) of total 7,840 affected entities 
are small entities. Specifically, the DEA examined the impact of the 
proposed changes regarding (1) mandatory electronic permit applications 
and filings, and (2) 180-calendar-day expiration for all declarations 
for the 7,321 small entities affected by the final rule, which consist 
of 310 controlled substances importers/exporters; 5,474 researchers; 
1,134 analytical labs; 218 DEA-registered listed chemical importers/
exporters; 72 non-registered listed chemical importers/exporters; 54 
tableting/encapsulating machine importers/exporters; 11 brokers of 
international transactions; 44 tableting/encapsulating machine domestic 
suppliers; and 4 entities selling EPH, PSE, PPA, and/or GHB by mail 
order.
    The DEA is mandating the electronic submission of all permit 
applications and other required filings and reports associated with the 
importation or exportation of tableting and encapsulating machines, 
controlled substances, and listed chemicals. Additionally, the DEA is 
mandating the electronic submission of all reports associated with the 
unusual or excessive loss or disappearance of a listed chemical, 
domestic regulated transactions in tableting or encapsulating machines, 
and mail order transactions of EPH, PSE, PPA, and GHB. The DEA would 
cease to accept paper filing of controlled substances import/export 
permit applications (other than transshipments), controlled substances 
import/export declarations, listed chemicals import/export 
declarations, and certain filings and reports specified as discussed 
previously in this document. Currently, some electronic forms 
associated with these activities are available online and are in use. 
Usage rates vary for each form and also vary by business activities. 
However, as virtually all paper submissions of permit applications and 
declarations are currently delivered via express common carrier with 
pre-paid return envelope or account information, savings are 
anticipated because of this change.
    The DEA estimates that each conversion to electronic filing from 
paper controlled substances import/export permit application and 
controlled substances import/export declaration will result in an 
estimated cost savings of $58.75 and $9.75, respectively. Based on 
DEA's registration data, the DEA assumes all affected entities have 
information systems capable of completing and submitting online forms 
and downloading, printing, and transmitting electronic documents at 
nominal additional cost. Among the affected establishments that hold 
DEA registrations, 92% of previous applications for registration or 
renewal of registration were made online. Furthermore, even though the 
email address is an optional data field, 99% of the registrations have 
an email address on record. Based on these facts and the high rate of 
internet penetration in the general U.S. population,\10\ it is 
reasonable to assume virtually all regulated establishments, 
registrants and non-registrants, have information systems capable of 
completing and submitting online forms and downloading, printing, and 
transmitting electronic documents at minimal additional cost. No 
special software or equipment will be needed to access the DEA 
Diversion Control Division secure network application.
---------------------------------------------------------------------------

    \10\ See note 15 of the accompanying Economic Impact Analysis 
(``An estimated 78.1 percent of people in U.S. households had a 
high-speed Internet connection in 2013. ``Computer and Internet Use 
in the United States: 2013,'' U.S. Census Bureau, http://
www.census.gov/content/dam/Census/library/publications/2014/acs/acs-
28.pdf.'').
---------------------------------------------------------------------------

    There are no anticipated cost savings for the conversion to 
electronic filing from paper for the listed chemicals import/export 
declarations and tableting

[[Page 97014]]

and encapsulating machine import/export notifications since virtually 
all are currently submitted via online, facsimile, or email, without 
the use of a common carrier. However, the DEA anticipates an additional 
cost associated with the new requirement for tableting/encapsulating 
machine importers/exporters to submit return information within 30 
calendar days after the release by a customs officer has taken place or 
within 10 calendar days after receipt of a written request by the 
Administration to the exporter/importer, whichever is sooner.
    The DEA estimates there will be no economic impact associated with 
the electronic submission of all reports associated with the unusual or 
excessive loss or disappearance of a listed chemical, domestic 
regulated transactions in tableting or encapsulating machines, and mail 
order transactions of EPH, PSE, PPA, and GHB. While the written reports 
would be required to be made online, the labor cost of making the 
report is expected to be the same, whether on paper or online.
    Based on the varying number of annual occurrences estimated for 
each of the business activities, the DEA estimates importers/exporters 
as a group would save $383,857, researchers as a group would save 
$4,316, and analytical labs as a group would save $37,567. The DEA 
estimates tableting/encapsulating machine importers/exporters as a 
group would have an additional cost of $3,978, for a total net savings 
of $421,761 for the electronic submissions requirement. (Figures are 
rounded). Based on the number of affected entities and the cost savings 
to the business activities as a group, the DEA estimated the average 
annual cost savings for each affected entity. The DEA estimates 
importers/exporters, researchers, and analytical labs will save on 
average $1,160, $1, and $31 per year, respectively, and tableting/
encapsulating machine importers/exporters would have a cost of $71 per 
year.
    In addition, the DEA is specifying that all controlled substance 
and listed chemical declarations expire in 180 calendar days, 
consistent with the controlled substance import/export permits. If 
release by a customs officer will occur more than 180 calendar days 
after the declaration is deemed filed, the declarant must submit a new 
declaration for the transaction. The 180-calendar-day expiration 
provision for all controlled substance and listed chemical declarations 
is estimated to cause a small increase in the number of re-submissions 
of the declarations. The DEA estimates approximately 1% of all 
declarations would require re-submissions to replace the expiring 
declaration, requiring a total of an additional 85 controlled substance 
declarations and 132 listed chemical declarations per year. The 
estimated cost of each re-submission of controlled substance 
declarations and listed chemical declarations, based on estimated labor 
rates and time to complete the forms, is $13.02 and $7.81, 
respectively. There is no cost to tableting/encapsulating machine 
importers/exporters and brokers of international transactions, as this 
provision does not apply to these business activities. Based on the 
varying number of annual re-submissions estimated for each of the 
business activities, the DEA estimates this provision, if promulgated, 
would cost importers/exporters as a group $1,023, researchers as a 
group $24, analytical labs as a group $54, chemical importers/exporters 
as a group $689, and non-registered chemical importers/exporters as a 
group $344, for a total of $2,132. Based on the number of affected 
entities and the cost to the business activities as a group, the DEA 
estimated the average annual cost for each affected entity. The DEA 
estimates importers/exporters, researchers, analytical labs, chemical 
importers/exporters, and non-registered chemical importers/exporters 
will have an average cost impact of $3; $0; $0; $3; and $5 per year, 
respectively. (Figures are rounded).
    In summary, the DEA combined the impact of the two provisions to 
estimate the net impact to the affected small entities. The DEA 
estimates an average annual net savings of $1,157 for the 310 
controlled substance importers/exporters, an average annual net savings 
of $1 for the 5,474 researchers, an average annual net savings of $31 
for the 1,134 analytical labs, an average annual net cost of $3 for the 
218 DEA-registered listed chemical importers/exporters, an average 
annual net cost of $5 for the 72 non-registered listed chemicals 
importers/exporters, an annual net cost of $71 for the 54 tableting/
encapsulating machine importers/exporters, no economic impact for the 
11 brokers of international transactions, no economic impact for the 44 
tableting/encapsulating machine domestic suppliers, and no economic 
impact for 4 entities selling EPH, PSE, PPA, and GHB by mail order.
    The DEA evaluated the net economic impact by size category for each 
of the business activities. The DEA estimates that the average annual 
cost savings of $1,157 for controlled substance importers/exporters is 
economically significant, cost savings greater than 1% of annual 
revenue, for 32 of 310 small importer/exporter entities. None of the 
remaining 7,011 small entities of the remaining business activities are 
estimated to be significantly impacted by this final rule. This rule 
will have a significant economic impact, in form of cost savings, on 32 
(0.4%) of the 7,321 affected small entities. It is the DEA's assessment 
that 0.4% of small entities does not constitute a substantial number. 
The DEA's evaluation of economic impact by size category indicates that 
the final rule will not have a significant effect on a substantial 
number of these small entities.

Unfunded Mandates Reform Act of 1995

    The estimated annual impact of this rule is $429,650; thus, the DEA 
has determined in accordance with the Unfunded Mandates Reform Act of 
1995 (UMRA), 2 U.S.C. 1501 et seq., that this action would not result 
in any federal mandate that may result in the expenditure by State, 
local, and tribal governments, in the aggregate, or by the private 
sector, of $100,000,000 or more (adjusted for inflation) in any one 
year. Therefore, neither a Small Government Agency Plan nor any other 
action is required under provisions of UMRA.

Paperwork Reduction Act of 1995

    Pursuant to section 3507(d) of the Paperwork Reduction Act of 1995 
(PRA) (44 U.S.C. 3501 et seq.), the DEA has identified the following 
collections of information related to this final rule and has submitted 
this collection request to the Office of Management and Budget (OMB) 
for review and approval. This final rule updates the DEA regulations 
for import and export of controlled substances, listed chemicals, and 
tableting and encapsulating machines. The rule also clarifies certain 
policies and reflects current procedures and technological 
advancements. It allows for the implementation of the President's 
Executive Order on streamlining the export/import process, requiring 
the government-wide utilization of the International Trade Data System 
(ITDS). The DEA is not authorized to impose a penalty on persons for 
violating information collection requirements which do not display a 
current OMB control number, if one is required. Copies of existing 
information collections approved by OMB may be obtained at http://www.reginfo.gov/public/do/PRAMain.

A. Collections of Information Associated With the Final Rule

    The DEA is revising existing information collections 1117-0004, 
1117-0009 and 1117-0013 by

[[Page 97015]]

establishing mandatory filing of return information for imports and 
exports of controlled substances.
    Additionally, the DEA is also revising existing information 
collection 1117-0024 by establishing two new forms for the reporting of 
transactions with listed chemicals, tableting machines, and 
encapsulating machines. Specifically, the DEA is creating new DEA Form 
452, ``Reports for Regulated Machines.'' The DEA Form 452 will be used 
by regulated persons to report both domestic regulated transactions as 
well as import and export regulated transactions of tableting and 
encapsulating machines. The DEA is also establishing mandatory filing 
of return information for the importing and exporting of tableting and 
encapsulating machines that would be incorporated into the DEA Form 
452. Additionally, the DEA is revising existing information collection 
1117-0024 by establishing a new form for the reporting of unusual or 
excessive loss or disappearance of a listed chemical. Regulated persons 
would report this information on new DEA Form 107, ``Reports of Loss or 
Disappearance of Listed Chemicals.''
    The DEA is revising existing information collection 1117-0033 by 
establishing a new form for reporting mail-order transactions involving 
specified listed chemicals. Specifically, the DEA is creating new DEA 
Form 453, ``Report of Mail Order Transactions.'' The DEA Form 453 will 
be used by regulated persons required to file monthly reports of 
transactions with nonregulated persons with EPH, PSE, PPA, or GHB 
(including drug products containing these chemicals or controlled 
substance) and use or attempt to use the U.S. Postal Service or any 
private or commercial carrier as well as regulated persons required to 
file monthly reports of export transactions with EPH, PSE, PPA, or GHB 
(including drug products containing these chemicals or controlled 
substance) and use or attempt to use the U.S. Postal Service or any 
private or commercial carrier.
1. Title: Application for Permit To Export Controlled Substances--DEA 
Form 161/Application for Permit To Export Controlled Substances for 
Subsequent Reexport--DEA Form 161R/Application for Permit To Export 
Controlled Substances for Subsequent Reexport Among Members of the 
European Economic Area--DEA Form 161R-EEA
    OMB Control Number: 1117-0004.
    Form Number: DEA Form 161, 161R, 161R-EEA.
    As part of the implementation of the ITDS, the DEA is mandating 
electronic filing of return information for any person who desires to 
export or reexport controlled substances listed in schedule I or II, 
any narcotic substance listed in schedules III or IV, or any non-
narcotic substance in schedule II which the Administrator has 
specifically designated by regulation in Sec.  1312.30, or any non-
narcotic substance in schedule IV or V which is also listed in schedule 
I or II of the Convention on Psychotropic Substances, 1971.
    The DEA is amending Sec.  1312.22 to provide clear instructions on 
the process of return information for controlled substances subject to 
export permit requirements, which will be submitted electronically as 
part of the DEA Form 161. Specifically, in Sec.  1312.22 the DEA is 
requiring that within 30 calendar days after a controlled substance is 
released by a customs officer at the port of export from the United 
States in accordance with the permitting process, or within 10 calendar 
days after receipt of a written request by the Administration to the 
exporter, whichever is sooner, the exporter must file a report with the 
Administration through the DEA Diversion Control Division secure 
network application (available on the DEA Diversion Control Division 
Web site) that such export has occurred and the specifics of the 
transaction.
    As part of the implementation of ITDS, the DEA is establishing a 
new DEA Form 161R-EEA, discussed in greater detail below, to be used by 
registrants or regulated persons who export controlled substances for 
reexport among members of the European Economic Area. The existing DEA 
Form 161R would remain in use for exports of controlled substances that 
will be reexported to countries that are not members of the European 
Economic Area. The DEA is amending Sec.  1312.22 to provide clear 
instructions on the process of return information for controlled 
substances subject to reexport permit requirements that will be 
reexported outside of the European Economic Area, which will be 
submitted electronically as part of the DEA Form 161R. Consistent with 
current requirements, the amended Sec.  1312.22 requires that within 30 
calendar days after a controlled substance is released by a customs 
officer at the port of export the exporter must file a report with the 
Administration through the DEA Diversion Control Division secure 
network application (available on the DEA Diversion Control Division 
Web site) that such export has occurred and the specifics of the 
transaction. Also consistent with current requirements, the amended 
text requires that the exporter must additionally electronically file a 
similar report of return information within 30 calendar days of the 
controlled substances being exported from the first country to the 
second country. As noted, the DEA Form 161R, and associated return 
information, are required to be accessed, completed, and submitted to 
the DEA through the DEA Diversion Control Division secure network 
application.
    This final rule contains amendments that implement section 4, Re-
exportation Among Members of the European Economic Area, of the 
Improving Regulatory Transparency for New Medical Therapies Act, Public 
Law 114-89, which was signed into law on November 25, 2015. Section 4 
amended section 1003 of the Controlled Substances Import and Export Act 
(21 U.S.C. 953) by making changes to paragraph (f) and adding paragraph 
(g) that allows for reexportation of controlled substances among 
members of the European Economic Area. While other reexports must be 
completed no later than 180 days after initial export from the United 
States, controlled substances may continue to be reexported among 
members of the European Economic Area indefinitely, so long as the 
statutory conditions are met. As part of the implementation, the DEA is 
establishing a new DEA Form 161R-EEA, ``Application for Permit to 
Export Controlled Substances for Subsequent Reexport Among Members of 
the European Economic Area,'' to be used by registrants or regulated 
persons who export controlled substances for reexport among members of 
the European Economic Area. Specifically, in Sec.  1312.22, the DEA is 
requiring that within 30 calendar days after the controlled substance 
is released by a customs officer at the port of export the exporter 
must file a report with the Administration through the DEA Diversion 
Control Division secure network application of the particulars of the 
transaction. The exporter must additionally file similar return 
information within 30 days of the controlled substances being exported 
from the first country to the second country and for each subsequent 
reexport among members of the European Economic Area. The DEA 
considered but ultimately did not choose to propose that such 
applications would be made electronically on the DEA Form 161R based on 
the fact that there are different application requirements for the two 
types of transactions required by the CSA. Most important of these

[[Page 97016]]

distinctions for tracking purposes are that reexports among members of 
the European Economic Area do not have a time period for which such 
transactions will ``close'' (i.e., all return information submitted). 
While under previous Sec.  1312.22(d)(7) (now Sec.  1312.22(h)(6)), 
other reexports must be completed no later than 180 days after release 
by a customs officer at the port of export from the United States, the 
2015 Act specifies that controlled substances may continue to be 
reexported among members of the European Economic Area indefinitely, so 
long as the statutory conditions are met. As noted, the DEA Form 161R-
EEA, and associated return information, would be required to be 
accessed, completed, and submitted to the DEA through the DEA Diversion 
Control Division secure network application.
    The DEA estimates that there will be 125 respondents to this 
information collection. The DEA estimates that the frequency of 
response will vary as DEA Form 161 is required to be completed by each 
respondent per each occurrence. The DEA estimates there will be a total 
of 5,386 responses. The DEA estimates, based on data from an already 
approved collection containing return information, that it will take 5 
minutes (online) to provide return information electronically and that 
the total annual burden will be 449 hours. The DEA estimates that the 
frequency of response will vary as DEA Form 161R and DEA Form 161R-EEA 
are required to be completed by each respondent per each occurrence. 
The DEA estimates there will be a combined total of 789 responses for 
DEA Form 161R and DEA Form 161R-EEA. Since the distinction between DEA 
Form 161R and DEA Form 161R-EEA does not currently exist, the DEA does 
not have an estimated number of responses for the two forms separately. 
Actual responses will be used for future information collection 
requests. Since return information is currently required for 
reexportations, the final rule does not create a new information 
collection burden for reexportations.
2. Title: Controlled Substances Import/Export Declaration--DEA Form 236
    OMB Control Number: 1117-0009.
    Form Number: DEA Form 236.
    As part of the implementation of the ITDS, the DEA is mandating 
electronic filing of return information for any person who desires to 
import non-narcotic substances in schedules III, IV, and V or to export 
non-narcotic substances in schedules III and IV and any other substance 
in schedule V.
    The DEA is amending to Sec.  1312.18(e) to provide clear 
instructions on the process of return information for controlled 
substances imported under declaration procedures, which will be 
submitted electronically as part of the DEA Form 236 (Import 
declaration). The amended regulation would state that within 30 
calendar days after actual receipt of a controlled substance at the 
importer's registered location, or within 10 calendar days after the 
receipt of a written request by the Administration to the importer, 
whichever is sooner, the importer must report to the Administration 
utilizing the secure network application available on the DEA Diversion 
Control Division Web site certifying that such import occurred and the 
details of the transaction.
    The DEA is amending to Sec.  1312.27(d) in the final rule to 
provide clear instructions on the process of return information for 
controlled substances exported and reexported under declaration 
procedures, which will be submitted electronically as part of the DEA 
Form 236 (Export declaration). The amended regulation would state that 
within 30 calendar days after the controlled substance is released by a 
customs officer at the port of export or within 10 calendar days after 
receipt of a written request by the Administration to the exporter, 
whichever is sooner, the exporter must report to the Administration 
through the DEA Diversion Control Division secure network application 
(available on the DEA Diversion Control Division Web site) certifying 
that such export has occurred and the details of the transaction. For 
reexports under declaration procedures, the amended regulation states 
that within 30 calendar days after the controlled substance is exported 
from the first country to the second country, or within 10 calendar 
days after the receipt of a written request by the Administration to 
the exporter, whichever is sooner, the exporter must report to the 
Administration through the DEA Diversion Control Division secure 
network application (available on the DEA Diversion Control Division 
Web site) certifying that such export from the first country has 
occurred and the details of the transaction.
    The DEA estimates that there will be 341 respondents to this 
information collection. The DEA estimates that the frequency of 
response will vary as DEA Form 236 is required to be completed by each 
respondent per each occurrence. The DEA estimates there will be a total 
of 6,026 responses. The DEA estimates, based on data from an already 
approved collection containing return information, that it will take 5 
minutes (online) to provide return information electronically and that 
the total annual burden will be 502 hours.
3. Title: Application for Permit To Import Controlled Substances for 
Domestic and/or Scientific Purposes Pursuant to 21 U.S.C. 952
    OMB Control Number: 1117-0013.
    Form Number: DEA Form 357.
    As part of the implementation of the ITDS, the DEA is mandating 
electronic filing of return information for any person who desires to 
import any controlled substance listed in schedule I or II or any 
narcotic controlled substance listed in schedule III, IV, or V or any 
non-narcotic controlled substance in schedule III which the 
Administrator has specifically designed by regulation in 21 CFR 1312.30 
or any non-narcotic controlled substance in schedule IV or V which is 
also listed in schedule I or II of the Convention on Psychotropic 
Substances.
    The DEA is adding Sec.  1312.12(d) to provide clear instructions on 
the process of return information for controlled substances imported 
under permit procedures, which will be submitted electronically as part 
of the DEA Form 357. Specifically, in Sec.  1312.12(d), the DEA is 
requiring that within 30 calendar days of actual receipt of a 
controlled substance at the importer's registered location, or within 
10 calendar days after receipt of a written request by the 
Administration, whichever is sooner, the importer must report to the 
Administration through the DEA Diversion Control Division secure 
network application (available on the DEA Diversion Control Division 
Web site) that such import occurred and the details of the transaction.
    The DEA estimates that there will be 148 respondents to this 
information collection. The DEA estimates that the frequency of 
response will vary as DEA Form 357 is required to be completed by each 
respondent per each occurrence. The DEA estimates there will be a total 
of 1,024 responses. The DEA estimates, based on data from an already 
approved collection containing return information, that it will take 5 
minutes (online) to provide return information electronically and that 
the total annual burden will be 85 hours.
4. Title: Reports of Loss or Disappearance of Listed Chemicals--DEA 
Form 107, and Regulated Transactions in Tableting/Encapsulating 
Machines--DEA Form 452
    OMB Control Number: 1117-0024.
    Form Number: DEA Form 107 and DEA Form 452.

[[Page 97017]]

    As part of the implementation of the ITDS, the DEA is establishing 
a new DEA Form 452 to be used by regulated persons involved in 
regulated transactions in tableting or encapsulating machines. The DEA 
would standardize the current report required in the previous Sec.  
1310.05(a)(4) for domestic regulated transactions in a tableting or 
encapsulating machine as well as the report required in the previous 
Sec.  1310.05(c) for import and export of tableting and encapsulating 
machines. DEA Form 452 would be required to be accessed, completed, and 
submitted to the DEA through the DEA Diversion Control Division secure 
network application.
    Moreover, under both the previous and revised regulation, each 
regulated person must orally report any domestic regulated transaction 
in a tableting machine or an encapsulating machine to the Special Agent 
in Charge of the DEA Divisional Office for the area in which the 
regulated person making the report is located. The DEA now clarifies 
that the report must be made when the order is placed with the seller. 
The regulated person must subsequently file a written report of the 
domestic regulated transaction (on DEA Form 452) with the 
Administration through the DEA Diversion Control Division secure 
network application within 15 calendar days after the order has been 
shipped by the seller. A report (on DEA Form 452) may contain multiple 
line entries for more than one transaction.
    Additionally, the DEA is mandating filing of return information for 
the import and export of tableting and encapsulating machines which 
will be electronically submitted as part of the DEA Form 452. The 
amended regulation states that within 30 calendar days of the shipment 
being released by a customs officer at the port of entry or port of 
export, or within 10 calendar days after the receipt of a written 
request by the Administration to the importer/exporter, whichever is 
sooner, the importer/exporter must report to the Administration through 
the DEA Diversion Control Division secure network application 
(available on the DEA Diversion Control Division Web site) certifying 
that such import/export occurred and the details of the transaction. 
Previously, Sec.  1310.05(c) instructed that regulated persons needed 
to provide notification of the import or export of a tableting machine 
or encapsulating machine on or before the date of exportation. However, 
the DEA has amended Sec.  1310.05(c) in order for DEA Form 452 to be 
submitted to the DEA at least 15 calendar days before the date of 
release by a customs officer at the port of entry or port of export in 
order to allow time for the DEA to review the information and transmit 
it into the ITDS prior to the actual import or export.
    As part of the implementation of the ITDS, the DEA is establishing 
a new DEA Form 107 to be used by regulated persons involved in 
reporting unusual or excessive loss or disappearance of a listed 
chemical. The DEA would standardize the current report required to be 
filed in the previous Sec.  1310.05(a)(3). Each regulated person must 
report to the Special Agent in Charge of the DEA Divisional Office for 
the area in which the regulated person making the report is located any 
unusual or excessive loss or disappearance of a listed chemical under 
the control of the regulated person. The regulated person will orally 
report to the Special Agent in Charge of the DEA Divisional Office at 
the earliest practicable opportunity after the regulated person becomes 
aware of the circumstances involved. The regulated person must also 
file a complete and accurate DEA Form 107 with the Administration 
through the DEA Diversion Control Division secure network application 
within 15 calendar days after becoming aware of the circumstances 
requiring the report. Unusual or excessive losses or disappearances 
must be reported whether or not the listed chemical is subsequently 
recovered or the responsible parties are identified and action taken 
against them. DEA Form 107 would be required to be accessed, completed, 
and submitted to the DEA through the DEA Diversion Control Division 
secure network application. While the report would be electronic, the 
filing requirements are essentially unchanged. The DEA estimates that 
the reporting burden would continue to be 20 minutes for each report.
    Specifically, based on publicly available information and 
historical data, the DEA estimates that there will be 130 respondents 
to this information collection, 60 for domestic transactions and 70 for 
imports or exports. The DEA estimates that the frequency of response 
will vary as DEA Form 452 is required to be completed by each 
respondent per each occurrence. As the DEA does not have a strong basis 
to estimate the number of responses for domestic transactions, the DEA 
makes an initial estimate (to be refined later) of 52 responses per 
week for each of 60 respondents, or a total of 3,120 domestic 
transaction related responses. Based on historical data, the DEA 
estimates there will be 917 import or export related responses for a 
grand total of 4,037 responses for domestic transactions, imports, and 
exports. Because of the information required on the DEA Form 452, the 
DEA estimates that this form will take 20 minutes to complete, 
including the oral report for domestic transactions and return 
information for imports and exports, and that the total annual burden 
will be 1,346 hours.
5. Title: Report of Mail Order Transactions--DEA Form 453
    OMB Control Number: 1117-0033.
    Form Number: DEA Form 453.
    As part of the implementation of the ITDS, the DEA is establishing 
a new DEA Form 453, ``Report of Mail Order Transactions,'' to be used 
by regulated persons required to file monthly reports of transactions 
with nonregulated persons with ephedrine, pseudoephedrine, 
phenylpropanolamine, or gamma-hydroxybutyric acid (including drug 
products containing these chemicals or controlled substance) and use or 
attempt to use the U.S. Postal Service or a private or commercial 
carrier as well as regulated persons required to file monthly reports 
of export transactions with ephedrine, pseudoephedrine, 
phenylpropanolamine, or gamma-hydroxybutyric acid (including drug 
products containing these chemicals or controlled substance) and use or 
attempt to use the U.S. Postal Service or a private or commercial 
carrier. The DEA would require reports under the previous Sec. Sec.  
1310.03(c) and 1310.06(i) to be submitted on a new DEA Form 453 which 
would be required to be accessed and submitted to the DEA through the 
DEA Diversion Control Division secure network application.
    Additionally, the form would require the following information: The 
mail order transaction supplier name and registration number; the 
purchaser's name and address; the name and address shipped to (if 
different from purchaser's name and address); the name of the chemical 
contained in the scheduled listed chemical product and total quantity 
shipped (e.g., pseudoephedrine, 3 grams); the date of shipment; the 
product name; the dosage form (e.g., tablet, liquid, powder); the 
dosage strength; the number of dosage units; the package type; the 
number of packages; and the lot number. Previously, Sec.  1310.05(e) 
instructed that regulated persons submit a written report, containing 
the information listed above, on or before the 15th day of each month 
following the month in which the distributions took place. However, the 
DEA is amending part 1310 in order for DEA Form 453 to be submitted to 
the DEA electronically on or before the 15th

[[Page 97018]]

day of each month following the month in which the distributions took 
place.
    Specifically, based on historical data, the DEA estimates that 
there will be 7 respondents to this information collection. The 
respondents will provide 12 responses per year. The DEA estimates there 
will be a total of 84 responses per year. The DEA estimates that this 
form will take 15 minutes to complete and that the total annual burden 
will be 21 hours.

Rule Text

List of Subjects

21 CFR Part 1300

    Chemicals, Drug traffic control.

21 CFR Part 1301

    Administrative practice and procedure, Drug traffic control, 
Exports, Imports, Security measures.

21 CFR Part 1302

    Drug traffic control, Exports, Imports, Labeling, Packaging and 
containers.

21 CFR Part 1303

    Administrative practice and procedure, Drug traffic control.

21 CFR Part 1304

    Drug traffic control, Reporting and recordkeeping requirements.

21 CFR Part 1308

    Administrative practice and procedure, Drug traffic control, 
Exports, Imports, Reporting and recordkeeping requirements.

21 CFR Part 1309

    Administrative practice and procedure, Drug traffic control, 
Exports, Imports.

21 CFR Part 1310

    Drug traffic control, Exports, Imports, Reporting and recordkeeping 
requirements.

21 CFR Part 1312

    Administrative practice and procedure, Drug traffic control, 
Exports, Imports, Reporting and recordkeeping requirements.

21 CFR Part 1313

    Administrative practice and procedure, Drug traffic control, 
Exports, Imports, Reporting and recordkeeping requirements.

21 CFR Part 1314

    Drug traffic control, Reporting and recordkeeping requirements.

21 CFR Part 1315

    Administrative practice and procedure, Chemicals, Drug traffic 
control, Imports, Reporting and recordkeeping requirements.

21 CFR Part 1316

    Administrative practice and procedure, Authority delegations 
(Government agencies), Drug traffic control, Research, Seizures and 
forfeitures.

21 CFR Part 1321

    Administrative practice and procedure.
    For the reasons stated in the preamble, the DEA amends 21 CFR parts 
1300, 1301, 1302, 1303, 1304, 1308, 1309, 1310, 1312, 1313, 1314, 1315, 
1316, and 1321 as follows:

PART 1300--DEFINITIONS

0
1. The authority citation for part 1300 continues to read as follows:

    Authority:  21 U.S.C. 802, 821, 822, 829, 871(b), 951, 958(f).


0
2. In Sec.  1300.01(b):
0
a. Revise definitions of ``Export'' and ``Import'';
0
b. Add definitions of ``Competent national authority'', ``Customs 
officer'', ``Port of entry'', ``Port of export'', ``Return 
information'', and ``United States'', in alphabetical order; and
0
c. Remove the definition of ``Jurisdiction of the United States''.
    The revisions and additions read as follows:


Sec.  1300.01  Definitions relating to controlled substances.

* * * * *
    (b) * * *
    Competent national authority, for purposes of importation and 
exportation of controlled substances and listed chemicals, means an 
entity lawfully entitled to authorize the import and export of 
controlled substances, and to regulate or enforce national controls 
over listed chemicals, and included as such in the directory of 
``Competent National Authorities Under the International Drug Control 
Treaties'' published by the United Nations Office on Drugs and Crime. 
For purposes of exports of narcotic drugs, the term also includes 
freely associated states authorized to receive such exports pursuant to 
48 U.S.C. 1972.
* * * * *
    Customs officer means either an Officer of the Customs as defined 
in 19 U.S.C. 1401(i) (that is, of the U.S. Customs and Border 
Protection), or any individual duly authorized to accept entries of 
merchandise, to collect duties, and to enforce the customs laws of any 
commonwealth, territory, or possession of the United States.
* * * * *
    Export means, with respect to any article, any taking out or 
removal of such article from the United States (whether or not such 
taking out or removal constitutes an exportation within the meaning of 
the customs laws, export control laws enforced by other agencies, or 
related laws of the United States).
* * * * *
    Import means, with respect to any article, any bringing in or 
introduction of such article into the customs territory of the United 
States from any place outside thereof (but within the United States), 
or into the United States from any place outside thereof (whether or 
not such bringing in or introduction constitutes an importation within 
the meaning of the tariff laws of the United States).
* * * * *
    Port of entry means, unless distinguished as being a foreign port 
of entry, any place at which a customs officer is duly authorized to 
accept entries of merchandise, to collect duties, and to enforce the 
various provisions of the customs laws of the United States (whether or 
not such place is a port of entry as defined in title 19 of the United 
States Code or its associated implementing regulations). Examples of 
ports of entry include, but are not limited to, places designated as 
ports of entry or customs stations in title 19 of the Code of Federal 
Regulations or by the governing customs authority of that area. When 
shipments are transported under U.S. Customs and Border Protection's 
immediate transportation procedures, the port of entry shall be the 
port of final destination.
    Port of export means, unless distinguished as being a foreign port 
of export, any place under the control of a customs officer where goods 
are loaded on an aircraft, vessel or other conveyance for export 
outside of the United States. For goods loaded aboard an aircraft or 
vessel in the United States, that stops at several ports before 
departing the United States, the port of export is the first port where 
the goods were actually loaded. For goods off-loaded from the original 
conveyance to another conveyance (even if the aircraft or vessel 
belongs to the same carrier) at any port subsequent to the port where 
the first on-loading occurred in the United States, the port where the 
goods were loaded onto the last conveyance before departing the United 
States is the port of export.
* * * * *

[[Page 97019]]

    Return information means supplemental information required to be 
reported to the Administration following an import or export 
transaction containing the particulars of the transaction and any other 
information as the Administration may specify.
* * * * *
    United States, when used in a geographic sense, means all places 
and waters, continental or insular, subject to the jurisdiction of the 
United States, which, in addition to the customs territory of the 
United States, include but are not limited to the U.S. Virgin Islands, 
Guam, American Samoa, and the Northern Mariana Islands.

0
3. In Sec.  1300.02(b):
0
a. Add definitions of ``Competent national authority'', ``Customs 
officer'', ``Export'', ``Import'', ``Port of entry'', ``Port of 
export'', ``Return information'', and ``United States'', in 
alphabetical order; and
0
b. Remove definitions of ``Chemical import'' and ``Jurisdiction of the 
United States''.
    The additions read as follows:


Sec.  1300.02  Definitions relating to listed chemicals.

* * * * *
    (b) * * *
    Competent national authority, for purposes of importation and 
exportation of controlled substances and listed chemicals, means an 
entity lawfully entitled to authorize the import and export of 
controlled substances, and to regulate or enforce national controls 
over listed chemicals, and included as such in the directory of 
``Competent National Authorities Under the International Drug Control 
Treaties'' published by the United Nations Office on Drugs and Crime.
    Customs officer means either an Officer of the Customs as defined 
in 19 U.S.C. 1401(i) (that is, of the U.S. Customs and Border 
Protection), or any individual duly authorized to accept entries of 
merchandise, to collect duties, and to enforce the customs laws of any 
commonwealth, territory, or possession of the United States.
* * * * *
    Export means, with respect to any article, any taking out or 
removal of such article from the United States (whether or not such 
taking out or removal constitutes an exportation within the meaning of 
the customs laws, export control laws enforced by other agencies, or 
related laws of the United States).
* * * * *
    Import means, with respect to any article, any bringing in or 
introduction of such article into the customs territory of the United 
States from any place outside thereof (but within the United States), 
or into the United States from any place outside thereof (whether or 
not such bringing in or introduction constitutes an importation within 
the meaning of the tariff laws of the United States).
* * * * *
    Port of entry, unless distinguished as being a foreign port of 
entry, means any place at which a customs officer is duly authorized to 
accept entries of merchandise, to collect duties, and to enforce the 
various provisions of the customs laws of the United States (whether or 
not such place is a port of entry as defined in title 19 of the United 
States Code or its associated implementing regulations). Examples of 
ports of entry include, but are not limited to, places designated as 
ports of entry or customs stations in title 19 of the Code of Federal 
Regulations or by the governing customs authority of that area. When 
shipments are transported under U.S. Customs and Border Protection 
immediate transportation procedures, the port of entry shall be the 
port of final destination.
    Port of export means, unless distinguished as being a foreign port 
of export, any place under the control of a customs officer where goods 
are loaded on an aircraft, vessel or other conveyance for export 
outside of the United States. For goods loaded aboard an aircraft or 
vessel in the United States that stops at several ports before 
departing the United States, the port of export is the first port where 
the goods were loaded. For goods off-loaded from the original 
conveyance to another conveyance (even if the aircraft or vessel 
belongs to the same carrier) at any port subsequent to the port where 
the first on-loading occurred in the United States, the port where the 
goods were loaded onto the last conveyance before departing the United 
States is the port of export. For reporting purposes, in the case of an 
otherwise lawful export occurring by mail, the port of export is the 
place of mailing.
* * * * *
    Return information means supplemental information required to be 
reported to the Administration following an import or export 
transaction containing the particulars of the transaction and any other 
information as the Administration may specify.
* * * * *
    United States, when used in a geographic sense, means all places 
and waters, continental or insular, subject to the jurisdiction of the 
United States, which, in addition to the customs territory of the 
United States, include but are not limited to the U.S. Virgin Islands, 
Guam, American Samoa, and the Northern Mariana Islands.
* * * * *

PART 1301--REGISTRATION OF MANUFACTURERS, DISTRIBUTORS, AND 
DISPENSERS OF CONTROLLED SUBSTANCES

0
4. The authority citation for part 1301 continues to read as follows:

    Authority:  21 U.S.C. 821, 822, 823, 824, 831, 871(b), 875, 877, 
886a, 951, 952, 953, 956, 957, 958, 965.


0
 5. In Sec.  1301.12, revise paragraph (b)(3) to read as follows:


Sec.  1301.12  Separate registrations for separate locations.

* * * * *
    (b) * * *
    (3) An office used by a practitioner (who is registered at another 
location in the same State in which he or she practices) where 
controlled substances are prescribed but neither administered nor 
otherwise dispensed as a regular part of the professional practice of 
the practitioner at such office, and where no supplies of controlled 
substances are maintained.
* * * * *

0
6. In Sec.  1301.24, revise paragraph (a)(1) to read as follows:


Sec.  1301.24  Exemption of law enforcement officials.

    (a) * * *
    (1) Any officer or employee of the Administration, any customs 
officer, any officer or employee of the U.S. Food and Drug 
Administration, and any other Federal or Insular officer who is 
lawfully engaged in the enforcement of any Federal law relating to 
controlled substances, drugs, or customs, and is duly authorized to 
possess or to import or export controlled substances in the course of 
his/her official duties; and
* * * * *

0
7. In Sec.  1301.26, revise paragraph (b) introductory text to read as 
follows:


Sec.  1301.26  Exemption from import or export requirements for 
personal medical use.

* * * * *
    (b) The individual makes a declaration to an appropriate customs 
officer stating:
* * * * *

0
8. In Sec.  1301.34, revise paragraph (c)(2) to read as follows:

[[Page 97020]]

Sec.  1301.34  Application for importation of Schedule I and II 
substances.

* * * * *
    (c) * * *
    (2) Employment of security procedures to guard against in-transit 
losses.
* * * * *

0
 9. In Sec.  1301.74, revise paragraph (c) introductory text to read as 
follows:


Sec.  1301.74  Other security controls for non-practitioners; narcotic 
treatment programs and compounders for narcotic treatment programs.

* * * * *
    (c) The registrant must notify the Field Division Office of the 
Administration in his or her area, in writing, of any theft or 
significant loss of any controlled substances within one business day 
of discovery of the theft or loss. Unless the theft or loss occurs 
during an import or export transaction, the supplier is responsible for 
reporting all in-transit losses of controlled substances by their agent 
or the common or contract carrier selected pursuant to paragraph (e) of 
this section, within one business day of discovery of such theft or 
loss. In an import transaction, once a shipment has been released by 
the customs officer at the port of entry, the importer is responsible 
for reporting all in-transit losses of controlled substances by their 
agent or the common or contract carrier selected pursuant to paragraph 
(e) of this section, within one business day of discovery of such theft 
or loss. In an export transaction, the exporter is responsible for 
reporting all in-transit losses of controlled substances by their agent 
or the common or contract carrier selected pursuant to paragraph (e) of 
this section within one business day of discovery of such theft or 
loss, until the shipment has been released by the customs officer at 
the port of export. The registrant must also complete, and submit to 
the Field Division Office in his or her area, DEA Form 106 regarding 
the theft or loss. Thefts and significant losses must be reported 
whether or not the controlled substances are subsequently recovered or 
the responsible parties are identified and action taken against them. 
When determining whether a loss is significant, a registrant should 
consider, among others, the following factors:
* * * * *

PART 1302--LABELING AND PACKAGING REQUIREMENTS FOR CONTROLLED 
SUBSTANCES

0
 10. The authority citation for part 1302 continues to read as follows:

    Authority:  21 U.S.C. 821, 825, 871(b), 958(e).


0
 11. Revise Sec.  1302.07 to read as follows:


Sec.  1302.07  Labeling and packaging requirements for imported and 
exported substances.

    (a) The symbol requirements of Sec. Sec.  1302.03 through 1302.05 
apply to every commercial container containing, and to all labeling of, 
controlled substances imported into the customs territory of the United 
States from any place outside thereof (but within the United States), 
or imported into the United States from any place outside thereof.
    (b) The symbol requirements of Sec. Sec.  1302.03 through 1302.05 
do not apply to any commercial containers containing, or any labeling 
of, a controlled substance intended for export.
    (c) The sealing requirements of Sec.  1302.06 apply to every 
bottle, multiple dose vial, or other commercial container of any 
controlled substance listed in schedule I or II, or any narcotic 
controlled substance listed in schedule III or IV imported into the 
customs territory of the United States from any place outside thereof 
(but within the United States), or imported into the United States from 
any place outside thereof. The sealing requirements of Sec.  1302.06 
apply to every bottle, multiple dose vial, or other commercial 
container of any controlled substance listed in schedule I or II, or 
any narcotic controlled substance listed in schedule III or IV, 
exported or intended for export from the United States. These sealing 
and labeling requirements are in addition to any sealing requirements 
required under applicable customs laws.

PART 1303--QUOTAS

0
 12. The authority citation for part 1303 continues to read as follows:

    Authority:  21 U.S.C. 821, 826, 871(b).


Sec.  1303.12  [Amended]

0
13. In Sec.  1303.12:
0
a. In paragraph (b), remove ``Drug and Chemical Evaluation Section, 
Drug Enforcement Administration'' and add in its place ``UN Reporting 
and Quota Section, Diversion Control Division''; and
0
b. In paragraph (d), remove ``Drug & Chemical Evaluation Section, Drug 
Enforcement Administration'' and add in its place ``UN Reporting and 
Quota Section, Diversion Control Division''.


Sec.  1303.22  [Amended]

0
14. In Sec.  1303.22 introductory text, remove ``Drug & Chemical 
Evaluation Section, Drug Enforcement Administration'' and add in its 
place ``UN Reporting and Quota Section, Diversion Control Division''.

PART 1304--RECORDS AND REPORTS OF REGISTRANTS

0
15. The authority citation for part 1304 continues to read as follows:

    Authority:  21 U.S.C. 821, 827, 831, 871(b), 958 (e)-(g), and 
965, unless otherwise noted.


0
 16. Revise Sec.  1304.02 to read as follows:


Sec.  1304.02  Definitions.

    Any term contained in this part shall have the definition set forth 
in section 102 of the Act (21 U.S.C. 802) or Sec.  1300.01, Sec.  
1300.03, Sec.  1300.04, or Sec.  1300.05 of this chapter.

0
17. In Sec.  1304.21, revise paragraph (d) to read as follows:


Sec.  1304.21  General requirements for continuing records.

* * * * *
    (d) In recording dates of receipt, distribution, other transfers, 
or destruction, the date on which the controlled substances are 
actually received, distributed, otherwise transferred, or destroyed 
will be used as the date of receipt, distribution, transfer, or 
destruction (e.g., invoices or packing slips, or DEA Form 41). In 
maintaining records concerning imports and exports, the registrant must 
record the anticipated date of release by a customs official for permit 
applications and declarations and the date on which the controlled 
substances are released by a customs officer at the port of entry or 
port of export for return information.
* * * * *


Sec.  1304.31  [Amended]

0
18. In Sec.  1304.31(a), remove ``Drug and Chemical Evaluation Section, 
Drug Enforcement Administration'' and add in its place ``UN Reporting 
and Quota Section, Diversion Control Division''.


Sec.  1304.32  [Amended]

0
19. In Sec.  1304.32(a), remove ``Drug and Chemical Evaluation Section, 
Drug Enforcement Administration'' and add in its place ``UN Reporting 
and Quota Section, Diversion Control Division''.

0
20. In Sec.  1304.33, revise paragraphs (a) and (f)(1) to read as 
follows:

[[Page 97021]]

Sec.  1304.33  Reports to Automation of Reports and Consolidated Orders 
System (ARCOS).

    (a) Reports generally. All reports required by this section shall 
be filed with the Pharmaceutical Investigations Section, Diversion 
Control Division, Drug Enforcement Administration on DEA Form 333, or 
on media which contains the data required by DEA Form 333 and which is 
acceptable to the Administration. See the Table of DEA Mailing 
Addresses in Sec.  1321.01 of this chapter for the current mailing 
address.
* * * * *
    (f) Exceptions. (1) A registered institutional practitioner that 
repackages or relabels exclusively for distribution or that distributes 
exclusively to (for dispensing by) agents, employees, or affiliated 
institutional practitioners of the registrant may be exempted from 
filing reports under this section by applying to the Pharmaceutical 
Investigations Section, Diversion Control Division, Drug Enforcement 
Administration. See the Table of DEA Mailing Addresses in Sec.  1321.01 
of this chapter for the current mailing address.
* * * * *

PART 1308--SCHEDULES OF CONTROLLED SUBSTANCES

0
 21. The authority citation for part 1308 is revised to read as 
follows:

    Authority:  21 U.S.C. 811, 812, 871(b), 956(b), unless otherwise 
noted.


0
 22. Revise Sec.  1308.01 to read as follows:


Sec.  1308.01  Scope of this part.

    Schedules of controlled substances established by section 202 of 
the Act (21 U.S.C. 812) and nonnarcotic substances, chemical 
preparations, veterinary anabolic steroid implant products, 
prescription products, anabolic steroid products, and cannabis plant 
material and products made therefrom that contain tetrahydrocannabinols 
excluded pursuant to section 201 of the Act (21 U.S.C. 811), as they 
are changed, updated, and republished from time to time, are set forth 
in this part.


Sec.  1308.21  [Amended]

0
23. In Sec.  1308.21(a), remove ``Office of Diversion Control, Drug 
Enforcement Administration'' and add in its place ``Drug and Chemical 
Evaluation Section, Diversion Control Division, Drug Enforcement 
Administration''.


Sec.  1308.23  [Amended]

0
24. In Sec.  1308.23(b), remove ``Office of Diversion Control, Drug 
Enforcement Administration'' and add in its place ``Drug and Chemical 
Evaluation Section, Diversion Control Division, Drug Enforcement 
Administration''.


Sec.  1308.25  [Amended]

0
25. In Sec.  1308.25(a), remove ``Office of Diversion Control, Drug 
Enforcement Administration'' and add in its place ``Drug and Chemical 
Evaluation Section, Diversion Control Division, Drug Enforcement 
Administration''.


Sec.  1308.31  [Amended]

0
26. In Sec.  1308.31(a), remove ``Office of Diversion Control, Drug 
Enforcement Administration'' and add in its place ``Drug and Chemical 
Evaluation Section, Diversion Control Division, Drug Enforcement 
Administration''.


Sec.  1308.33  [Amended]

0
27. In Sec.  1308.33(b), remove ``Office of Diversion Control, Drug 
Enforcement Administration'' and add in its place ``Drug and Chemical 
Evaluation Section, Diversion Control Division, Drug Enforcement 
Administration''.

0
 28. Revise Sec.  1308.49 to read as follows:


Sec.  1308.49  Temporary scheduling.

    (a) Pursuant to 21 U.S.C. 811(h) and without regard to the 
requirements of 21 U.S.C. 811(b) relating to the scientific and medical 
evaluation of the Secretary of Health and Human Services, the Drug 
Enforcement Administration may place a substance into Schedule I on a 
temporary basis, if it determines that such action is necessary to 
avoid an imminent hazard to the public safety. An order issued under 
this section may not be effective before the expiration of 30 calendar 
days from:
    (1) The date of publication by the Administration of a notice in 
the Federal Register of its intention to issue such order and the 
grounds upon which such order is to be issued; and
    (2) The date the Administration has transmitted notification to the 
Secretary of Health and Human Services of the Administration's 
intention to issue such order.
    (b) An order issued under this section will be vacated upon the 
conclusion of a subsequent rulemaking proceeding initiated under 
section 201(a) (21 U.S.C. 811(a)) with respect to such substance or at 
the end of two years from the effective date of the order scheduling 
the substance, except that during the pendency of proceedings under 
section 201(a) (21 U.S.C. 811(a)) with respect to the substance, the 
Administration may extend the temporary scheduling for up to one year.

PART 1309--REGISTRATION OF MANUFACTURERS, DISTRIBUTORS, IMPORTERS 
AND EXPORTERS OF LIST I CHEMICALS

0
29. The authority citation for part 1309 continues to read as follows:

    Authority:  21 U.S.C. 802, 821, 822, 823, 824, 830, 871(b), 875, 
877, 886a, 952, 953, 957, 958.


0
30. In Sec.  1309.26, revise paragraph (a)(1) to read as follows:


Sec.  1309.26  Exemption of law enforcement officials.

    (a) * * *
    (1) Any officer or employee of the Administration, any customs 
officer, any officer or employee of the U.S. Food and Drug 
Administration, and any Federal or Insular officer who is lawfully 
engaged in the enforcement of any federal law relating to listed 
chemicals, controlled substances, drugs, or customs, and is duly 
authorized to possess and distribute List I chemicals in the course of 
his/her official duties; and
* * * * *

0
31. In Sec.  1309.32, revise paragraph (d) to read as follows:


Sec.  1309.32  Application forms; contents; signature.

* * * * *
    (d) Each application for registration must include the 
Administration Chemical Code Number, as set forth in Sec.  1310.02 of 
this chapter, for each List I chemical to be manufactured, distributed, 
imported, or exported.
* * * * *


Sec.  1309.46  [Amended]

0
 32. In Sec.  1309.46(d), remove ``Sec.  1309.54'' and add in its place 
``Sec.  1309.53''.


Sec.  1309.51  [Amended]

0
 33. In Sec.  1309.51(a), remove ``1309.57'' and add in its place 
``1309.55''.

0
 34. In Sec.  1309.71, revise paragraphs (b)(5) and (7) to read as 
follows:


Sec.  1309.71  General security requirements.

* * * * *
    (b) * * *
    (5) The extent of unsupervised public access to the facility;
* * * * *
    (7) The procedures for handling business guests, visitors, 
maintenance personnel, and nonemployee service personnel in areas where 
List I chemicals are processed or stored; and
* * * * *

[[Page 97022]]

PART 1310--RECORDS AND REPORTS OF LISTED CHEMICALS AND CERTAIN 
MACHINES; IMPORTATION AND EXPORTATION OF CERTAIN MACHINES

0
35. The authority citation for part 1310 continues to read as follows:

    Authority:  21 U.S.C. 802, 827(h), 830, 871(b), 890.


0
36. Revise the heading of part 1310 to read as set forth above.

0
37. In Sec.  1310.03:
0
a. In paragraph (b), remove ``Section 1310.05'' and add in its place 
``Sec.  1310.05''; and
0
b. Revise paragraph (c).
    The revision reads as follows:


Sec.  1310.03  Persons required to keep records and file reports.

* * * * *
    (c)(1) Each regulated person who engages in a transaction with a 
nonregulated person which:
    (i) Involves ephedrine, pseudoephedrine, phenylpropanolamine, or 
gamma hydroxybutyric acid (including drug products containing these 
chemicals or controlled substance); and
    (ii) Uses or attempts to use the U.S. Postal Service or any private 
or commercial carrier must, on a monthly basis, report to the 
Administration each such transaction conducted during the previous 
month as specified in Sec. Sec.  1310.05(e) and 1310.06(k) on DEA Form 
453 through the DEA Diversion Control Division secure network 
application.
    (2) Each regulated person who engages in an export transaction 
which:
    (i) Involves ephedrine, pseudoephedrine, phenylpropanolamine, or 
gamma hydroxybutyric acid (including drug products containing these 
chemicals or controlled substance); and
    (ii) Uses or attempts to use the U.S. Postal Service or any private 
or commercial carrier must, on a monthly basis, report each such 
transaction conducted during the previous month as specified in 
Sec. Sec.  1310.05(e) and 1310.06(k) on DEA Form 453 through the DEA 
Diversion Control Division secure network application.

0
38. In Sec.  1310.05, revise paragraphs (a), (b), (c), (d) and (e) to 
read as follows:


Sec.  1310.05  Reports.

    (a)(1) Each regulated person must report to the Special Agent in 
Charge of the DEA Divisional Office for the area in which the regulated 
person making the report is located any regulated transaction involving 
an extraordinary quantity of a listed chemical, an uncommon method of 
payment or delivery, or any other circumstance that the regulated 
person believes may indicate that the listed chemical will be used in 
violation of this part. The regulated person will orally report to the 
Special Agent in Charge of the DEA Divisional Office at the earliest 
practicable opportunity after the regulated person becomes aware of the 
circumstances involved and as much in advance of the conclusion of the 
transaction as possible. The regulated person must file a written 
report of the transaction(s) with the Special Agent in Charge of the 
DEA Divisional Office as set forth in Sec.  1310.06 within 15 calendar 
days after the regulated person becomes aware of the circumstances of 
the event.
    (2) Each regulated person must report to the Special Agent in 
Charge of the DEA Divisional Office for the area in which the regulated 
person making the report is located any proposed regulated transaction 
with a person whose description or other identifying characteristic the 
Administration has previously furnished to the regulated person. The 
regulated person will orally report to the Special Agent in Charge of 
the DEA Divisional Office at the earliest practicable opportunity after 
the regulated person becomes aware of the circumstances involved. A 
transaction may not be completed with a person whose description or 
identifying characteristic has previously been furnished to the 
regulated person by the Administration unless the transaction is 
approved by the Administration.
    (b)(1) Each regulated person must report to the Special Agent in 
Charge of the DEA Divisional Office for the area in which the regulated 
person making the report is located any unusual or excessive loss or 
disappearance of a listed chemical under the control of the regulated 
person. The regulated person will orally report to the Special Agent in 
Charge of the DEA Divisional Office at the earliest practicable 
opportunity after the regulated person becomes aware of the 
circumstances involved. Unless the loss or disappearance occurs during 
an import or export transaction, the supplier is responsible for 
reporting all in-transit losses of any listed chemical by their agent 
or the common or contract carrier. In an import transaction, once a 
shipment has been released by the customs officer at the port of entry, 
the importer is responsible for reporting all in-transit losses of any 
listed chemical by their agent or the common or contract carrier. In an 
export transaction, the exporter is responsible for reporting all in-
transit losses of any listed chemical by their agent or the common or 
contract carrier until the shipment has been released by the customs 
officer at the port of export. The regulated person must also file a 
complete and accurate DEA Form 107, in accordance with Sec.  
1310.06(d), with the Administration through the DEA Diversion Control 
Division secure network application within 15 calendar days after 
becoming aware of the circumstances requiring the report. Unusual or 
excessive losses or disappearances must be reported whether or not the 
listed chemical is subsequently recovered or the responsible parties 
are identified and action taken against them. When determining whether 
a loss or disappearance of a listed chemical was unusual or excessive, 
the regulated persons should consider, among others, the following 
factors:
    (i) The actual quantity of a listed chemical;
    (ii) The specific listed chemical involved;
    (iii) Whether the loss or disappearance of the listed chemical can 
be associated with access to those listed chemicals by specific 
individuals, or whether the loss or disappearance can be attributed to 
unique activities that may take place involving the listed chemical; 
and
    (iv) A pattern of losses or disappearances over a specific time 
period, whether the losses or disappearances appear to be random, and 
the result of efforts taken to resolve the losses.
    (v) If known, the regulated person should also consider whether the 
specific listed chemical was a likely candidate for diversion as well 
as local trends and other indicators of the diversion potential of the 
listed chemical.
    (2) Each regulated person must orally report any domestic regulated 
transaction in a tableting machine or an encapsulating machine to the 
Special Agent in Charge of the DEA Divisional Office for the area in 
which the regulated person making the report is located when the order 
is placed with the seller. The regulated person also must file a report 
of the transaction (on DEA Form 452) with the Administration through 
the DEA Diversion Control Division secure network application within 15 
calendar days after the order has been shipped by the seller. A report 
(DEA Form 452) may list more than one machine for a single transaction. 
Upon receipt and review, the Administration will assign a completed 
report a transaction identification number. The report will not be 
deemed filed until a

[[Page 97023]]

transaction identification number has been issued by the 
Administration.
    (c) Imports and exports of tableting machines and encapsulating 
machines. (1) Each regulated person who imports or exports a tableting 
machine, or encapsulating machine, must file a report of such 
importation or exportation on DEA Form 452 with the Administration 
through the DEA Diversion Control Division secure network application, 
at least 15 calendar days before the anticipated arrival at the port of 
entry or port of export. In order to facilitate the importation or 
exportation of any tableting machine or encapsulating machine and 
implement the purpose of the Act, regulated persons may report to the 
Administration as far in advance as possible. A separate report (DEA 
Form 452) must be filed for each shipment, in accordance with Sec.  
1310.06(e). Upon receipt and review, the Administration will assign a 
completed report a transaction identification number. The report will 
not be deemed filed until a transaction identification number has been 
issued by the Administration. The importer or exporter may only proceed 
with the transaction once the transaction identification number has 
been issued. Any tableting machine or encapsulating machine may be 
imported or exported if that machine is needed for medical, commercial, 
scientific, or other legitimate uses. However, an importation or 
exportation of a tableting machine or encapsulating machine may not be 
completed with a person whose description or identifying characteristic 
has previously been furnished to the regulated person by the 
Administration unless the transaction is approved by the 
Administration.
    (2) Denied release at the port of entry. In the event that a 
shipment of tableting or encapsulating machine(s) has been denied 
release by a customs officer at the port of entry for any reason, the 
importer who attempted to import the shipment must, within 5 business 
days of the denial, report to the Administration that the shipment was 
denied, the basis for denial, and such other information as is required 
by Sec.  1310.06(g). Such report must be transmitted to the 
Administration through the DEA Diversion Control Division secure 
network application. Upon the importer's report of a denied entry, DEA 
will assign the report a transaction identification number and the 
original import notification will be void and of no effect. No shipment 
of tableting machines or encapsulating machines denied entry for any 
reason will be allowed entry without a subsequent refiling of an 
amended DEA Form 452 by the regulated person. In such circumstances, 
the regulated person may proceed with the release of the tableting 
machines or encapsulating machines upon receipt of a transaction 
identification number for the refiled and amended DEA Form 452 without 
regard to the 15-day advance filing requirement in paragraph (c)(1) of 
this section, so long as the article is otherwise cleared for entry 
under U.S. customs laws.
    (d) Each regulated bulk manufacturer of a listed chemical must 
submit manufacturing, inventory and use data on an annual basis as set 
forth in Sec.  1310.06(j). This data must be submitted annually to the 
Drug and Chemical Evaluation Section, Diversion Control Division, Drug 
Enforcement Administration, on or before the 15th day of March of the 
year immediately following the calendar year for which submitted. See 
the Table of DEA Mailing Addresses in Sec.  1321.01 of this chapter for 
the current mailing address. A business entity which manufactures a 
listed chemical may elect to report separately by individual location 
or report as an aggregate amount for the entire business entity 
provided that they inform the DEA of which method they will use. This 
reporting requirement does not apply to drugs or other products that 
are exempted under paragraph (1)(iv) or (v) of the definition of 
regulated transaction in Sec.  1300.02 of this chapter except as set 
forth in Sec.  1310.06(i)(5). Bulk manufacturers that produce a listed 
chemical solely for internal consumption are not required to report for 
that listed chemical. For purposes of these reporting requirements, 
internal consumption consists of any quantity of a listed chemical 
otherwise not available for further resale or distribution. Internal 
consumption includes (but is not limited to) quantities used for 
quality control testing, quantities consumed in-house, or production 
losses. Internal consumption does not include the quantities of a 
listed chemical consumed in the production of exempted products. If an 
existing standard industry report contains the information required in 
Sec.  1310.06(j) and such information is separate or readily 
retrievable from the report, that report may be submitted in 
satisfaction of this requirement. Each report must be submitted to the 
DEA under company letterhead and signed by an appropriate, responsible 
official. For purposes of this paragraph (d) only, the term regulated 
bulk manufacturer of a listed chemical means a person who manufactures 
a listed chemical by means of chemical synthesis or by extraction from 
other substances. The term bulk manufacturer does not include persons 
whose sole activity consists of the repackaging or relabeling of listed 
chemical products or the manufacture of drug dosage forms of products 
which contain a listed chemical.
    (e) Each regulated person required to report pursuant to Sec.  
1310.03(c) must file a report containing the transaction identification 
number for each such transaction (if the regulated person is required 
to obtain a transaction identification number under part 1313 of this 
chapter) and information set forth in Sec.  1310.06(k), on or before 
the 15th day of each month following the month in which the 
distributions took place.
* * * * *

0
39. Revise Sec.  1310.06 to read as follows:


Sec.  1310.06  Content of records and reports.

    (a) Each record required by Sec.  1310.03(a) must include the 
following:
    (1) The name/business name, address/business address, and contact 
information (e.g., telephone number(s), email address (es), etc.), and, 
if required, DEA registration number of each party to the regulated 
transaction.
    (2) The date of the regulated transaction.
    (3) The quantity, chemical name, and, if applicable, National Drug 
Code (NDC) number. If NDC number is not applicable, the form of 
packaging of the listed chemical or a description of the tableting 
machine or encapsulating machine (including make, model, serial number, 
if any, and whether the machine is manual or electric).
    (4) The method of transfer (company truck, picked up by customer, 
etc.).
    (5) The type of identification used by the purchaser and any unique 
number on that identification.
    (b) For purposes of this section, normal business records will be 
considered adequate if they contain the information listed in paragraph 
(a) of this section and are readily retrievable from other business 
records of the regulated person. For prescription drug products, 
prescription and hospital records kept in the normal course of medical 
treatment will be considered adequate for satisfying the requirements 
of paragraph (a) of this section with respect to dispensing to 
patients, and records required to be maintained pursuant to the U.S. 
Food and Drug Administration regulations relating to the distribution 
of prescription drugs, as set forth in 21 CFR part 205, will be 
considered adequate for satisfying the requirements of paragraph (a) of 
this section with respect to distributions.

[[Page 97024]]

    (c)(1) Each report required by Sec.  1310.05(a) must include the 
information as specified by paragraph (a) of this section, the basis 
for making the report, and, where obtainable, the registration number 
of the other party, if such party is registered. A report of an 
uncommon method of payment or delivery submitted in accordance with 
Sec.  1310.05(a)(1) must also include a reason why the method of 
payment or delivery was uncommon.
    (2) A suggested format for the reports in Sec.  1310.05(a)(1) is 
provided below:

    Supplier:
Registration Number (if registered)------------------------------------
Name-------------------------------------------------------------------
Address----------------------------------------------------------------
City-------------------------------------------------------------------
State------------------------------------------------------------------
Zip--------------------------------------------------------------------
Contact Information:---------------------------------------------------

    Purchaser:
Registration Number (if registered)------------------------------------
Name-------------------------------------------------------------------
Address----------------------------------------------------------------
City-------------------------------------------------------------------
State------------------------------------------------------------------
Zip--------------------------------------------------------------------
Contact Information----------------------------------------------------
Identification---------------------------------------------------------

    Shipping Address (if different than purchaser Address):

Street-----------------------------------------------------------------
City-------------------------------------------------------------------
State------------------------------------------------------------------
Zip--------------------------------------------------------------------
Date of Shipment-------------------------------------------------------

    Description of Listed Chemical:
Chemical Name----------------------------------------------------------
Quantity---------------------------------------------------------------
National Drug Code (NDC) Number(s), or Form(s) of Packaging------------

    Other:
The basis (i.e., reason) for making the report:------------------------
Any additional pertinent information:----------------------------------

    (d) Each report of an unusual or excessive loss or disappearance of 
a listed chemical required by Sec.  1310.05(b)(1) (on DEA Form 107), 
must include the following information:
    (1) The name/business name, address/business address, and contact 
information (e.g., telephone number(s), email address (es), etc.), and, 
if applicable, DEA registration number of each party to the regulated 
transaction.
    (2) The date (or estimated date) on which unusual or excessive loss 
or disappearance occurred, and the actual date on which the unusual or 
excessive loss or disappearance was discovered by the regulated person.
    (3) The quantity, chemical name, and National Drug Code (NDC) 
number, if applicable or if not the form of packaging of the listed 
chemical.
    (4) The type of business conducted by the regulated person, (e.g., 
grocery store, pharmacy/drug store, discount department store, 
warehouse club or superstore, convenience store, specialty food store, 
gas station, mobile retail vendor, mail-order, etc.) if the regulated 
person is not a DEA registrant.
    (e)(1) Each report of an importation of a tableting machine or an 
encapsulating machine required by Sec.  1310.05(c)(1) (on DEA Form 452) 
must include the following information:
    (i) The name/business name, address/business address, and contact 
information (e.g., telephone number(s), email address(es), etc.) of the 
regulated person; the name/business name, address/business address, and 
contact information (e.g., telephone number(s), email address(es), 
etc.) of the import broker or forwarding agent, if any;
    (ii) A description of each machine (including make, model, serial 
number, if any, and whether the machine is manual or electric) and the 
number of machines being received;
    (iii) The anticipated date of arrival at the port of entry, and the 
anticipated port of entry;
    (iv) The name/business name, address/business address, and contact 
information (e.g., telephone number(s), email address(es), etc.) of the 
consignor in the foreign country of exportation;
    (v) The intended medical, commercial, scientific, or other 
legitimate use of the machine; and
    (vi) Any proposed changes in identifying information of the 
imported machines (e.g., name, brand, serial number, if any, etc.) that 
will take place after importation.
    (2) Each report of an exportation of a tableting machine or an 
encapsulating machine required by Sec.  1310.05(c)(1) (on DEA Form 452) 
must include the following information:
    (i) The name/business name, address/business address, and contact 
information (e.g., telephone number(s), email address(es), etc.) of the 
regulated person; the name/business name, address/business address, and 
contact information (e.g., telephone number(s), email address(es), 
etc.) of the export broker (if applicable);
    (ii) A description of each machine (including make, model, serial 
number, if any, and whether the machine is manual or electric) and the 
number of machines being received;
    (iii) The anticipated date of arrival at the port of export, the 
foreign port and country of entry; and
    (iv) The name/business name, address/business address, and contact 
information (e.g., telephone number(s), email address(es), etc.) of the 
consignee in the country where the shipment is destined; the name(s)/
business name(s) and address(es)/business address(es), and contact 
information (e.g., telephone number(s), email address(es), etc.) of the 
intermediate consignee(s) (if any).
    (f) Each report of a domestic regulated transaction in a tableting 
machine or encapsulating machine required by Sec.  1310.05(b)(2) (on 
DEA Form 452) must include the following information:
    (1) The name/business name, address/business address, and contact 
information (e.g., telephone number(s), email address(es), etc.) of the 
regulated person; the name/business name, address/business address, and 
contact information (e.g., telephone number(s), email address(es), 
etc.) of the purchaser;
    (2) A description of each machine (including make, model, serial 
number, if any, and whether the machine is manual or electric) and the 
number of machines being received; and
    (3) Any changes made by the regulated person in identifying 
information of the machines (e.g., name, brand, serial number, etc.).
    (g) Each report of a denied release by a customs officer at the 
port of entry of a tableting machine or an encapsulating machine 
required by Sec.  1310.05(c)(2) must include the following information: 
the quantity of machines denied release; a concise description of the 
machines denied release; the date on which release was denied; the port 
where the denial of release was issued from; and the basis for the 
denial.
    (h) Return information. (1) Within 30 calendar days after actual 
receipt of a tableting or encapsulating machine, or within 10 calendar 
days after receipt of a written request by the Administration to the 
importer, whichever is sooner, the importer must file a report with the 
Administration (on DEA Form 452) specifying the particulars of the 
transaction utilizing the DEA Diversion Control Division secure network 
application. This report must include the following information: The 
date on which a customs officer at the port of entry released the 
machine(s); the date on which the machine(s) arrived at the final 
destination; the port of entry where the machine(s) were actually 
released by a customs officer; the actual quantity of machines released 
by a customs officer; the actual quantity of machines that arrived at 
the final destination; a description of each tableting or encapsulating 
machine imported (including make, model, and serial number, if any); 
any changes in identifying information of the imported machines (e.g., 
name, brand, serial number, if any, etc.) that will take place after 
importation; and any other

[[Page 97025]]

information as the Administration may from time to time specify. Upon 
receipt and review, the Administration will assign a transaction 
identification number to a completed report. The report will not be 
deemed filed until the Administration has issued a transaction 
identification number. A single return declaration may include the 
particulars of both the importation and distribution. For DEA reporting 
purposes, import responsibilities are concluded upon the receipt of the 
machines by the importer. Once machines are received by the importer, 
domestic transaction reporting requirements commence. Distributions of 
tableting and encapsulating machines from the importer to their 
customers must be reported as domestic regulated transactions in 
accordance with Sec.  1310.05(b)(2).
    (2) Within 30 calendar days after the tableting or encapsulating 
machine is released by a customs officer at the port of export, or 
within 10 calendar days after receipt of a written request by the 
Administration to the exporter, whichever is sooner, the exporter must 
file a report with the Administration (on DEA Form 452) through the DEA 
Diversion Control Division secure network application specifying the 
particulars of the transaction. This report must include the following 
information: The date on which the machine(s) was (were) released by a 
customs officer at the port of export; the actual quantity of machines 
released; a description of each tableting or encapsulating machine 
released (including make, model, serial number, if any, and whether the 
machine is manual or electric); and any other information as the 
Administration may from time to time specify.
    (i) Declared exports of machines which are refused, rejected, or 
otherwise deemed undeliverable may be returned to the U.S. exporter of 
record. A brief written report outlining the circumstances must be 
filed with the Administration through the DEA Diversion Control 
Division secure network application, following the return at the 
earliest practicable opportunity after the regulated person becomes 
aware of the circumstances involved. This provision does not apply to 
shipments that have cleared foreign customs, been delivered, and 
accepted by the foreign consignee. Returns to third parties in the 
United States will be regarded as imports.
    (j) Each annual report required by Sec.  1310.05(d) must provide 
the following information for each listed chemical manufactured:
    (1) The name/business name, address/business address, and contact 
information (e.g., telephone number(s), email address(es), etc.) and 
chemical registration number (if any) of the manufacturer.
    (2) The aggregate quantity of each listed chemical that the company 
manufactured during the preceding calendar year.
    (3) The year-end inventory of each listed chemical as of the close 
of business on the 31st day of December of each year. (For each listed 
chemical, if the prior period's ending inventory has not previously 
been reported to DEA, this report should also detail the beginning 
inventory for the period.) For purposes of this requirement, inventory 
shall reflect the quantity of listed chemicals, whether in bulk or non-
exempt product form, held in storage for later distribution. Inventory 
does not include waste material for destruction, material stored as an 
in-process intermediate or other in-process material.
    (4) The aggregate quantity of each listed chemical used for 
internal consumption during the preceding calendar year, unless the 
chemical is produced solely for internal consumption.
    (5) The aggregate quantity of each listed chemical manufactured 
which becomes a component of a product exempted from paragraph (1)(iv) 
or (v) of the definition of regulated transaction in Sec.  1300.02 of 
this chapter during the preceding calendar year.
    (6) Data shall identify the specific isomer, salt or ester when 
applicable but quantitative data shall be reported as anhydrous base or 
acid in kilogram units of measure.
    (k) Each monthly report required by Sec. Sec.  1310.03(c) and 
1310.05(e) (on DEA Form 453) must provide the following information for 
each transaction:
    (1) Supplier name/business name, address/business address, and 
contact information (e.g., telephone number(s), email address(es), 
etc.) and registration number.
    (2) Purchaser's name/business name, address/business address, and 
contact information (e.g., telephone number(s), email address(es), 
etc.).
    (3) Name/business name, address/business address shipped to (if 
different from purchaser's name/address).
    (4) Chemical name, National Drug Code (NDC) number, if applicable, 
and total amount shipped.
    (5) Date of shipment.
    (6) Product name (if drug product).
    (7) Dosage form (if drug product) (e.g., pill, tablet, liquid).
    (8) Dosage strength (if drug product) (e.g., 30mg, 60mg, per dose 
etc.).
    (9) Number of dosage units (if drug product) (e.g., 100 doses per 
package).
    (10) Package type (if drug product) (e.g., bottle, blister pack, 
etc.).
    (11) Number of packages (if drug product) (e.g., 10 bottles).
    (12) Lot number (if drug product).
    (l) Information provided in reports required by Sec.  1310.05(e) 
which is exempt from disclosure under section 552(a) of title 5, by 
reason of section 552(b)(6) of title 5, will be provided the same 
protections from disclosure as are provided in section 310(c) of the 
Act (21 U.S.C. 830(c)) for confidential business information.


Sec.  1310.13  [Amended]

0
40. In Sec.  1310.13(b), remove ``Office of Diversion Control, Drug 
Enforcement Administration'' and add in its place ``Drug and Chemical 
Evaluation Section, Diversion Control Division, Drug Enforcement 
Administration''.

PART 1312--IMPORTATION AND EXPORTATION OF CONTROLLED SUBSTANCES

0
41. The authority citation for part 1312 continues to read as follows:

    Authority:  21 U.S.C. 952, 953, 954, 957, 958.

0
42. Add Sec.  1312.03 to read as follows:


Sec.  1312.03  Forms applicable to this part.

------------------------------------------------------------------------
                   Form                          Access/ submission
------------------------------------------------------------------------
DEA Form 35, Permit to Import.............  electronic.
DEA Form 36, Permit to Export.............  electronic.
DEA Form 161, Application for Permit to     electronic.
 Export Controlled Substances.
DEA Form 161R, Application for Permit to    electronic.
 Export Controlled Substances For
 Subsequent Reexport.
DEA Form 161R-EEA, Application for Permit   electronic.
 to Export Controlled Substances for
 Subsequent Reexport Among Members of the
 European Economic Area.
DEA Form 236, Controlled Substances Import/ electronic.
 Export Declaration.

[[Page 97026]]

 
DEA Form 357, Application for Permit to     electronic.
 Import Controlled Substances for Domestic
 And/Or Scientific Purposes.
------------------------------------------------------------------------


0
43. Revise Sec.  1312.11 to read as follows:


Sec.  1312.11  Requirement of authorization to import.

    (a) No person shall import, or cause to be imported, into the 
customs territory of the United States from any place outside thereof 
(but within the United States), or into the United States from any 
place outside thereof, any controlled substances listed in Schedule I 
or II, or any narcotic controlled substance listed in Schedule III, IV, 
or V, or any non-narcotic controlled substance listed in Schedule III 
which the Administrator has specifically designated by regulation in 
Sec.  1312.30 or any non-narcotic controlled substance listed in 
Schedule IV or V which is also listed in Schedule I or II of the 
Convention on Psychotropic Substances, 1971, unless and until such 
person is properly registered under the Act (or, in accordance with 
part 1301 of this chapter, exempt from registration) and the 
Administration has issued him or her a permit to do so in accordance 
with Sec.  1312.13.
    (b) No person shall import, or cause to be imported, into the 
customs territory of the United States from any place outside thereof 
(but within the United States), or into the United States from any 
place outside thereof, any non-narcotic controlled substance listed in 
Schedule III, IV, or V, excluding those described in paragraph (a) of 
this section, unless and until such person is properly registered under 
the Act (or, in accordance with part 1301 of this chapter, exempt from 
registration) and has filed an import declaration to do so in 
accordance with Sec.  1312.18.
    (c) A separate permit or declaration is required for each shipment 
of a controlled substance to be imported.

0
44. Revise Sec.  1312.12 to read as follows:


Sec.  1312.12  Application for import permit; return information.

    (a) Registered importers, other registrants authorized to import as 
a coincident activity of their registrations, and persons who in 
accordance with part 1301 of this chapter are exempt from registration, 
seeking to import a controlled substance in schedule I or II; any 
narcotic drug in schedule III, IV, or V; any non-narcotic drug in 
schedule III that has been specifically designated by regulation in 
Sec.  1312.30; or any non-narcotic substance listed in schedule IV or V 
that is also listed in schedule I or II of the Convention on 
Psychotropic Substances, 1971, must submit an application for a permit 
to import controlled substances on DEA Form 357. All applications and 
supporting materials must be submitted to the Administration through 
the DEA Diversion Control Division secure network application. The 
application must be signed and dated by the importer and must contain 
the importer's registered address to which the controlled substances 
will be imported.
    (b) The applicant must include on the DEA Form 357 the registration 
number of the importer and a detailed description of each controlled 
substance to be imported including the drug name, dosage form, National 
Drug Code (NDC) number, the Administration Controlled Substance Code 
Number as set forth in part 1308 of this chapter, the number and size 
of the packages or containers, the name and quantity of the controlled 
substance contained in any finished dosage units, and the quantity of 
any controlled substance (expressed in anhydrous acid, base or 
alkaloid) given in kilograms or parts thereof. The application must 
also include the following:
    (1) The name/business name, address/business address, contact 
information (e.g., telephone number(s), email address(es), etc.), and 
business of the consignor, if known at the time the application is 
submitted, but if unknown at that time, the fact should be indicated 
and the name and address afterwards furnished to the Administration as 
soon as ascertained by the importer;
    (2) The foreign port and country of initial exportation (i.e., the 
place where the article will begin its journey of exportation to the 
United States);
    (3) The port of entry into the United States;
    (4) The latest date said shipment will leave said foreign port or 
country;
    (5) The stock on hand of the controlled substance desired to be 
imported;
    (6) The name of the importing carrier or vessel (if known), or if 
unknown it should be stated whether the shipment will be made by 
express, freight, or otherwise, imports of controlled substances in 
Schedules I or II and narcotic drugs in Schedules III, IV, or V by mail 
being prohibited);
    (7) The total tentative allotment to the importer of such 
controlled substance for the current calendar year; and
    (8) The total number of kilograms of said allotment for which 
permits have previously been issued and the total quantity of 
controlled substance actually imported during the current year to date.
    (c) If desired, alternative foreign ports of exportation within the 
same country may be indicated upon the application (e.g., 1. Kolkata, 
2. Mumbai). If a permit is issued pursuant to such application, it will 
bear the names of the two ports in the order given in the application 
and will authorize shipment from either port. Alternative ports in 
different countries will not be authorized in the same permit.
    (d) Return information. Within 30 calendar days after actual 
receipt of a controlled substance at the importer's registered 
location, or within 10 calendar days after receipt of a written request 
by the Administration to the importer, whichever is sooner, the 
importer must file a report with the Administration through the DEA 
Diversion Control Division secure network application specifying the 
particulars of the transaction. This report must include the following 
information: The date the controlled substance was released by a 
customs officer at the port of entry; the date on which the controlled 
substance arrived at the registered location; the actual quantity of 
the controlled substance released by a customs officer at the port of 
entry; and the actual quantity of the controlled substance that arrived 
at the registered location. Upon receipt and review, the Administration 
will assign a transaction identification number to a completed report. 
The report will not be deemed filed until the Administration has issued 
a transaction identification number.
    (e) Denied release at the port of entry. In the event that a 
shipment of controlled substances has been denied release by a customs 
officer at the port of entry for any reason, the importer who attempted 
to have the shipment released must, within 5 business days of the 
denial, report to the Administration that the shipment was denied and 
the reason for denial. Such report must be transmitted to the 
Administration through the DEA Diversion Control

[[Page 97027]]

Division secure network application. This report must include the 
following information: The quantity of the controlled substance denied 
release; the date on which release was denied; and the basis for the 
denied release. Upon the importer's report of a denied release at the 
port of entry, the DEA will assign the report a transaction 
identification number and the import permit will be void and of no 
effect. No shipment of controlled substances denied release for any 
reason will be allowed to be released into the United States unless the 
importer submits a new DEA Form 357 and the Administration issues a new 
import permit.

0
45. In Sec.  1312.13, revise paragraph (e) to read as follows:


Sec.  1312.13  Issuance of import permit.

* * * * *
    (e) If an importation is approved, the Administrator will issue an 
import permit bearing his or her signature or that of his or her 
delegate. Each permit will be assigned a unique permit number. A permit 
must not be altered or changed by any person after being signed. Any 
change or alteration upon the face of any permit after it has been 
signed renders it void and of no effect. Permits are not transferable. 
The Administrator or his/her delegate will date and certify on each 
permit that the importer named therein is thereby permitted as a 
registrant under the Act, to import, through the port of entry named, 
one shipment of not to exceed the specified quantity of the named 
controlled substances, shipment to be made before a specified date. 
Only one shipment may be made on a single import permit. A single 
import permit shall authorize a quantity of goods to be imported/
exported at one place, at one time, for delivery to one consignee, on a 
single conveyance, at one place, on one bill of lading, air waybill, or 
commercial loading document; a single permit shall not authorize a 
quantity of goods to be imported/exported if the goods are divided onto 
two or more conveyances. The permit must state that the Administration 
is satisfied that the consignment proposed to be imported is required 
for legitimate purposes.
* * * * *

0
46. Revise Sec.  1312.14 to read as follows:


Sec.  1312.14  Distribution of import permits.

    The Administration shall transmit the import permit to the 
competent national authority of the exporting country and shall make an 
official record of the import permit available to the importer through 
secure electronic means. The importer, or their agent, must submit an 
official record of the import permit and/or required data concerning 
the import transaction to a customs officer at the port of entry in 
compliance with all import control requirements of agencies with import 
control authorities under the Act or statutory authority other than the 
Controlled Substances Import and Export Act. The importer must maintain 
an official record of the import permit (available from the DEA 
Diversion Control Division secure network application after issuance) 
in accordance with part 1304 of this chapter as the record of authority 
for the importation and shall transmit an official record of the permit 
to the foreign exporter. If required by the foreign competent national 
authority, the importer shall ensure that an official record of the 
import permit is provided (e.g., by transmitting an official record of 
the permit to the foreign exporter who shall transmit such record to 
the competent national authority of the exporting county). The importer 
must ensure that an official record of the permit accompanies the 
shipment of controlled substances to its final destination, the 
registered location of the importer (i.e., drop shipments are 
prohibited).


Sec.  1312.15  [Amended]

0
47. In Sec.  1312.15:
0
a. In paragraph (a):
0
i. Remove the phrase ``the U.S. Customs Service'' and add in its place 
``U.S. Customs and Border Protection or customs service of an Insular 
Area''; and
0
ii. At the end of the first sentence, add the phrase ``in accordance 
with Sec.  1312.16(a)''; and
0
b. In paragraph (b):
0
i. Remove the phrase ``the U.S. Customs Service'' and add in its place 
``U.S. Customs and Border Protection or customs service of an Insular 
Area''; and
0
ii. In the final sentence, remove ``Director of the Administration'' 
and add in its place ``Administrator''.

0
48. Revise Sec.  1312.16 to read as follows:


Sec.  1312.16  Amendment, cancellation, expiration of import permit.

    (a) Importers may only request that an import permit or application 
for an import permit be amended in accordance with paragraphs (a)(1) 
through (7) of this section. Requests for an amendment must be 
submitted through the DEA Diversion Control Division secure network 
application. Except as provided in paragraph (a)(5) of this section and 
Sec.  1312.15(a), importers must submit all requests for an amendment 
at least one full business day in advance of the date of release by a 
customs officer. Importers must specifically request that an amendment 
be made; supplementary information submitted by an importer through the 
DEA Diversion Control Division secure network application will not 
automatically trigger the amendment process. While the request for an 
amendment is being reviewed by the Administration, the original permit 
will be temporarily stayed and may not be used to authorize entry of a 
shipment of controlled substances. If the importer's request for an 
amendment to an issued permit is granted by the Administration, the 
Administration will immediately cancel the original permit and re-issue 
the permit, as amended, with a revised permit number. The DEA and 
importer will distribute the amended permit in accordance with Sec.  
1312.14. If a request for an amendment is denied by the Administration, 
the temporary stay will be lifted; once lifted, the originally issued 
permit may immediately be used to authorize entry of a shipment in 
accordance with the terms of the permit, subject to the shipment being 
compliant with all other applicable laws.
    (1) An importer may request that an import permit or application 
for a permit be amended to change the National Drug Control number, 
description of the packaging, or trade name of the product, so long as 
the description is for the same basic class of controlled substance as 
in the original permit.
    (2) An importer may request that an import permit or application 
for a permit be amended to change the proposed port of entry, the date 
of release by a customs officer, or the method of transport.
    (3) An importer may request that an import permit or application 
for a permit be amended to change the justification provided as to why 
an import shipment is needed to meet the legitimate scientific or 
medical needs of the United States.
    (4) An importer may request that an import permit or application 
for a permit be amended to change any registrant notes.
    (5) Prior to departure of the shipment from its original foreign 
location, an importer may request that an import permit or application 
for a permit be amended to increase the total base weight of a 
controlled substance. At the U.S. port of entry, an importer may 
request that an import permit be amended in accordance with Sec.  
1312.15(a). Importers are not required to amend an import permit for 
the sole purpose of decreasing the total base weight of a controlled 
substance

[[Page 97028]]

authorized to be imported. However, the balance of any unimported 
authorized quantity of controlled substances on an import permit is 
void upon entry of a shipment on the issued permit or upon expiration 
of the unused permit in accordance with paragraph (b) of this section, 
whichever is sooner. Other than for an amendment to an import permit 
under Sec.  1312.15(a), importers must submit a request for an 
amendment to increase the total base weight of a controlled substance 
at least three business days in advance of the date of release by a 
customs officer.
    (6) An importer may request that an import permit be amended to 
remove a controlled substance from the permit. However, an importer may 
not amend an import permit to add or replace a controlled substance/
Administration controlled substance code number to the item(s) to be 
imported. Importers who desire to import a different controlled 
substance than that contained on their issued import permit or permit 
application must submit a request for the permit or permit application 
to be canceled and request a new permit in accordance with Sec.  
1312.12.
    (7) An importer may not amend the importer's name (as it appears on 
their DEA certificate of registration) or the name of the foreign 
exporter as provided in the DEA Form 357. Importers who need to make 
any changes to any of these fields must submit a request for the permit 
or permit application to be canceled and request a new permit in 
accordance with Sec.  1312.12.
    (b) An import permit will be void and of no effect after the 
expiration date specified therein, and in no event will the date be 
more than 180 calendar days after the date the permit is issued. 
Amended import permits will retain the original expiration date.
    (c) An import permit may be canceled after being issued, at the 
request of the importer submitted to the Administration through the DEA 
Diversion Control Division secure network application, provided that no 
shipment has been made thereunder.
    Nothing in this part will affect the right, hereby reserved by the 
Administration, to cancel a permit at any time for proper cause.

0
49. In Sec.  1312.18:
0
a. Revise the section heading and paragraphs (b), (c) introductory 
text, and (c)(3); and
0
b. Add paragraphs (e) through (h).
    The revisions and additions read as follows:


Sec.  1312.18  Import declaration.

* * * * *
    (b) Any person registered or authorized to import and seeking to 
import any non-narcotic controlled substance listed in Schedules III, 
IV, or V which is not subject to the requirement of an import permit as 
described in paragraph (a) of this section, must file a controlled 
substances import declaration (DEA Form 236) with the Administration 
through the DEA Diversion Control Division secure network application 
not later than 15 calendar days prior to the anticipated date of 
release by a customs officer and distribute an official record of the 
declaration as hereinafter directed in Sec.  1312.19. The declaration 
must be signed and dated by the importer and must specify the address 
of the final destination for the shipment, which must be the importer's 
registered location. Upon receipt and review, the Administration will 
assign a transaction identification number to each completed 
declaration. The import declaration is not deemed filed, and therefore 
is not valid, until the Administration has issued a transaction 
identification number. The importer may only proceed with the import 
transaction once the transaction identification number has been issued.
    (c) DEA Form 236 must include the following information:
* * * * *
    (3) The anticipated date of release by a customs officer at the 
port of entry, the foreign port and country of exportation to the 
United States, the port of entry, and the name, address, and 
registration number of the recipient in the United States; and
* * * * *
    (e) Return information. Within 30 calendar days after actual 
receipt of a controlled substance at the importer's registered 
location, or within 10 calendar days after receipt of a written request 
by the Administration to the importer, whichever is sooner, the 
importer must file a report with the Administration through the DEA 
Diversion Control Division secure network application specifying the 
particulars of the transaction. This report must include the following 
information: The date on which the controlled substance was released by 
a customs officer at the port of entry; the date on which the 
controlled substance arrived at the registered location; the actual 
quantity of the controlled substance released by a customs officer at 
the port of entry; the actual quantity of the controlled substance that 
arrived at the registered location; and the actual port of entry. Upon 
receipt and review, the Administration will assign a transaction 
identification number to a completed report. The report will not be 
deemed filed until the Administration has issued a transaction 
identification number.
    (f) An importer may amend an import declaration in the same 
circumstances in which an importer may request amendment to an import 
permit, as set forth in Sec.  1312.16(a)(1) through (7). Amendments to 
declarations must be submitted through the DEA Diversion Control 
Division secure network application. Except as provided in Sec. Sec.  
1312.16(a)(5) and 1312.15(a), importers must submit all amendments at 
least one full business day in advance of the date of release by a 
customs officer. Importers must specifically note that an amendment is 
being made; supplementary information submitted by an importer through 
the DEA Diversion Control Division secure network application will not 
automatically be considered an amendment. While the amendment is being 
processed by the Administration, the original declaration will be 
temporarily stayed and may not be used to authorize release of a 
shipment of controlled substances. Upon receipt and review, the 
Administration will assign each completed amendment a transaction 
identification number. The amendment will not be deemed filed until the 
Administration issues a transaction identification number. The DEA and 
importer will distribute the amended declaration in accordance with 
Sec.  1312.19. A filed amendment will not change the date that the 
declaration becomes void and of no effect pursuant to paragraph (g) of 
this section.
    (g) An import declaration may be canceled after being filed with 
the Administration, at the request of the importer by the importer 
submitting to the Administration the request through the DEA Diversion 
Control Division secure network application, provided that no shipment 
has been made thereunder. Import declarations shall become void and of 
no effect 180 calendar days after the date the declaration is deemed 
filed with the Administration.
    (h) Denied release at the port of entry. In the event that a 
shipment of controlled substances has been denied release by a customs 
officer at the port of entry for any reason, the importer who attempted 
to have the shipment released, within 5 business days of the denial, 
report to the Administration that the shipment was denied release and 
the reason for denial. Such report must be transmitted to the 
Administration through the DEA Diversion Control Division secure 
network application.

[[Page 97029]]

This report must include the following information: The quantity of the 
controlled substance denied release; the date on which release was 
denied; and the basis for the denied release. Upon the importer's 
report of a denied release, the DEA will assign the report a 
transaction identification number and the import declaration will 
become void and of no effect. No shipment of controlled substances 
denied release for any reason will be allowed to be released into the 
United States until the importer has filed a new import declaration and 
the Administration has issued a new transaction identification number.

0
50. Revise Sec.  1312.19 to read as follows:


Sec.  1312.19  Distribution of import declaration.

    The importer must furnish an official record of the declaration 
(available through the DEA Diversion Control Division secure network 
application after the Administration issues a transaction 
identification number) to the foreign shipper. The foreign shipper must 
submit an official record of the declaration to the competent national 
authority of the exporting country, if required as a prerequisite to 
export authorization. The importer, or their agent, must submit an 
official record of the declaration and/or required data concerning the 
import transaction to a customs officer at the port of entry in 
compliance with all import control requirements of agencies with import 
control authorities under the Act or statutory authority other than the 
Controlled Substances Import and Export Act. The importer must ensure 
that an official record of the declaration accompanies the shipment to 
its final destination, which must only be the registered location of 
the importer (i.e., drop shipments are prohibited). The importer must 
maintain an official record of the declaration in accordance with part 
1304 of this chapter.

0
51. Revise Sec.  1312.21 to read as follows:


Sec.  1312.21  Requirement of authorization to export.

    (a) No person shall in any manner export, or cause to be exported, 
from the United States any controlled substance listed in Schedule I or 
II, or any narcotic controlled substance listed in Schedule III or IV, 
or any non-narcotic controlled substance in Schedule III which the 
Administrator has specifically designated by regulation in Sec.  
1312.30 or any non-narcotic controlled substance in Schedule IV or V 
which is also listed in Schedule I or II of the Convention on 
Psychotropic Substances, 1971, unless and until such person is properly 
registered under the Act (or, in accordance with part 1301 of this 
chapter, exempt from registration) and the Administrator has issued him 
or her a permit to do so in accordance with Sec.  1312.23.
    (b) No person shall in any manner export, or cause to be exported, 
from the United States any non-narcotic controlled substance listed in 
Schedule III, IV, or V, excluding those described in paragraph (a) of 
this section, or any narcotic controlled substance listed in Schedule 
V, unless and until such person is properly registered under the Act 
(or, in accordance with part 1301 of this chapter, exempt from 
registration) and has furnished an export declaration as provided by 
section 1003 of the Act (21 U.S.C. 953(e)) to the Administration in 
accordance with Sec.  1312.28.
    (c) A separate permit or declaration is required for each shipment 
of controlled substance to be exported.

0
52. Revise Sec.  1312.22 to read as follows:


Sec.  1312.22  Application for export or reexport permit; return 
information.

    (a) Registered exporters, and persons who in accordance with part 
1301 of this chapter are exempt from registration, seeking to export 
controlled substances must submit an application for a permit to export 
controlled substances on DEA Form 161. Registered exporters, and 
persons who in accordance with part 1301 of this chapter are exempt 
from registration, seeking to reexport controlled substances must 
submit an application for a permit to reexport controlled substances on 
DEA Form 161R or DEA Form 161R-EEA, whichever applies. All applications 
and supporting materials must be submitted to the Administration 
through the DEA Diversion Control Division secure network application. 
The application must be signed and dated by the exporter and contain 
the exporter's registered address from which the controlled substances 
will be exported. Controlled substances may not be exported until a 
permit number has been issued.
    (b) Exports of controlled substances by mail are prohibited.
    (c) Applications. (1) Except as provided in paragraph (c)(2) of 
this section, each application for a permit to export or reexport must 
include the following information:
    (i) The exporter's name/business name, address/business address, 
and contact information (e.g., telephone number(s), email address (es), 
etc.);
    (ii) The exporter's registration number, address, and contact 
information (e.g., telephone number(s), etc.) from which the controlled 
substances will be exported;
    (iii) A detailed description of each controlled substance to be 
exported including the drug name, dosage form, National Drug Code (NDC) 
number, Administration Controlled Substance Code Number as set forth in 
part 1308 of this chapter, the number and size of the packages or 
containers, the name and quantity of the controlled substance contained 
in any finished dosage units, and the quantity of any controlled 
substance (expressed in anhydrous acid, base, or alkaloid) given in 
kilograms or parts thereof;
    (iv) The name/business name, address/business address, contact 
information (e.g., telephone number(s), email address(es), etc.) and 
business of the consignee in the first country (the country to which 
the controlled substance is exported from the United States), foreign 
port and country of entry/first country of entry, the port of export, 
the anticipated date of release by a customs officer at the port of 
export, the name of the exporting carrier or vessel (if known), or if 
unknown it should be stated whether the shipment will be made by 
express, freight, or otherwise), the date and number, if any, of the 
supporting foreign import license or permit accompanying the 
application, and the authority by whom such foreign license or permit 
was issued; and
    (v) An affidavit that the packages or containers are labeled in 
conformance with obligations of the United States under international 
treaties, conventions, or protocols in effect at the time of the export 
or reexport. The affidavit shall further state that to the best of the 
affiant's knowledge and belief, the controlled substances therein are 
to be applied exclusively to medical or scientific uses within the 
country to which exported, will not be reexported therefrom and that 
there is an actual need for the controlled substance for medical or 
scientific uses within such country, unless the application is 
submitted for reexport in accordance with paragraphs (f), (g), and (h) 
of this section. In the case of exportation of crude cocaine, the 
affidavit may state that to the best of affiant's knowledge and belief, 
the controlled substances will be processed within the country to which 
exported, either for medical or scientific use within that country or 
for reexportation in accordance with the laws of that country to 
another for medical or scientific use within that country.

[[Page 97030]]

    (2) With respect to reexports among members of the European 
Economic Area in accordance with section 1003(f) of the Act (21 U.S.C. 
953(f)), the requirements of paragraph (c)(1) of this section shall 
apply only with respect to the export from the United States to the 
first country and not to any subsequent export from that country to 
another country of the European Economic Area.
    (d)(1) Except as provided in paragraph (d)(2) of this section, the 
applicant must also submit with the application any import license or 
permit or a certified copy of any such license or permit issued by the 
competent national authority in the country of destination, or other 
documentary evidence deemed adequate by the Administration, showing: 
That the merchandise is consigned to an authorized permittee; that it 
is to be applied exclusively to medical or scientific use within the 
country of destination; that it will not be reexported from such 
country (unless the application is submitted for reexport in accordance 
with paragraphs (f), (g), and (h) of this section); and that there is 
an actual need for the controlled substance for medical or scientific 
use within such country or countries. If the import license or permit, 
or the certified copy of such, is not written in English or bilingual 
with another language and English, the registrant must also submit with 
their application a certified translation of the permit or license. For 
purposes of this requirement, certified translation means that the 
translator has signed the translation legally attesting the accuracy of 
the translation. (In the case of exportation of bulk coca leaf 
alkaloid, the applicant need only include with the application the 
material outlined in paragraph (c) of this section.)
    (2) With respect to reexports among members of the European 
Economic Area in accordance with section 1003(f) of the Act (21 U.S.C. 
953(f)), the requirements of paragraph (d)(1) of this section shall 
apply only with respect to the export from the United States to the 
first country and not to any subsequent export from that country to 
another country of the European Economic Area.
    (e) Return information for exports (on a DEA Form 161). Within 30 
calendar days after the controlled substance is released by a customs 
officer at the port of export, or within 10 calendar days after receipt 
of a written request by the Administration to the exporter, whichever 
is sooner, the exporter must report to the Administration through the 
DEA Diversion Control Division secure network application the 
particulars of the transaction. This report must include the following 
information: The date on which the controlled substance left the 
registered location; the date on which the controlled substance was 
released by a customs officer at the port of export; the actual 
quantity of controlled substance that left the registered location; and 
the actual quantity of the controlled substance released by a customs 
officer at the port of export; the actual port of export, and any other 
information as the Administration may from time to time specify. Upon 
receipt and review, the Administration will assign a transaction 
identification number to a completed report. The report will not be 
deemed filed until the Administration has issued a transaction 
identification number.
    (f) Reexports outside of the European Economic Area. Except as 
provided in paragraph (g) of this section, the Administration may 
authorize any controlled substance listed in Schedule I or II, or any 
narcotic drug listed in Schedule III or IV, to be exported from the 
United States to a country for subsequent export from that country to 
another country, if each of the following conditions is met, in 
accordance with section 1003(f) of the Act (21 U.S.C. 953(f)):
    (1) Both the country to which the controlled substance is exported 
from the United States (referred to in this section as the ``first 
country'') and the country to which the controlled substance is 
exported from the first country (referred to in this section as the 
``second country'') are parties to the Single Convention on Narcotic 
Drugs, 1961, and the Convention on Psychotropic Substances, 1971;
    (2) The first country and the second country have each instituted 
and maintain, in conformity with such Conventions, a system of controls 
of imports of controlled substances which the Administration deems 
adequate;
    (3) With respect to the first country, the controlled substance is 
consigned to a holder of such permits or licenses as may be required 
under the laws of such country, and a permit or license to import the 
controlled substance has been issued by the country;
    (4) With respect to the second country, substantial evidence is 
furnished to the Administration by the applicant for the export permit 
that--
    (i) The controlled substance is to be consigned to a holder of such 
permits or licenses as may be required under the laws of such country, 
and a permit or license to import the controlled substance is to be 
issued by the country; and
    (ii) The controlled substance is to be applied exclusively to 
medical, scientific, or other legitimate uses within the country;
    (5) The controlled substance will not be exported from the second 
country;
    (6) The exporter has complied with paragraph (h) of this section 
and a permit to export the controlled substance from the United States 
has been issued by the Administration; and
    (7) Return information for reexports outside of the European 
Economic Area (on DEA Form 161R)--(i) Return information for export 
from the United States, for reexport. Within 30 calendar days after the 
controlled substance is released by a customs officer at the port of 
export the exporter must file a report with the Administration through 
the DEA Diversion Control Division secure network application 
specifying the particulars of the transaction. This report must include 
the following information: The date on which the controlled substance 
left the registered location; the date on which the controlled 
substance was released by a customs officer at the port of export; the 
actual quantity of controlled substance released by a customs officer 
at the port of export; and the actual port of export. Upon receipt and 
review, the Administration will assign a completed report a transaction 
identification number. The report will not be deemed filed until the 
Administration has issued a transaction identification number. In 
determining whether the exporter has complied with the requirement to 
file within 30 calendar days, the report shall be deemed filed on the 
first date on which a complete report is filed.
    (ii) Return information for export from a first country that is or 
is not a member of the European Economic Area to a country outside of 
the European Economic Area; return information for export from a first 
country that is not a member of the European Economic Area to a member 
of the European Economic Area. Within 30 calendar days after the 
controlled substance is exported from the first country to the second 
country the exporter must file a report with the Administration through 
the DEA Diversion Control Division secure network application 
specifying the particulars of the export from the first country. If the 
permit issued by the Administration authorized the reexport of a 
controlled substance from the first country to more than one second 
country, a report for each individual reexport is required. These 
reports must include the following information: Name of second country; 
actual quantity of controlled substance shipped; and the date shipped 
from the first country, the actual port from which the controlled

[[Page 97031]]

substances were shipped from the first country. Upon receipt and 
review, the Administration will assign each completed report a 
transaction identification number. The report will not be deemed filed 
until the Administration has issued a transaction identification 
number.
    (g) Reexports among members of the European Economic Area (on DEA 
Form 161R-EEA). The Administration may authorize any controlled 
substance listed in Schedule I or II, or any narcotic drug listed in 
Schedule III or IV, to be exported from the United States to a country 
of the European Economic Area for subsequent export from that country 
to another country of the European Economic Area, if the following 
conditions and the conditions of paragraphs (f)(1) through (4) and (6) 
of this section are met, in accordance with section 1003(f) of the Act 
(21 U.S.C. 953(f)):
    (1)(i) The controlled substance will not be exported from the 
second country, except that the controlled substance may be exported 
from a second country that is a member of the European Economic Area to 
another country that is a member of the European Economic Area, 
provided that the first country is also a member of the European 
Economic Area; and
    (ii) Subsequent to any reexportation described in paragraph 
(g)(1)(i) of this section, a controlled substance may continue to be 
exported from any country that is a member of the European Economic 
Area to any other such country, if--
    (A) The conditions applicable with respect to the first country 
under paragraphs (f)(1) through (4) and (6) of this section and 
paragraph (g)(2) are met with respect to each subsequent country from 
which the controlled substance is exported pursuant to this paragraph 
(g); and
    (B) The conditions applicable with respect to the second country 
under paragraphs (f)(1) through (4) and (6) of this section and 
paragraph (g)(2) of this section are met with respect to each 
subsequent country to which the controlled substance is exported 
pursuant to this paragraph (g).
    (2) Return information for reexports among members of the European 
Economic Area--(i) Return information for export from the United 
States, for reexport among members of the European Economic Area. 
Exporters must comply with the return reporting requirements of 
paragraph (f)(7)(i) of this section.
    (ii) Reexports among members of the European Economic Area. Within 
30 calendar days after the controlled substance is exported from the 
first country to the second country, and within 30 calendar days of 
each subsequent reexport within the European Economic Area, if any, the 
U.S. exporter must file a report with the Administration through the 
DEA Diversion Control Division secure network application specifying 
the particulars of the export. These reports must include the name of 
country to which the controlled substance was reexported, i.e., another 
member of the European Economic Area; the actual quantity of controlled 
substance shipped; the date shipped from the first country, the name/
business name, address/business address, contact information (e.g., 
telephone number(s), email address(es), etc.) and business of the 
consignee; and the name/business name, address/business address, 
contact information (e.g., telephone number(s), email address(es), 
etc.) and business of the exporter. Upon receipt and review, the 
Administration will assign each completed report a transaction 
identification number. The report will not be deemed filed until the 
Administration has issued a transaction identification number.
    (h) Where a person is seeking to export a controlled substance for 
reexport outside of the European Economic Area in accordance with 
paragraph (f) of this section, the requirements of paragraphs (h)(1) 
through (7) of this section shall apply in addition to (and not in lieu 
of) the requirements of paragraphs (a) through (d) of this section. 
Where a person is seeking to export a controlled substance for reexport 
among members of the European Economic Area in accordance with 
paragraph (g) of this section, the requirements of paragraph (h)(4) of 
this section shall apply in addition to (and not in lieu of) the 
requirements of paragraphs (a) through (d) of this section.
    (1) Bulk substances will not be reexported in the same form as 
exported from the United States, i.e., the material must undergo 
further manufacturing process. This further manufactured material may 
only be reexported to a second country.
    (2) Finished dosage units, if reexported, must be in a commercial 
package, properly sealed and labeled for legitimate medical use in the 
second country.
    (3) Any proposed reexportation must be made known to the 
Administration at the time the initial DEA Form 161R is submitted. In 
addition, the following information must also be provided where 
indicated on the form:
    (i) Whether the drug or preparation will be reexported in bulk or 
finished dosage units;
    (ii) The product name, dosage strength, commercial package size, 
and quantity; and
    (iii) The name of consignee, complete address, and expected 
shipment date, as well as the name and address of the ultimate 
consignee in the second country.
    (4) The application must contain an affidavit that the consignee in 
the second country, and any country of subsequent reexport within the 
European Economic Area, is authorized under the laws and regulations of 
the second and/or subsequent country to receive the controlled 
substances. The affidavit must also contain the following statements, 
in addition to the statements required under paragraph (c) of this 
section:
    (i) That the packages are labeled in conformance with the 
obligations of the United States under the Single Convention on 
Narcotic Drugs, 1961, the Convention on Psychotropic Substances, 1971, 
and any amendments to such treaties in effect;
    (ii) That the controlled substances are to be applied exclusively 
to medical or scientific uses within the second country, or country of 
subsequent reexport within the European Economic Area;
    (iii) That the controlled substances will not be further reexported 
from the second country except as provided by paragraph (f) of section 
1003 of the Act (21 U.S.C. 953(f)); and
    (iv) That there is an actual need for the controlled substances for 
medical or scientific uses within the second country, or country of 
subsequent reexport within the European Economic Area.
    (5) If the applicant proposes that the shipment of controlled 
substances will be separated into parts after it arrives in the first 
country and then reexported to more than one second country, the 
applicant must so indicate on the DEA Form 161R and provide all the 
information required in this section for each second country.
    (6) Except in the case of reexports among countries of the European 
Economic Area in accordance with section 1003(f) of the Act (21 U.S.C. 
953(f)), the controlled substance will be reexported from the first 
country to the second country (or second countries) no later than 180 
calendar days after the controlled substance was released by a customs 
officer from the United States.
    (7) Shipments that have been exported from the United States and 
are refused by the consignee in either the

[[Page 97032]]

first or second country, or subsequent member of the European Economic 
Area, or are otherwise unacceptable or undeliverable, may be returned 
to the registered exporter in the United States upon authorization of 
the Administration. In these circumstances, the exporter in the United 
States must submit a written request for the return of the controlled 
substances to the United States with a brief summary of the facts that 
warrant the return, along with a completed DEA Form 357 through the DEA 
Diversion Control Division secure network application. The 
Administration will evaluate the request after considering all the 
facts as well as the exporter's registration status with the 
Administration. If the exporter provides sufficient justification, the 
Administration may issue an import permit for the return of these 
drugs, and the exporter may then obtain an export permit from the 
country of original importation. The substance may not be returned to 
the United States until after a permit has been issued by the 
Administration.
    (i) In considering whether to grant an application for a permit 
under paragraphs (f), (g), and (h) of this section, the Administration 
shall consider whether the applicant has previously obtained such a 
permit and, if so, whether the applicant complied fully with the 
requirements of this section with respect to that previous permit.
    (j) Denied release at the port of export. In the event that a 
shipment of controlled substances has been denied release by a customs 
officer at the port export from the United States for any reason, the 
exporter who attempted to have the shipment released must, within 5 
business days of the denial, report to the Administration that the 
shipment was denied release and the reason for denial. Such report must 
be transmitted to the Administration through the DEA Diversion Control 
Division secure network application. This report must include the 
following information: The quantity of the controlled substance denied 
release; the date on which release was denied; the basis for the denied 
release, the port from which the denial was issued, and any other 
information as the Administration may from time to time specify. Upon 
the exporter's report of a denied release, DEA will assign the report a 
transaction identification number and the export permit will be void 
and of no effect. No shipment of controlled substances denied release 
for any reason will be allowed to be released from the United States 
unless the exporter submits a new DEA Form 161, 161R, or 161R-EEA, as 
appropriate, and the Administration issues a new export permit.

0
53. In Sec.  1312.23, revise paragraph (e) as follows:


Sec.  1312.23  Issuance of export permit.

* * * * *
    (e) If an exportation is approved, the Administrator shall issue an 
export permit bearing his or her signature or that of his or her 
delegate. Each permit will be assigned a permit number that is a 
unique, randomly generated identifier. A permit shall not be altered or 
changed by any person after being signed. Any change or alteration upon 
the face of any permit after it has been signed renders it void and of 
no effect. Permits are not transferable. The Administrator or his/her 
delegate shall date and certify on each permit that the exporter named 
therein is thereby permitted as a registrant under the Act, to export, 
through the port of export named, one shipment of not to exceed the 
specified quantity of the named controlled substances, shipment to be 
made before a specified date. Only one shipment may be made on a single 
export permit. A single export permit shall authorize a quantity of 
goods to be exported at one place, at one time, for delivery to one 
consignee, on a single conveyance, at one place, on one bill of lading, 
air waybill, or commercial loading document; a single permit shall not 
authorize a quantity of goods to be exported if the goods are divided 
onto two or more conveyances. Each export permit shall be predicated 
upon, inter alia, an import certificate or other documentary evidence 
issued by a foreign competent national authority.
* * * * *

0
54. Revise Sec.  1312.24 to read as follows:


Sec.  1312.24  Distribution of export permit.

    The Administration shall transmit the export permit to the 
competent national authority of the importing country and shall make 
available to the exporter an official record of the export permit 
through secure electronic means. The exporter, or their agent, must 
submit an official record of the export permit and/or required data 
concerning the export transaction to a customs officer at the port of 
export in compliance with all export control requirements of agencies 
with export control authorities under the Act or statutory authority 
other than the Controlled Substances Import and Export Act. The 
exporter must maintain an official record of the export permit 
(available from the secure network application on the DEA Diversion 
Control Division Web site after the Administration issues a transaction 
identification number) in accordance with part 1304 of this chapter as 
the record of authority for the exportation and shall transmit an 
official record of the export permit to the foreign importer. The 
exporter must ensure that an official record of the permit accompanies 
the shipment to its final destination. No shipment of controlled 
substances denied release for any reason shall be allowed to be 
released from the United States without subsequent authorization from 
the Administration.

0
55. Revise Sec.  1312.25 to read as follows:


Sec.  1312.25  Amendment, cancellation, expiration of export permit.

    (a) Exporters may only request that an export permit or application 
for an export permit be amended in accordance with paragraphs (a)(1) 
through (7) of this section. Requests for an amendment must be 
submitted through the DEA Diversion Control Division secure network 
application. Except as provided in paragraph (a)(5) of this section 
exporters must submit all requests for an amendment at least one full 
business day in advance of the date of release from the port of export. 
Exporters must specifically request that an amendment be made; 
supplementary information submitted by an exporter through the DEA 
Diversion Control Division secure network application will not 
automatically trigger the amendment process. While the request for an 
amendment is being reviewed by the Administration, the original permit 
will be temporarily stayed and may not be used to authorize release of 
a shipment of controlled substances. If the exporter's request for an 
amendment to an issued permit is granted by the Administration, the 
Administration will immediately cancel the original permit and re-issue 
the permit, as amended, with a revised permit number. The DEA and 
exporter will distribute the amended permit in accordance with Sec.  
1312.24. If a request for an amendment is denied by the Administration, 
the temporary stay will be lifted; once lifted, the originally issued 
permit may immediately be used to authorize release of a shipment in 
accordance with the terms of the permit.
    (1) An exporter may request that an export permit or application 
for a permit be amended to change the National Drug Control number, 
description of the packaging, or trade name of the product, so long as 
the description is for the same basic class of controlled substance as 
in the original permit.

[[Page 97033]]

    (2) An exporter may request that an export permit or application 
for a permit be amended to change the proposed port of export, the 
anticipated date of release by a customs officer, or the method of 
transport.
    (3) An exporter may request that an export permit or application 
for a permit be amended to change the justification provided as to why 
an export shipment is needed to meet the legitimate scientific or 
medical needs of the country of import.
    (4) An exporter may request that an export permit or application 
for a permit be amended to change any registrant notes.
    (5) Prior to departure of the shipment from the exporter's 
registered location, an exporter may request that an export permit or 
application for a permit be amended to increase the total base weight 
of a controlled substance. However, the total base weight or the 
strength of the product (if listed) of a controlled substance may not 
exceed that permitted for import as indicated on the import permit from 
the foreign competent national authority. Exporters are not required to 
amend an export permit for the sole purpose of decreasing the total 
base weight of a controlled substance authorized to be exported. 
However, the balance of any unexported authorized quantity of 
controlled substances on an export permit is void upon release of a 
shipment on the issued permit or upon expiration of the unused permit 
in accordance with paragraph (b) of this section, whichever is sooner. 
Exporters must submit a request for an amendment to increase the total 
base weight of a controlled substance at least three business days in 
advance of the date of release from the port of export.
    (6) An exporter may request that an export permit be amended to 
remove a controlled substance from the permit. However, an exporter may 
not amend an export permit to add or replace a controlled substance to 
the item(s) to be exported. Exporters who desire to export a different 
controlled substance than that contained on their issued export permit 
or permit application must submit a request for the permit or permit 
application to be canceled and request a new permit in accordance with 
Sec.  1312.22.
    (7) An exporter may not amend the exporter's name (as it appears on 
their DEA certificate of registration), the name of the foreign 
importer(s), or the foreign permit information as provided in the DEA 
Form 161, 161R, or 161R-EEA. Exporters who need to make any changes to 
any of these fields must submit a request for the permit or permit 
application to be canceled and request a new permit in accordance with 
Sec.  1312.22.
    (b) An export permit will be void and of no effect after the date 
specified therein, which date must conform to the expiration date 
specified in the supporting import certificate or other documentary 
evidence upon which the export permit is founded, but in no event will 
the date be more than 180 calendar days after the date the permit is 
issued.
    (c) An export permit may be canceled after being issued, at the 
request of the exporter submitted to the Administration through the DEA 
Diversion Control Division secure network application, provided that no 
shipment has been made thereunder. Nothing in this part will affect the 
right, hereby reserved by the Administration, to cancel an export 
permit at any time for proper cause.

0
56. Revise Sec.  1312.26 to read as follows:


Sec.  1312.26  Records required of exporter.

    In addition to any other records required by this chapter, the 
exporter must keep a record of any serial numbers that might appear on 
packages of narcotic drugs in quantities of one ounce or more in such a 
manner as will identify the foreign consignee, along with an official 
record of the export permit, in accordance with part 1304 of this 
chapter.

0
57. In Sec.  1312.27:
0
a. Revise the section heading and paragraphs (a) and (b); and
0
b. Add paragraphs (d) through (g).
    The revisions and additions read as follows:


Sec.  1312.27  Export/reexport declaration.

    (a) Any person registered or authorized to export and seeking to 
export any non-narcotic controlled substance listed in Schedule III, 
IV, or V, which is not subject to the requirement of an export permit 
pursuant to Sec.  1312.23(b) or (c), or any person registered or 
authorized to export and seeking to export any controlled substance in 
Schedule V, must file a controlled substances export declaration (DEA 
Form 236) with the Administration through the DEA Diversion Control 
Division secure network application not less than 15 calendar days 
prior to the anticipated date of release by a customs officer at the 
port of export, and distribute an official record of the declaration as 
hereinafter directed in Sec.  1312.28. The declaration must be signed 
and dated by the exporter and must contain the address of the 
registered location from which the substances will be shipped for 
exportation. Upon receipt and review, the Administration will issue a 
completed declaration a transaction identification number. The export 
declaration is not deemed filed, and therefore not valid, until the 
Administration has issued a transaction identification number. The 
exporter may only proceed with the export transaction once the 
transaction identification number has been issued.
    (b)(1) DEA Form 236 must include the following information:
    (i) The name/business name, address/business address, contact 
information (e.g., telephone number(s), email address(es), etc.), and 
registration number, if any, of the exporter; and the name/business 
name, address/business address, contact information (e.g., telephone 
number(s), email address(es), etc.), and registration number of the 
export broker, if any.
    (ii) A detailed description of each controlled substance to be 
exported including the drug name, dosage form, National Drug Code (NDC) 
number, Administration Controlled Substance Code Number as set forth in 
part 1308 of this chapter, the number and size of the packages or 
containers, the name and quantity of the controlled substance contained 
in any finished dosage units, and the quantity of any controlled 
substance (expressed in anhydrous acid, base, or alkaloid) given in 
kilograms or parts thereof.
    (iii) The anticipated date of release by a customs officer at the 
port of export, the port of export, the foreign port and country of 
entry, the carriers and shippers involved, method of shipment, the name 
of the vessel if applicable, and the name, address, and registration 
number, if any, of any forwarding agent utilized.
    (iv) The name/business name, address/business address, and contact 
information (e.g., telephone number(s), email address(es), etc.) of the 
consignee in the country of destination, and any registration or 
license number if the consignee is required to have such numbers either 
by the country of destination or under United States law. In addition, 
documentation must be provided to show that:
    (A) The consignee is authorized under the laws and regulations of 
the country of destination to receive the controlled substances; and
    (B) The substance is being imported for consumption within the 
importing country to satisfy medical, scientific or other legitimate 
purposes.
    (v) The reexport of non-narcotic controlled substances in Schedules 
III and IV, and controlled substances in

[[Page 97034]]

Schedule V is not permitted under the authority of 21 U.S.C. 953(e), 
except as provided below and in paragraph (b)(1)(vi) of this section:
    (A) Bulk substances will not be reexported in the same form as 
exported from the United States, i.e., the material must undergo 
further manufacturing process. This further manufactured material may 
only be reexported to a country of ultimate consumption.
    (B) Finished dosage units, if reexported, will be in a commercial 
package, properly sealed and labeled for legitimate medical use in the 
country of destination.
    (C) Any reexportation be made known to DEA at the time the initial 
DEA Form 236, Controlled Substances Import/Export Declaration is 
completed, by checking the box marked ``other'' on the certification. 
The following information will be furnished in the remarks section:
    (1) Indicate ``for reexport''.
    (2) Indicate if reexport is bulk or finished dosage units.
    (3) Indicate product name, dosage strength, commercial package 
size, and quantity.
    (4) Indicate name of consignee, complete address, and expected 
shipment date, as well as, the name and address of the ultimate 
consignee in the country to where the substances will be reexported.
    (5) A statement that the consignee in the country of ultimate 
destination is authorized under the laws and regulations of the country 
of ultimate destination to receive the controlled substances.
    (D) Shipments that have been exported from the United States and 
are refused by the consignee in either the first or second country, or 
subsequent member of the European Economic Area, or are otherwise 
unacceptable or undeliverable, may be returned to the registered 
exporter in the United States upon authorization of the Administration. 
In this circumstance, the exporter in the United States must file a 
written request for reexport, along with a completed DEA Form 236, with 
the Administration through the DEA Diversion Control Division secure 
network application. A brief summary of the facts that warrant the 
return of the substance to the United States along with an 
authorization from the country of export must be included with the 
request. DEA will evaluate the request after considering all the facts 
as well as the exporter's registration status with DEA. The substance 
may be returned to the United States only after affirmative 
authorization is issued in writing by DEA.
    (vi) The reexport of non-narcotic controlled substances in 
Schedules III and IV, and controlled substances in Schedule V is 
permitted among members of the European Economic Area only as provided 
below:
    (A) The controlled substance will not be exported from the second 
country or a subsequent country, except that the controlled substance 
may be exported from a second country or a subsequent country that is a 
member of the European Economic Area to another country that is a 
member of the European Economic Area, provided that the first country 
is also a member of the European Economic Area; each country is a party 
to the Convention on Psychotropic Substances, 1971, as amended; and 
each country has instituted and maintains, in conformity with such 
Convention, a system of controls of imports of controlled substances 
which the Attorney General deems adequate.
    (B) Each shipment of finished dosage units, if reexported, must be 
in a commercial package, properly sealed and labeled for legitimate 
medical use in the country of destination.
    (C) Any reexportation must be made known to DEA at the time the 
initial DEA Form 236, Controlled Substances Import/Export Declaration 
is completed, by checking the box marked ``other'' on the 
certification. In addition to the requirements of paragraph (b) of this 
section, the following information will be furnished in the remarks 
section:
    (1) Indicate ``for reexport among members of the European Economic 
Area''.
    (2) Indicate if reexport is bulk or finished dosage units.
    (3) Indicate product name, dosage strength, commercial package 
size, and quantity.
    (4) Indicate the name/business name, address/business address, 
contact information (e.g., telephone number(s), email address(es) and 
business of the consignee in the first country).
    (5) A statement that the consignee in the second country, and any 
subsequent consignee within the European Economic Area, is authorized 
under the laws and regulations of the second and/or subsequent country 
to receive the controlled substances.
    (2) With respect to reexports among members of the European 
Economic Area, the requirements of paragraph (b)(1) of this section 
shall apply only with respect to the export from the United States to 
the first country and not to any subsequent export from that country to 
another country of the European Economic Area.
* * * * *
    (d) Return information--(1) Return information for exports. Within 
30 calendar days after the controlled substance is released by a 
customs officer at the port of export, or within 10 calendar days after 
receipt of a written request by the Administration to the exporter, 
whichever is sooner, the exporter must file a report with the 
Administration through the DEA Diversion Control Division secure 
network application specifying the particulars of the transaction. This 
report must include the following information: The date on which the 
controlled substance left the registered location; the date on which 
the controlled substance was released by a customs officer; the actual 
quantity of the controlled substance that left the registered location; 
and the actual quantity of the controlled substance released by a 
customs officer at the port of export; the actual port of export. Upon 
receipt and review, the Administration will assign a completed report a 
transaction identification number. The report will not be deemed filed 
until the Administration has issued a transaction identification 
number.
    (2) Return information for reexports outside of the European 
Economic Area--(i) Return information for export from the United 
States, for reexport. Within 30 calendar days after the controlled 
substance is released by a customs officer at the port of export the 
exporter must file a report with the Administration through the DEA 
Diversion Control Division secure network application specifying the 
particulars of the transaction. This report must include the following 
information: The date on which the controlled substance left the 
registered location; the date on which the controlled substance was 
released by a customs officer at the port of export; the actual 
quantity of controlled substance released by a customs officer at the 
port of export; and the actual port of export. Upon receipt and review, 
the Administration will assign a completed report a transaction 
identification number. The report will not be deemed filed until the 
Administration has issued a transaction identification number.
    (ii) Return information for export from a first country that is or 
is not a member of the European Economic Area to a country outside of 
the European Economic Area; return information for export from a first 
country that is not a member of the European Economic Area to a member 
of the European Economic Area. Within 30 calendar days after the 
controlled substance is exported from

[[Page 97035]]

the first country to the second country the exporter must file a report 
with the Administration through the DEA Diversion Control Division 
secure network application specifying the particulars of the export 
from the first country. If the permit issued by the Administration 
authorized the reexport of a controlled substance from the first 
country to more than one second country, a report for each individual 
reexport is required. These reports must include the following 
information: Name of second country; actual quantity of controlled 
substance shipped; the date shipped from the first country; and the 
actual port from which the controlled substances were shipped from the 
first country. Upon receipt and review, the Administration will assign 
each completed report a transaction identification number. The report 
will not be deemed filed until the Administration has issued a 
transaction identification number.
    (3) Reexports among members of the European Economic Area--(i) 
Return information for exports from the United States, for reexport 
among members of the European Economic Area. Exporters must comply with 
the return reporting requirements of paragraph (d)(2)(i) of this 
section.
    (ii) Reexports among members of the European Economic Area. Within 
30 calendar days after the controlled substance is exported from the 
first country to the second country, and within 30 calendar days of 
each subsequent reexport within the European Economic Area, if any, the 
exporter must file a report with the Administration through the DEA 
Diversion Control Division secure network application specifying the 
particulars of the export. These reports must include the name of 
country to which the controlled substance was reexported to another 
member of the European Economic Area; the actual quantity of controlled 
substance shipped; the date shipped from the first country, the name/
business name, address/business address, contact information (e.g., 
telephone number(s), email address(es), etc.) and business of the 
consignee; and the name/business name, address/business address, 
contact information (e.g., telephone number(s), email address(es), 
etc.) and business of the exporter. Upon receipt and review, the 
Administration will assign each completed report a transaction 
identification number. The report will not be deemed filed until the 
Administration has issued a transaction identification number.
    (e) An exporter may amend an export declaration in the same 
circumstances in which an exporter may request amendment to an export 
permit, as set forth in Sec.  1312.25(a)(1) through (7). Amendments to 
declarations must be submitted through the DEA Diversion Control 
Division secure network application. Except as provided in Sec.  
1312.25(a)(5) exporters must submit all amendments at least one full 
business day in advance of the date of release by a customs officer. 
Exporters must specifically note that an amendment is being made; 
supplementary information submitted by an exporter through the DEA 
Diversion Control Division secure network application will not 
automatically be considered an amendment. Upon receipt and review, the 
Administration will assign each completed amendment a transaction 
identification number. The amendment will not be deemed filed until the 
Administration issues a transaction identification number. The DEA and 
the exporter will distribute the amended declaration in accordance with 
Sec.  1312.28. A filed amendment will not change the date that the 
declaration becomes void and of no effect in accordance with paragraph 
(f) of this section.
    (f) An export declaration may be canceled after being filed with 
the Administration, at the request of the exporter, provided no 
shipment has been made thereunder. Export declarations shall become 
void and of no effect 180 calendar days after the date the declaration 
is deemed filed with the Administration.
    (g) Denied release at the port of export. In the event that a 
shipment of controlled substances has been denied release by a customs 
officer at the port of export for any reason, the exporter who 
attempted to have the shipment released must, within 5 business days of 
the denial, report to the Administration that the shipment was denied 
release and the reason for denial. Such report must be transmitted to 
the Administration through the DEA Diversion Control Division secure 
network application. This report must include the following 
information: The quantity of the controlled substance denied release; 
the date on which release was denied; and the basis for the denied 
release. Upon the exporter's report of a denied release, DEA will 
assign the report a transaction identification number and the export 
declaration will be void and of no effect. No shipment of controlled 
substances denied release for any reason will be allowed to be released 
unless the exporter files a new declaration and the Administration 
issues a new transaction identification number.

0
58. Revise Sec.  1312.28 to read as follows:


Sec.  1312.28  Distribution of export declaration.

    (a) The exporter must ensure that an official record of the export 
declaration (available from the DEA Diversion Control Division secure 
network application after the Administration issues a transaction 
identification number) accompanies the shipment of controlled 
substances to its destination.
    (b) The exporter, or their agent, must submit an official record of 
the export declaration and/or required data concerning the export 
transaction to a customs officer at the port of export in compliance 
with all export control requirements of agencies with export control 
authorities under the Act or statutory authority other than the 
Controlled Substances Import and Export Act.
    (c) The exporter must maintain an official record of the export 
declaration and return information (both available from the Diversion 
Control Division secure network application after the Administration 
issues a transaction identification number) required pursuant to Sec.  
1312.27(d) as his or her record of authority for the exportation, in 
accordance with part 1304 of this chapter.

0
59. In Sec.  1312.31:
0
a. Revise paragraph (b) introductory text;
0
b. In paragraph (d)(2), remove the word ``and'' at the end of the 
paragraph;
0
c. In paragrarph (d)(3), remove the period at the end of the paragraph 
and add ``; and'' in its place; and
0
d. Add paragraph (d)(4).
    The revision and addition read as follows:


Sec.  1312.31  Schedule I: Application for prior written approval.

* * * * *
    (b) An application for a transshipment permit must be submitted to 
the Regulatory Section, Diversion Control Division, Drug Enforcement 
Administration, at least 30 calendar days, or in the case of an 
emergency as soon as is practicable, prior to the expected date of 
arrival at the first port in the United States. See the Table of DEA 
Mailing Addresses in Sec.  1321.01 of this chapter for the current 
mailing address. A separate permit is required for each shipment of 
controlled substance to be imported, transferred, or transshipped. Each 
application must contain the following:
* * * * *

[[Page 97036]]

    (d) * * *
    (4) If the import license or permit, or the certified copy of such, 
is not written in English or bilingual with another language and 
English, the application must include a certified translation of the 
permit or license. For purposes of this requirement, certified 
translation means that the translator has signed the translation 
legally attesting the accuracy of the translation.
* * * * *

0
 60. Revise Sec.  1312.32 to read as follows:


Sec.  1312.32  Schedules II, III, IV: Advance notice.

    (a) A controlled substance listed in Schedules II, III, or IV may 
be imported into the United States for transshipment, or may be 
transferred or transshipped within the United States for immediate 
exportation, provided that written notice is submitted to the 
Regulatory Section, Diversion Control Division, Drug Enforcement 
Administration, at least 15 calendar days prior to the expected date of 
date of arrival at the first port in the United States. See the Table 
of DEA mailing Addresses in Sec.  1321.01 of this chapter for the 
current mailing addresses.
    (b) A separate advance notice is required for each shipment of 
controlled substance to be imported, transferred, or transshipped. Each 
advance notice must contain those items required by Sec.  1312.31(b) 
and (c). If the export license, permit, or other authorization, issued 
by a competent national authority of the country of origin, is not 
written in English or bilingual with another language and English, the 
notice must be accompanied by a certified translation of the export 
license, permit, or other authorization. For purposes of this 
requirement, certified translation means that the translator has signed 
the translation legally attesting the accuracy of the translation.

PART 1313--IMPORTATION AND EXPORTATION OF LIST I AND LIST II 
CHEMICALS

0
61. The authority citation for part 1313 continues to read as follows:

    Authority: 21 U.S.C. 802, 830, 871(b), 971.


0
62. Add Sec.  1313.03 to read as follows:


Sec.  1313.03  Forms applicable to this part.

------------------------------------------------------------------------
                   Form                          Access/ submission
------------------------------------------------------------------------
DEA Form 486, Import/Export Declaration     electronic.
 for List I and List II Chemicals.
DEA Form 486A Import Declaration for        electronic.
 ephedrine, pseudoephedrine, and
 phenylpropanolamine (including drug
 products containing these chemicals).
------------------------------------------------------------------------


0
63. In Sec.  1313.12, revise the section heading and paragraphs (a), 
(b), (c) introductory text, (d), and (e) introductory text to read as 
follows:


Sec.  1313.12  Notification prior to import.

    (a) Each regulated person who seeks to import a listed chemical 
that meets or exceeds the threshold quantities identified in Sec.  
1310.04(f) of this chapter or is a listed chemical for which no 
threshold has been established as identified in Sec.  1310.04(g) of 
this chapter, must notify the Administration of the intended import by 
filing an import declaration (on DEA Form 486/486A) not later than 15 
calendar days before the date of release by a customs officer at the 
port of entry. Regulated persons who seek to import a listed chemical 
below the threshold quantities identified in Sec.  1310.04(f) are not 
required to file an import declaration in advance of the release by a 
customs officer.
    (b) A complete and accurate declaration (DEA Form 486/486A) must be 
filed with the Administration through the DEA Diversion Control 
Division secure network application not later than 15 calendar days 
prior to the date of release by a customs officer at the port of entry. 
The declaration must be signed and dated by the importer and must 
contain the address of the final destination for the shipment, which 
for List I chemicals must be a registered location of the importer. 
Upon receipt and review, the Administration will assign a transaction 
identification number to each completed declaration. The 15 calendar 
days shall begin on the date that the regulated person submits a 
completed declaration, without regard to the date that the 
Administration assigns a transaction identification number. Listed 
chemicals meeting or exceeding the threshold quantities identified in 
Sec.  1310.04(f) of this chapter or for which no threshold has been 
established may not be imported until a transaction identification 
number has been issued.
    (c) The 15-calendar-day advance notification requirement for listed 
chemical imports may be waived, in whole or in part, for the following:
* * * * *
    (d) For imports meeting the requirements of paragraph (c)(1) of 
this section, the declaration (DEA Form 486/486A) must be filed with 
the Administration through the DEA Diversion Control Division secure 
network application at least three business days before the date of 
release by a customs officer at the port of entry. The declaration must 
be signed and dated by the importer and must contain the address of the 
final destination for the shipment, which must be a registered location 
of the importer (for List I chemicals). Upon receipt and review, the 
Administration will assign a transaction identification number to each 
completed declaration. The importer may proceed with the import 
transaction only once the transaction identification number has been 
issued.
    (e) For importations where advance notification is waived pursuant 
to paragraph (c)(2) of this section no DEA Form 486 is required; 
however, the regulated person must submit quarterly reports to the 
Regulatory Section, Diversion Control Division, Drug Enforcement 
Administration, not later than the 15th day of the month following the 
end of each quarter. See the Table of DEA Mailing Addresses in Sec.  
1321.01 of this chapter for the current mailing address. The report 
shall contain the following information regarding each individual 
importation:
* * * * *

0
64. Revise Sec.  1313.13 to read as follows:


Sec.  1313.13  Requirements of import declaration.

    (a) Any List I or List II chemical listed in Sec.  1310.02 of this 
chapter may be imported if that chemical is necessary for medical, 
commercial, scientific, or other legitimate uses within the United 
States. Chemical importations into the United States for immediate 
transfer/transshipment outside the United States must comply with the 
procedures set forth in Sec.  1313.31 and all other applicable laws.
    (b) The DEA Form 486/486A must include the following information:
    (1) The name/business name, address/business address, and contact 
information (e.g., telephone number(s), email address(es), etc.) of the 
chemical importer; the name/business name, address/business address, 
and contact information (e.g., telephone number(s), email address(es), 
etc.) of the broker or forwarding agent (if any); and
    (2) The name and description of each listed chemical as it appears 
on the label or container, the name of each chemical as it is 
designated in Sec.  1310.02 of this chapter, the size or weight of 
container,

[[Page 97037]]

the number of containers, the net weight of each listed chemical given 
in kilograms or parts thereof, and the gross weight of the shipment 
given in kilograms or parts thereof; and
    (3) The date of release by a customs officer at the port of entry, 
the foreign port and country of export, and the port of entry; and
    (4) The name/business name, address/business address, and contact 
information (e.g., telephone number(s), email address(es), etc.) of the 
consignor in the foreign country of exportation; and
    (5) The name/business name, address/business address, and contact 
information (e.g., telephone number(s), email address(es), etc.) of the 
person or persons to whom the importer intends to transfer the listed 
chemical and the quantity to be transferred to each transferee.
    (c) Any regulated person importing ephedrine, pseudoephedrine, or 
phenylpropanolamine must submit, on the import declaration (DEA Form 
486A), all information known to the importer on the chain of 
distribution of the chemical from the manufacturer to the importer. 
Ephedrine, pseudoephedrine, or phenylpropanolamine include each of the 
salts, optical isomers, and salts of optical isomers of the chemical.
    (d) Import declarations shall become void and of no effect 180 
calendar days after the date the declaration is deemed filed with the 
Administration.

0
65. Revise Sec.  1313.14 to read as follows:


Sec.  1313.14  Disposition of import declaration.

    The importer, or their agent, must submit an official record of the 
import declaration and/or required data concerning the import 
transaction to a customs officer at the port of entry in compliance 
with all import control requirements of agencies with import control 
authorities under the Act or statutory authority other than the 
Controlled Substances Import and Export Act. For List I chemicals, the 
final destination of the import transaction must only be the registered 
location of the importer (i.e., drop shipments are prohibited). A 
regulated person must maintain an official record of the declaration 
(available from the DEA Diversion Control Division secure network 
application after the Administration issues a transaction 
identification number) in accordance with part 1310 of this chapter as 
the record of the import. Official records of import declarations 
involving listed chemicals must be retained for two years.

0
65. In Sec.  1313.15, revise the section heading and paragraph (b) to 
read as follows:


Sec.  1313.15  Qualification of regular importers.

* * * * *
    (b) Each regulated person making application under paragraph (a) of 
this section shall be considered a ``regular importer'' 30 calendar 
days after receipt of the application by the Administration, as 
indicated on the return receipt, unless the regulated person is 
otherwise notified in writing by the Administration.
* * * * *

0
67. In Sec.  1313.16, revise the section heading and paragraph (b) to 
read as follows:


Sec.  1313.16  Updated notice for change in circumstances.

* * * * *
    (b) After a notice under Sec.  1313.12(a) or (d) is submitted to 
the Administration, if circumstances change and the importer will not 
be transferring the listed chemical to the transferee identified in the 
notice, or will be transferring a greater quantity of the chemical than 
specified in the notice, the importer must update the notice to 
identify the most recent prospective transferee or the most recent 
quantity or both (as the case may be) and may not transfer the listed 
chemical until after the expiration of the 15 calendar day period 
beginning on the date on which the update is filed with the 
Administration, or, if the import is being made by a regular importer 
or intended for transfer to a regular customer, three business days. 
The preceding sentence applies with respect to changing circumstances 
regarding a transferee or quantity identified in an update to the same 
extent and in the same manner as the sentence applies with respect to 
changing circumstances regarding a transferee or quantity identified in 
the original notice under Sec.  1313.12(a) or (d). Amended declarations 
must be submitted to the Administration through the DEA Diversion 
Control Division secure network application. The amendment must be 
signed and dated by the importer. Upon receipt and review, the 
Administration will assign each completed amendment a transaction 
identification number. Such shipment of listed chemicals may not be 
imported into the United States until the transaction identification 
number has been issued.
* * * * *

0
68. Revise Sec.  1313.17 to read as follows:


Sec.  1313.17  Return declaration for imports.

    (a) Return information. Within 30 calendar days after actual 
receipt of a listed chemical at the importer's registered location or 
place of business if not required to be registered, the importer must 
file a report with the Administration through the DEA Diversion Control 
Division secure network application specifying the particulars of the 
transaction. This report must include the following information: The 
date on which the listed chemical was released by a customs officer at 
the port of entry; the date on which the listed chemical arrived at the 
importer's registered location or place of business; the actual 
quantity of the listed chemical released; the actual quantity of the 
listed chemical that arrived at the importer's location; the date of 
any subsequent transfer; a description of the subsequent transfer, 
including the actual quantity transferred, chemical, container, and 
name of transferees; the actual port of entry; and any other 
information as the Administration may specify. A single report may 
include the particulars of both the importation and distribution. If 
the importer has not distributed all chemicals imported by the end of 
the initial 30 calendar day period, the importer must file supplemental 
reports not later than 30 calendar days from the date of any further 
distribution, until the distribution or other disposition of all 
chemicals imported under the import declaration or any amendment or 
other update is accounted for. Upon receipt and review, the 
Administration will assign each completed report a transaction 
identification number. In determining whether the importer has complied 
with the requirement to file within 30 calendar days, the report shall 
be deemed filed on the first date on which a complete report is filed.
    (b) If an importation for which a DEA Form 486/486A has been filed 
fails to take place, the importer must report to the Administration 
that the importation did not occur through the DEA Diversion Control 
Division secure network application.
    (c) Denied release at the port of entry. In the event that a 
shipment of listed chemicals has been denied release by a customs 
officer at the port of entry for any reason, the importer who attempted 
to have the shipment released, within 5 business days of the denial, 
report to the Administration that the shipment was denied release and 
the reason for denial. Such report must be transmitted to the 
Administration through the DEA

[[Page 97038]]

Diversion Control Division secure network application. This report must 
include the following information: The quantity of the listed chemical 
denied release; the date on which release was denied; and the basis for 
the denied release. Upon the importer's report of a denied release, the 
DEA will assign the report a transaction identification number and the 
import declaration will be void and of no effect. No shipment of listed 
chemicals denied release for any reason will be allowed entry into the 
United States without a subsequent refiling of an import declaration. 
Following such refiling the importer may request release of the listed 
chemicals immediately after receipt of a transaction identification 
number without regard to the 15 day advance filing requirement in Sec.  
1313.12(b).

0
69. In Sec.  1313.21, revise the section heading and paragraphs (a), 
(b), (c) introductory text, (d), and (e) introductory text and add 
paragraph (h) to read as follows:


Sec.  1313.21  Notification prior to export.

    (a) Each regulated person who seeks to export a listed chemical 
that meets or exceeds the threshold quantities identified in Sec.  
1310.04(f) of this chapter, or is a listed chemical for which no 
threshold has been established as identified in Sec.  1310.04(g) of 
this chapter, must notify the Administration of the intended export by 
filing an export declaration (DEA Form 486) not later than 15 calendar 
days before the date of release by a customs officer at the port of 
export. Regulated persons who seek to export a listed chemical below 
the threshold quantities identified in Sec.  1310.04(f) are not 
required to file an export declaration in advance of the export.
    (b) A complete and accurate declaration (DEA Form 486) must be 
filed with the Administration through the DEA Diversion Control 
Division secure network application not later than 15 calendar days 
prior to the date of release by a customs officer at the port of 
export. The declaration must be signed and dated by the exporter and 
must contain the address from which the listed chemicals will be 
shipped for exportation. Upon receipt and review, the Administration 
will assign a transaction identification number to each completed 
declaration. The 15 calendar days shall begin on the date that the 
regulated person files a completed declaration without regard to the 
date that the Administration assigns a transaction identification 
number. Exporters may not request release of a listed chemical until a 
transaction identification number has been issued.
    (c) The 15 calendar day advance notification requirement for listed 
chemical exports may be waived, in whole or in part, for:
* * * * *
    (d) For exports meeting the requirements of paragraph (c)(1) of 
this section, the declaration (DEA Form 486) must be filed with the 
Administration through the DEA Diversion Control Division secure 
network application at least three business days before the date of 
release by a customs officer. The declaration must be signed and dated 
by the exporter and must contain the address from which the listed 
chemicals will be shipped for exportation. Upon receipt and review, the 
Administration will assign a transaction identification number to each 
completed declaration. The exporter may only proceed with the export 
transaction once the transaction identification number has been issued.
    (e) For exportations where advance notification is waived pursuant 
to paragraph (c)(2) of this section no DEA Form 486 is required; 
however, the regulated person must submit quarterly reports with the 
Regulatory Section, Diversion Control Division, Drug Enforcement 
Administration, not later than the 15th day of the month following the 
end of each quarter. See the Table of DEA Mailing Addresses in Sec.  
1321.01 of this chapter for the current mailing address. Such report 
shall contain the following information regarding each individual 
exportation:
* * * * *
    (h) Export declarations shall become void and of no effect 180 
calendar days after the date the declaration is deemed filed with the 
Administration.

0
70. Revise Sec.  1313.22 to read as follows:


Sec.  1313.22  Export declaration.

    (a) Any List I or List II chemical listed in Sec.  1310.02 of this 
chapter which meets or exceeds the quantitative threshold criteria 
established in Sec.  1310.04(f) of this chapter or is a listed chemical 
for which no threshold has been established as identified in Sec.  
1310.04(g) of this chapter, may be exported if that chemical is needed 
for medical, commercial, scientific, or other legitimate uses.
    (b) The export declaration (DEA Form 486) must include all the 
following information:
    (1) The name/business name, address/business address, and contact 
information (e.g., telephone number(s), email address(es), etc.) of the 
chemical exporter; the name/business name, address/business address, 
and contact information (e.g., telephone number(s), email address(es), 
etc.) of the export broker, if any;
    (2) The name and description of each listed chemical as it appears 
on the label or container, the name of each listed chemical as it is 
designated in Sec.  1310.02 of this chapter, the size or weight of 
container, the number of containers, the net weight of each listed 
chemical given in kilograms or parts thereof, and the gross weight of 
the shipment given in kilograms or parts thereof;
    (3) The anticipated date of release by a customs officer at the 
port of export, the port of export, and the foreign port and country of 
entry; and
    (4) The name/business name, address/business address, and contact 
information (e.g., telephone number(s), email address(es), etc.) of the 
consignee in the country where the chemical shipment is destined; the 
name(s) and address(es) of any intermediate consignee(s); and a copy of 
the foreign permit, license or registration issued by the competent 
national authority of the consignee and any intermediate consignees.
    (c) Declared exports of listed chemicals which are refused, 
rejected, or otherwise deemed undeliverable by the foreign competent 
national authority may be returned to the U.S. chemical exporter of 
record. The regulated person must provide notification through the DEA 
Diversion Control Division secure network application (this does not 
require a DEA Form 486) outlining the circumstances within a reasonable 
time following the return. Upon receipt and review, the Administration 
will assign the completed notice a transaction identification number. 
The notice will not be deemed filed until the Administration issues a 
transaction identification number. Listed chemicals so returned may not 
be reexported until the exporter has filed a new DEA Form 486 and the 
Administration has issued a new transaction identification number. This 
provision does not apply to shipments that have cleared foreign 
customs, been delivered, and accepted by the foreign consignee. Returns 
to third parties in the United States will be regarded as imports.

0
71. Revise Sec.  1313.23 to read as follows:


Sec.  1313.23  Disposition of export declaration.

    The exporter, or their agent, must submit an official record of the 
export declaration and/or required data concerning the export 
transaction to a customs officer at the port of export in compliance 
with all export control requirements of agencies with export control 
authorities under the Act or

[[Page 97039]]

statutory authority other than the Controlled Substances Import and 
Export Act. An official record of the declaration (available from the 
DEA Diversion Control Division secure network application after the 
Administration issues a transaction identification number) must be 
maintained by the chemical exporter as the official record of the 
export in accordance with part 1310 of this chapter. Export 
declarations involving a listed chemical must be retained for two 
years.

0
72. In Sec.  1313.26, revise the section heading and paragraph (b) to 
read as follows:


Sec.  1313.26  Updated notice for change in circumstances.

* * * * *
    (b) After a notice under Sec.  1313.21(a) is submitted to the 
Administration, if circumstances change and the exporter will not be 
transferring the listed chemical to the transferee identified in the 
notice, or will be transferring a greater quantity of the chemical than 
specified in the notice, the exporter must update the notice to 
identify the most recent prospective transferee or the most recent 
quantity or both (as the case may be). The exporter may not transfer 
the listed chemical until after the expiration of the 15 calendar day 
period beginning on the date on which the update is filed with the 
Administration. Except, if the listed chemical is intended for transfer 
to a regular customer, the exporter may not transfer the listed 
chemical until after the expiration of three business days. The 
preceding sentence applies with respect to changing circumstances 
regarding a transferee or quantity identified in an update to the same 
extent and in the same manner as the sentence applies with respect to 
changing circumstances regarding a transferee or quantity identified in 
the original notice under paragraph (a) of this section. Amended 
declarations must be submitted to the Administration through the DEA 
Diversion Control Division secure network application. The amendment 
must be signed and dated by the exporter. Upon receipt and review, the 
Administration will assign each completed amendment a transaction 
identification number. The amendment will not be deemed filed until the 
Administration issues a transaction identification number.
* * * * *

0
73. Revise Sec.  1313.27 to read as follows:


Sec.  1313.27  Return declaration for exports.

    (a) Return information. Within 30 calendar days after a listed 
chemical is released by a customs officer at the port of export, the 
exporter must file a report with the Administration through the DEA 
Diversion Control Division secure network application specifying the 
particulars of the transaction. This report must include the following 
information: The date on which the listed chemical left the registered 
location or place of business; the date on which the listed chemical 
was released by a customs officer at the port of export; the actual 
quantity of listed chemical that left the registered location or place 
of business; the actual quantity of the listed chemical released by a 
customs officer at the port of export; chemical; container; name of 
transferees; and any other information as the Administration may 
specify. Upon receipt and review, the Administration will assign a 
completed report a transaction identification number. The report will 
not be deemed filed until the Administration has issued a transaction 
identification number. In determining whether the exporter has complied 
with the requirement to file within 30 calendar days, the report shall 
be deemed filed on the first date on which a complete report is filed.
    (b) If an exportation for which a DEA Form 486 has been filed fails 
to take place, the exporter must report to the Administration that the 
exportation did not occur through the DEA Diversion Control Division 
secure network application.
    (c) Denied release at the port of export. In the event that a 
shipment of listed chemicals has been denied release by a customs 
officer at the port of export for any reason, the exporter who 
attempted to have the shipment released must, within 5 business days of 
the denial, report to the Administration that the shipment was denied 
release and the reason for denial. Such report must be transmitted to 
the Administration through the DEA Diversion Control Division secure 
network application. This report must include the following 
information: The quantity of the listed chemicals denied release; the 
date on which release was denied; and the basis for the denied release. 
Upon the exporter's report of a denied release, DEA will assign the 
report a transaction identification number and the export declaration 
will be void and of no effect. No shipment of listed chemicals denied 
release for any reason will be allowed to be released from the United 
States without a subsequent refiling of a complete and accurate export 
declaration. Following such refiling, the exporter may request the 
release of the listed chemicals immediately after receipt of a 
transaction identification number without regard to the 15 day advance 
filing required by Sec.  1313.21(b).

0
74. In Sec.  1313.31, revise paragraphs (b) introductory text and 
(b)(7), (8), (14), and (15) to read as follows:


Sec.  1313.31  Advance notice of importation for transshipment or 
transfer.

* * * * *
    (b) Advance notification must be provided to the Regulatory 
Section, Diversion Control Division, Drug Enforcement Administration, 
not later than 15 calendar days prior to the proposed date the listed 
chemical will transship or transfer through the United States. See the 
Table of DEA Mailing Addresses in Sec.  1321.01 of this chapter for the 
current mailing address. A separate notification is required for each 
shipment of listed chemicals to be transferred or transshipped. The 
written notification (not a DEA Form 486) must contain the following 
information:
* * * * *
    (7) The name/business name, address/business address, and contact 
information (e.g., telephone number(s), email address(es), etc.) and 
type of business of the foreign exporter;
    (8) The foreign port and country of export;
* * * * *
    (14) The name/business name, address/business address, and contact 
information (e.g., telephone number(s), email address(es), etc.) and 
type of business of the consignee at the foreign port or country of 
entry;
    (15) The shipping route from the U.S. port of export to the foreign 
port or country of entry at final destination;
* * * * *

0
75. Revise Sec.  1313.32 to read as follows:


Sec.  1313.32  Notification of international transactions.

    (a) A broker or trader must notify the Administration prior to an 
international transaction involving a listed chemical which meets or 
exceeds the threshold quantities identified in Sec.  1310.04(f) of this 
chapter or is a listed chemical for which no threshold has been 
established as identified in Sec.  1310.04(g) of this chapter, in which 
the broker or trader participates. Notification must be made not later 
than 15 calendar days before the transaction is to take place. In order 
to facilitate an international transaction involving listed chemicals 
and implement the purpose of the Act,

[[Page 97040]]

regulated persons may wish to provide advance notification to the 
Administration as far in advance of the 15 calendar days as possible.
    (b) A completed DEA Form 486 must be submitted to the 
Administration through the DEA Diversion Control Division secure 
network application, not later than 15 calendar days prior to the 
international transaction. The DEA Form 486 must be signed and dated by 
the broker or trader. Upon receipt and review, the Administration will 
assign a transaction identification number to each completed 
notification. A notification is not deemed filed, and therefore is not 
valid, until the Administration assigns the notification a transaction 
identification number. An international transaction may not take place 
until after a transaction identification number has been assigned and 
the expiration of the 15 calendar day period beginning on the date on 
which the broker or trader submits a complete notification to the 
Administration.
    (c) No person shall serve as a broker or trader for an 
international transaction involving a listed chemical knowing or having 
reasonable cause to believe that the transaction is in violation of the 
laws of the country to which the chemical is exported or the chemical 
will be used to manufacture a controlled substance in violation of the 
laws of the country to which the chemical is exported. The 
Administration will publish a notice of foreign import restrictions for 
listed chemicals of which DEA has knowledge as provided in Sec.  
1313.25.
    (d) After a notice under paragraph (a) of this section is submitted 
to the Administration, if circumstances change and the broker or trader 
will not be transferring the listed chemical to the transferee 
identified in the notice, or will be transferring a greater quantity of 
the chemical than specified in the notice, the broker or trader must 
amend the notice through the DEA Diversion Control Division secure 
network application to identify the most recent prospective transferee 
or the most recent quantity or both (as applicable) and may not 
transfer the listed chemical until after the expiration of the 15 
calendar day period beginning on the date on which the update is 
submitted to the Administration. The preceding sentence applies with 
respect to changing circumstances regarding a transferee or quantity 
identified in an amendment to the same extent and in the same manner as 
the sentence applies with respect to changing circumstances regarding a 
transferee or quantity identified in the original notice under 
paragraph (a) of this section.
    (e) For purposes of this section:
    (1) The term transfer, with respect to a listed chemical, includes 
the sale of the chemical.
    (2) The term transferee means a person to whom an exporter 
transfers a listed chemical.

0
 76. In Sec.  1313.33, revise the paragraphs (b) and (c) to read as 
follows:


Sec.  1313.33  Contents of an international transaction declaration.

* * * * *
    (b) Any broker or trader who desires to arrange an international 
transaction, defined in 21 U.S.C. 802(42), involving a listed chemical 
which meets the threshold criteria set forth in Sec.  1310.04 of this 
chapter must notify the Administration through the procedures outlined 
in Sec.  1313.32(b).
    (c) The DEA Form 486 must include:
    (1) The name/business name, address/business address, and contact 
information (e.g., telephone number(s), email address(es), etc.) of the 
chemical exporter; the name/business name, address/business address, 
and contact information (e.g., telephone number(s), email address(es), 
etc.) of the chemical importer;
    (2) The name and description of each listed chemical as it appears 
on the label or container, the name of each listed chemical as it is 
designated in Sec.  1310.02 of this chapter, the size or weight of 
container, the number of containers, the net weight of each listed 
chemical given in kilograms or parts thereof, and the gross weight of 
the shipment given in kilograms or parts thereof;
    (3) The anticipated date of release at the foreign port of export, 
the anticipated foreign port and country of export, and the foreign 
port and country of entry; and
    (4) The name/business name, address/business address, and contact 
information (e.g., telephone number(s), email address(es), etc.) of the 
consignee in the country where the chemical shipment is destined; the 
name(s) and address(es) of any intermediate consignee(s).

0
 77. Revise Sec.  1313.34 to read as follows:


Sec.  1313.34  Disposition of the international transaction 
declaration.

    The broker or trader must retain an official record of the 
declaration (DEA Form 486) (available from the DEA Diversion Control 
Division secure network application after the Administration issues a 
transaction identification number) as the official record of the 
international transaction. In accordance with part 1310 of this 
chapter, declarations involving listed chemicals must be retained for 
two years.

0
78. Revise Sec.  1313.35 to read as follows:


Sec.  1313.35  Return declaration or amendment to Form 486 for 
international transactions.

    (a) Within 30 calendar days after an international transaction is 
completed, the broker or trader must file a report with the 
Administration through the DEA Diversion Control Division secure 
network application about the particulars of the transaction. This 
report must include the following information: The date(s) on which the 
listed chemical was released by the foreign customs officer(s) at the 
port(s); the actual quantity of listed chemical that left the country 
of export; the actual quantity of the listed chemical released by a 
customs officer at the port of entry; chemical; container; name of 
transferees; and the transaction identification and any other 
information as the Administration may specify. Upon receipt and review, 
the Administration will assign a completed report a transaction 
identification number. The report will not be deemed filed until the 
Administration has issued a transaction identification number.
    (b) If an international transaction for which a DEA Form 486 has 
been filed fails to take place, the broker or trader must report to the 
Administration that the international transaction did not occur 
utilizing the DEA Diversion Control Division secure network application 
as soon as the broker or trader becomes aware of the circumstances.

PART 1314--RETAIL SALE OF SCHEDULED LISTED CHEMICAL PRODUCTS

0
79. The authority citation for part 1314 continues to read as follows:

    Authority:  21 U.S.C. 802, 830, 842, 871(b), 875, 877, 886a.


Sec.  1314.110  [Amended]

0
80. In Sec.  1314.110, in paragraphs (a)(1) and (2), remove the phrase 
``Import/Export Unit,'' and add in its place ``Regulatory Section, 
Diversion Control Division''.

PART 1315--IMPORTATION AND PRODUCTION QUOTAS FOR EPHEDRINE, 
PSEUDOEPHEDRINE, AND PHENYLPROPANOLAMINE

0
81. The authority citation for part 1315 continues to read as follows:


[[Page 97041]]


    Authority:  21 U.S.C. 802, 821, 826, 871(b), 952.


0
82. In part 1315, remove ``Drug & Chemical Evaluation Section, Drug 
Enforcement Administration'' and ``Drug & Chemical Evaluation Section'' 
and add in their place ``UN Reporting & Quota Section, Diversion 
Control Division, Drug Enforcement Administration''.

PART 1316--ADMINISTRATIVE FUNCTIONS, PRACTICES, AND PROCEDURES

Subpart D--Administrative Hearings

0
 83. The authority citation for part 1316, subpart D, continues to read 
as follows:

    Authority:  21 U.S.C. 811, 812, 871(b), 875, 958(d), 965.


0
 84. In Sec.  1316.47, revise paragraph (a) to read as follows:


Sec.  1316.47  Request for hearing.

    (a) Any person entitled to a hearing and desiring a hearing shall, 
within the period permitted for filing, file a request for a hearing 
and/or an answer that complies with the following format (see the Table 
of DEA Mailing Addresses in Sec.  1321.01 of this chapter for the 
current mailing address):

(Date)-----------------------------------------------------------------
Drug Enforcement Administration, Attn: Hearing Clerk/OALJ

(Mailing Address)------------------------------------------------------
Subject: Request for Hearing

Dear Sir:

    The undersigned ______ (Name of the Person) hereby requests a 
hearing in the matter of: ______ (Identification of the proceeding).
    (A) (State with particularity the interest of the person in the 
proceeding.)
    (B) (State with particularity the objections or issues, if any, 
concerning which the person desires to be heard.)
    (C) (State briefly the position of the person with regard to the 
particular objections or issues.)
    All notices to be sent pursuant to the proceeding should be 
addressed to:

(Name)-----------------------------------------------------------------
(Street Address)-------------------------------------------------------
(City and State)-------------------------------------------------------

Respectfully yours,
(Signature of Person)--------------------------------------------------
* * * * *

0
85. Revise Sec.  1316.48 to read as follows:


Sec.  1316.48  Notice of appearance.

    Any person entitled to a hearing and desiring to appear in any 
hearing, shall, if he or she has not filed a request for hearing, file 
within the time specified in the notice of proposed rulemaking, a 
written notice of appearance in the following format (see the Table of 
DEA Mailing Addresses in Sec.  1321.01 of this chapter for the current 
mailing address):

(Date)-----------------------------------------------------------------
Drug Enforcement Administration, Attn: Hearing Clerk/OALJ

(Mailing Address)------------------------------------------------------
Subject: Notice of Appearance

Dear Sir:

    Please take notice that ______ (Name of person) will appear in the 
matter of: ______ (Identification of the proceeding).
    (A) (State with particularity the interest of the person in the 
proceeding.).
    (B) (State with particularity the objections or issues, if any, 
concerning which the person desires to be heard.).
    (C) (State briefly the position of the person with regard to the 
particular objections or issues.).
    All notices to be sent pursuant to this appearance should be 
addressed to:

(Name)-----------------------------------------------------------------
(Street Address)-------------------------------------------------------
(City and State)-------------------------------------------------------

Respectfully yours,
(Signature of Person)--------------------------------------------------

PART 1321--DEA MAILING ADDRESSES

0
86. The authority citation for part 1321 continues to read:

    Authority: 21 U.S.C. 871(b).

0
87. Revise Sec.  1321.01 to read as follows:


Sec.  1321.01  DEA mailing addresses.

    The following table provides information regarding mailing 
addresses to be used when sending specified correspondence to the Drug 
Enforcement Administration.

                     Table of DEA Mailing Addresses
------------------------------------------------------------------------
Code of Federal Regulations Section--Topic       DEA mailing address
------------------------------------------------------------------------
                            DEA Administrator
------------------------------------------------------------------------
1308.43(b)--Petition to initiate            Drug Enforcement
 proceedings for rulemaking.                 Administration, Attn:
1316.23(b)--Petition for grant of            Administrator, 8701
 confidentiality for research subjects.      Morrissette Drive,
1316.24(b)--Petition for exemption from      Springfield, VA 22152.
 prosecution for researchers.
------------------------------------------------------------------------
                     DEA Diversion Control Division
------------------------------------------------------------------------
1307.03--Exception request filing.          Drug Enforcement
1307.22--Delivery of surrendered and         Administration, Attn:
 forfeited controlled substances.            Diversion Control Division/
1310.21(b)--Sale by Federal departments or   DC, 8701 Morrissette Drive,
 agencies of chemicals which could be used   Springfield, VA 22152.
 to manufacture controlled substances
 certification request.\2\

[[Page 97042]]

 
                         DEA Regulatory Section
------------------------------------------------------------------------
1301.71(d)--Security system compliance      Drug Enforcement
 review for controlled substances.           Administration, Attn:
1309.71(c)--Security system compliance       Regulatory Section/DRG,
 review for List I chemicals.                8701 Morrissette Drive,
1310.03(c)--Mail-Order reports involving     Springfield, VA 22152.
 transactions with nonregulated persons or
 exports.\1\
1310.05(b)(1)--Unusual or excessive loss
 or disappearance of listed chemicals.
1310.05(b)(2)--Reports of domestic
 regulated transactions in a tableting
 machine or an encapsulating machine.\1\
1310.05(c)(1)--Reports of imports and
 exports of a tableting machine or an
 encapsulating machine.\1\
1310.05(c)(2)--Report of declared exports
 of machines refused, rejected, or
 returned.
1312.12(a)--Application for import permit
 (DEA Form 357).\1\
1312.18(b)--Import declaration (DEA Form
 236) submission.\1\
1312.22(g)(8)--Request for return of
 unacceptable or undeliverable exported
 controlled substances.\1\
1312.27(a)--Controlled substances export
 declaration (DEA Form 236) filing.\1\
1312.31(b)--Controlled substances
 transshipment permit application.
1312.32(a)--Advanced notice of importation
 for transshipment or transfer of
 controlled substances.
1313.12(b)--Authorization to import listed
 chemicals (DEA Form 486/486A).\1\
1313.12(e)--Quarterly reports of listed
 chemicals importation.
1313.21(b)--Authorization to export listed
 chemicals (DEA Form 486).\1\
1313.21(e)--Quarterly reports of listed
 chemicals exportation.
1313.22(c)--Notice of declared exports of
 listed chemicals refused, rejected or
 undeliverable.\1\
1313.31(b)--Advanced notice of importation
 for transshipment or transfer of listed
 chemicals.
1313.32(b)(1)--International transaction
 authorization (DEA Form 486).\1\
1314.110(a)(1)--Reports for mail-order
 sales.
1314.110(a)(2)--Request to submit mail-
 order sales reports.
------------------------------------------------------------------------
                 DEA Drug & Chemical Evaluation Section
------------------------------------------------------------------------
1308.21(a)--Exclusion of nonnarcotic        Drug Enforcement
 substance.                                  Administration, Attn: Drug
1308.23(b)--Exemption for chemical           & Chemical Evaluation
 preparations.                               Section/DRE, 8701
1308.24(d)--Exempt narcotic chemical         Morrissette Drive,
 preparations importer/exporter reporting.   Springfield, VA 22152.
1308.24(i)--Exempted chemical preparations
 listing.
1308.25(a)--Exclusion of veterinary
 anabolic steroid implant product
 application.
1308.26(a)--Excluded veterinary anabolic
 steroid implant products listing.
1308.31(a)--Exemption of a nonnarcotic
 prescription product application.
1308.32--Exempted prescription products
 listing.
1308.33(b)--Exemption of certain anabolic
 steroid products application.
1308.34--Exempted anabolic steroid
 products listing.
1310.13(b)--Exemption for chemical
 preparations.
1310.05(d)--Bulk manufacturer of listed
 chemicals reporting.
------------------------------------------------------------------------
                      UN Reporting & Quota Section
------------------------------------------------------------------------
1303.12(b)--Application for controlled      Drug Enforcement
 substances procurement quota (DEA Form      Administration, Attn: UN
 250) filing and request.                    Reporting & Quota Section/
                                             DRQ, 8701 Morrissette
                                             Drive, Springfield, VA
                                             22152.

[[Page 97043]]

 
1303.12(d)--Controlled substances quota
 adjustment request.
1303.22--Application for individual
 manufacturing quota (DEA Form 189) filing
 and request for schedule I or II
 controlled substances.
1304.31(a)--Manufacturers importing
 narcotic raw material report submission.
1304.32(a)--Manufacturers importing coca
 leaves report submission.
1315.22--Application for individual
 manufacturing quota for ephedrine,
 pseudoephedrine, phenylpropanolamine (DEA
 Form 189) filing and request.
1315.32(e)--Application for procurement
 quota for ephedrine, pseudoephedrine,
 phenylpropanolamine (DEA Form 250) filing
 and request.
1315.32(g)--Procurement quota adjustment
 request for ephedrine, pseudoephedrine,
 and phenylpropanolamine.
1315.34(d)--Application for import quota
 for ephedrine, pseudoephedrine,
 phenylpropanolamine (DEA Form 488)
 request and filing.
1315.36(b)--Request import quota increase
 for ephedrine, pseudoephedrine, or
 phenylpropanolamine.
------------------------------------------------------------------------
                  Pharmaceutical Investigations Section
------------------------------------------------------------------------
1304.04(d)--ARCOS separate central          Drug Enforcement
 reporting identifier request.               Administration, Attn: ARCOS
1304.33(a)--Reports to ARCOS.                Unit/DOPT, P.O. Box 2520,
                                             Springfield, VA 22152-2520
                                             OR Drug Enforcement
                                             Administration, Attn: ARCOS
                                             Unit, 8701 Morrissette
                                             Drive, Springfield, VA
                                             22152.
------------------------------------------------------------------------
                        DEA Registration Section
------------------------------------------------------------------------
1301.03--Procedures information request     Drug Enforcement
 (controlled substances registration).       Administration, Attn:
1301.13(e)(2)--Request DEA Forms 224, 225,   Registration Section/DRR
 and 363.                                    P.O. Box 2639, Springfield,
1301.14(a)--Controlled substances            VA 22152-2639.
 registration application submission.
1301.18(c)--Research project controlled
 substance increase request.
1301.51--Controlled substances
 registration modification request.
1301.52(b)--Controlled substances
 registration transfer request.
1301.52(c)--Controlled substances
 registration discontinuance of business
 activities notification.
1309.03--List I chemicals registration
 procedures information request.
1309.32(c)--Request DEA Form 510.
1309.33(a)--List I chemicals registration
 application submission.
1309.61--List I chemicals registration
 modification request.
------------------------------------------------------------------------
                            DEA Hearing Clerk
------------------------------------------------------------------------
1301.43--Request for hearing or             Drug Enforcement
 appearance; waiver.                         Administration, Attn:
1303.34--Request for hearing or              Hearing Clerk/OALJ, 8701
 appearance; waiver.                         Morrissette Drive,
1308.44--Request for hearing or              Springfield, VA 22152.
 appearance; waiver.
1316.45--Hearings documentation filing.
1316.46(a)--Inspection of record.
1316.47(a)--Request for hearing.
1316.48--Notice of appearance.
------------------------------------------------------------------------
                   DEA Federal Register Representative
------------------------------------------------------------------------
1301.33(a)--Filing of written comments      Drug Enforcement
 regarding application for bulk              Administration, Attn:
 manufacture of Schedule I and II            Federal Register
 substances.\2\                              Representative/DRW, 8701
1301.34(a)--Filing of written comments       Morrissette Drive,
 regarding application for importation of    Springfield, VA 22152.
 Schedule I and II substances.\2\           http://www.regulations.gov/.
1303.11(c)--Filing of written comments
 regarding notice of an aggregate
 production quota.\2\
1303.13(c)--Filing of written comments
 regarding adjustments of aggregate
 production quotas.\2\
1303.13(c)--Filing of written comments
 regarding adjustments of aggregate
 production quotas.\2\
1308.43(g)--Filing of written comments
 regarding initiation of proceedings for
 rulemaking.\2\
------------------------------------------------------------------------
\1\ Applications/filings/reports are required to be filed electronically
  in accordance with this chapter.
\2\ Applications/filings/reports may be filed electronically in
  accordance with this chapter.



[[Page 97044]]

    Dated: November 28, 2016.
Chuck Rosenberg,
Acting Administrator.
[FR Doc. 2016-28966 Filed 12-29-16; 8:45 am]
BILLING CODE 4410-09-P